<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0302256792
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DOCETAXEL ACCORD 20 mg/ml Vial
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DOCETAXEL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        444.4
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="INTAS PHARMACEUTICALS LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            INTAS PHARMACEUTICALS LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Accord Healthcare S.L.U
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01CD02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The name of this medicine is Docetaxel Accord. Its common name is Docetaxel. Docetaxel is a substance derived from the needles of yew trees.<br />Docetaxel belongs to the group of anticancer medicines called taxoids.<br />Docetaxel Accord has been prescribed by your doctor for the treatment of breast cancer, special forms of lung cancer (non small cell lung cancer), prostate cancer, gastric cancer or head and neck cancer:<br />&bull; For the treatment of advanced breast cancer, Docetaxel could be administered either alone or in combination with Doxorubicin, or Trastuzumab, or Capecitabine.<br />&bull; For the treatment of early breast cancer with or without lymph node involvement, Docetaxel could be administered in combination with Doxorubicin and Cyclophosphamide.<br />&bull; For the treatment of lung cancer, Docetaxel could be administered either alone or in combination with Cisplatin.<br />&bull; For the treatment of prostate cancer, Docetaxel is administered in combination with Prednisone or Prednisolone.<br />&bull; For the treatment of metastatic gastric cancer, Docetaxel is administered in combination with Cisplatin and 5-Fluorouracil.<br />&bull; For the treatment of head and neck cancer, Docetaxel is administered in combination with Cisplatin and 5-Fluorouracil.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You must not be given Docetaxel Accord</p><p>&bull; if you are allergic (hypersensitive) to Docetaxel or any of the other ingredients of Docetaxel Accord.<br />&bull; if the number of white blood cells is too low.<br />&bull; if you have a severe liver disease.</p><p>Warnings and Precautions<br />Before each treatment with Docetaxel Accord, you will have blood tests to check that you have enough blood cells and sufficient liver function to receive Docetaxel Accord. In case of white blood cells disturbances, you may experience associated fever or infections.<br />Tell your doctor, hospital pharmacist or nurse if you have vision problems. In case of vision problems, in particular blurred vision, you should immediately have your eyes and vision examined.<br />If you develop acute or worsening problems with your lungs (fever, shortness of breath or cough), please tell your doctor, hospital pharmacist or nurse immediately. Your doctor may stop your treatment immediately.<br />You will be asked to take premedication consisting of an oral corticosteroid such as Dexamethasone, one day prior to Docetaxel Accord administration and to continue for one or two days after it in order to minimize certain undesirable effects which may occur after the infusion of Docetaxel Accord in particular allergic reactions and fluid retention (swelling of the hands, feet, legs or weight gain).<br />During treatment, you may be given other medicines to maintain the number of your blood cells.<br />Docetaxel Accord contains alcohol. Discuss with your doctor if you suffer from alcohol dependency or liver impairment. See also section &ldquo;Docetaxel Accord contains ethanol (alcohol)&rdquo; below.</p><p>Other medicines and Docetaxel Accord<br />Please tell your doctor or hospital pharmacist if you are taking or have recently taken any other medicine, including medicines obtained without a prescription. This is because Docetaxel Accord or the other medicine may not work as well as expected and you may be more likely to get a side effect.</p><p>Pregnancy, Breastfeeding and Fertility<br />Ask your doctor for advice before being given any medicine.<br />Docetaxel Accord must NOT be administered if you are pregnant unless clearly indicated by your doctor.<br />You must not become pregnant during treatment with this medicine and must use an effective method of contraception during therapy, because Docetaxel may be harmful for the unborn baby. If pregnancy occurs during your treatment, you must immediately inform your doctor.<br />You must not breastfeed while you are treated with Docetaxel.<br />If you are a man being treated with Docetaxel Accord you are advised not to father a child during and up to 6 months after treatment and to seek advice on conservation of sperm prior to treatment because Docetaxel may alter male fertility.</p><p>Driving and using machines<br />The amount of alcohol in this medicinal product may impair your ability to drive or use machines.<br />You may experience side effects of this medicine that may impair your ability to drive, use tools or<br />operate machines (see section 4 Possible side effects). If this happens, do not drive or use any tools or<br />machines before discussing with your doctor, nurse or hospital pharmacist.<br />Docetaxel Accord contains ethanol (alcohol) This medicine contains 50 vol % ethanol (alcohol) which means:<br />a) One vial of 1ml of concentrate contains up to 0.395g (0.5ml) ethanol, equivalent to 10ml of beer or 4ml wine<br />b) One vial of 4ml concentrate contains up to 1.58g (2ml) ethanol, equivalent to 40ml of beer or 17ml wine<br />c) One vial of 8ml concentrate contains up to 3.16g (4ml) ethanol, equivalent to 80ml of beer or 33ml wine.<br />Harmful for those suffering from alcoholism. To be taken into account if you are pregnant or if you are breastfeeding, in children and high-risk groups such as patients with liver disease, or epilepsy.<br />The amount of alcohol in this medicine may alter the effects of other medicines.<br />The amount of alcohol in this medicine may impair your ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Docetaxel Accord will be administered to you by a healthcare professional.<br />Recommended dose<br />The dose will depend on your weight and your general condition. Your doctor will calculate your body surface area in square metre (m&sup2;) and will determine the dose you should receive.<br />Method and route of administration<br />Docetaxel Accord will be given by infusion into one of your veins (intravenous use). The infusion will last approximately one hour during which you will be in the hospital.<br />Frequency of administration<br />You should usually receive your infusion once every 3 weeks.<br />Your doctor may change the dose and frequency of dosing depending on your blood tests, your general condition and your response to Docetaxel Accord. In particular, please inform your doctor in case of diarrhoea, sores in the mouth, feeling of numbness or pins and needles, fever and give any results of your blood tests to your doctor. Such information will allow your doctor to decide whether a dose reduction is needed. If you have any further questions on the use of this medicine, ask your doctor, or hospital pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Your doctor will discuss these with you and will explain the potential risks and benefits of your treatment.<br />The most commonly reported adverse reactions of Docetaxel alone are: decrease in the number of red blood cells or white blood cells, alopecia, nausea, vomiting, sores in the mouth, diarrhoea and tiredness.<br />The severity of adverse events of Docetaxel may be increased when Docetaxel is given in combination with other chemotherapeutic agents.<br />During the infusion at the hospital the following allergic reactions (may affect more than 1 in 10 people):<br />&bull; flushing, skin reactions, itching<br />&bull; chest tightness; difficulty in breathing<br />&bull; fever or chills<br />&bull; back pain<br />&bull; low blood pressure.<br />More severe reactions may occur.<br />If you had an allergic reaction to paclitaxel, you may also experience an allergic reaction to docetaxel,<br />which may be more severe.<br />The hospital staff will monitor your condition closely during treatment. Tell them immediately if you notice any of these effects.<br />Between infusions of Docetaxel the following may occur, and the frequency may vary with the combinations of medicines that are received</p><p>Very common (may affect more than 1 in 10 people):<br />&bull; infections, decrease in the number of red (anaemia), or white blood cells (which are important in fighting infection) and platelets<br />&bull; fever: if this happens you must tell your doctor immediately<br />&bull; allergic reactions as described above<br />&bull; loss of appetite (anorexia)<br />&bull; insomnia<br />&bull; feeling of numbness or pins and needles or pain in the joints or muscles<br />&bull; headache<br />&bull; alteration in sense of taste<br />&bull; inflammation of the eye or increased tearing of the eyes<br />&bull; swelling caused by faulty lymphatic drainage<br />&bull; shortness of breath<br />&bull; nasal drainage; inflammation of the throat and nose; cough<br />&bull; bleeding from the nose<br />&bull; sores in the mouth<br />&bull; stomach upsets including nausea, vomiting and diarrhoea, constipation<br />&bull; abdominal pain<br />&bull; indigestion</p><p>&bull; hair loss (in most cases normal hair growth should return)<br />&bull; redness and swelling of the palms of your hands or soles of your feet which may cause your skin to peel (this may also occur on the arms, face, or body)<br />&bull; change in the colour of your nails, which may detach<br />&bull; muscle aches and pains; back pain or bone pain<br />&bull; change or absence of menstrual period<br />&bull; swelling of the hands, feet, legs<br />&bull; tiredness; or flu-like symptoms<br />&bull; weight gain or loss<br />Common (may affect up to 1 in 10 people):<br />&bull; oral candidiasis<br />&bull; dehydration<br />&bull; dizziness<br />&bull; hearing impaired<br />&bull; decrease in blood pressure; irregular or rapid heart beat<br />&bull; heart failure<br />&bull; oesophagitis<br />&bull; dry mouth<br />&bull; difficulty or painful swallowing<br />&bull; haemorrhage<br />&bull; raised liver enzymes (hence the need for regular blood tests)</p><p>Uncommon (may affect up to 1 in 100 people):<br />&bull; fainting<br />&bull; at the injection site, skin reactions, phlebitis (inflammation of the vein) or swelling<br />&bull; inflammation of the colon, small intestine; intestinal perforation<br />&bull; blood clots.<br />Rare (may affect up to 1 in 1,000 people):<br />&bull; inflammation of the colon, small intestine, which could be fatal (frequency not known); intestinal perforation.<br />Frequency not known (cannot be estimated from the available data):<br />&bull; interstitial lung disease (inflammation of the lungs causing coughing and difficulty breathing. Inflammation of the lungs can also develop when Docetaxel therapy is used with radiotherapy)<br />&bull; pneumonia (infection of the lungs)<br />&bull; pulmonary fibrosis (scarring and thickening in the lungs with shortness of breath)<br />&bull; blurred vision due to swelling of the retina within the eye (cystoid macular oedema)<br />&bull; decrease of the sodium, potassium, magnesium, and/or calcium in your blood (electrolyte balance<br />disorders).<br />&bull; ventricular arrhythmia or ventricular tachycardia (manifested as irregular and/or rapid heartbeat,<br />severe shortness of breath, dizziness, and/or fainting). Some of these symptoms can be serious. If<br />this happens, you must tell your doctor immediately<br />&bull; injection site reactions at the site of a previous reaction..</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, hospital pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of sight and reach of children.<br />Do not store above 25&deg;C. Store in the original pack in order to protect from light.<br />Do not use this medicine after the expiry date which is stated on the pack. The expiry date refers to the last day of that month.<br />Use the vial immediately after its opening. If not used immediately, in-use storage times and conditions are the responsibility of the user.<br />From a microbiological point of view, dilution must take place in controlled and aseptic conditions.<br />Use the medicine immediately after it is added into the infusion bag. If not used immediately, in-use storage times and conditions are the responsibility of the user and would normally not be longer than 6 hours below 25&deg;C including the one hour infusion.<br />Physical and chemical in-use stability of the infusion solution prepared as recommended has been demonstrated in non-PVC bags up to 48 hours when stored between 2&deg; to 8&deg;C.<br />Prepare the infusion solution as recommended. Do not couple the infusion solution to the infusion set for more than 8 hours when stored at 25&deg;C.<br />Docetaxel infusion solution is supersaturated, therefore may crystallize over time. If crystals appear, the solution must no longer be used and shall be discarded.<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Docetaxel. Each ml of concentrate for solution for infusion contains 20mg Docetaxel.<br />One vial of 1ml of concentrate contains 20mg of Docetaxel.<br />One vial of 4ml of concentrate contains 80mg of Docetaxel.<br />One vial of 8ml of concentrate contains 160mg of Docetaxel.<br />The other ingredients are polysorbate 80, ethanol anhydrous and citric acid anhydrous</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Docetaxel Accord concentrate for solution for infusion is a clear pale yellow to brownish-yellow solution.
Pack size:
1 X 1ml vial (20mg/1ml)
1 X 4ml vial (80mg/4ml)
1 X 8ml vial (160mg/8ml)
Not all pack sizes maybe marketed
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder (MAH):<br />Accord Healthcare Limited<br />Sage House, 319 Pinner Road, North Harrow, Middlesex HA1 4HF, United Kingdom<br />Tel: +44 208 863 1427<br />Fax: +44 208 863 1426<br />E-mail: mena-info@accord-healthcare.com</p><p>Manufactured for Accord Healthcare Limited by<br />Intas Pharmaceuticals Limited, Ahmedabad, Gujarat state, India<br />For any information about this medicinal product, please contact the local representative of the MAH:<br />Accord Healthcare KSA Scientific Office<br />PO Box 390897, Riyadh 11365, Saudi Arabia Tel: +966 50 3141435<br />E-mail: mena-pv@accord-healthcare.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 12/2018,
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>اسم الدواء هو دوسيتاكسيل أكورد والاسم الشائع هو دوسيتاكسيل. ودوسيتاكسيل هي مادة مُستخلصة من إبر أشجار الطقسوس.<br />ينتمي دوسيتاكسيل إلى مجموعة من الأدوية المضادة للسرطان تسمى التاكسويدات.<br />تم وصف دوسيتاكسيل أكورد من قبل الطبيب المعالج لك من أجل علاج حالات سرطان الثدي، أنواع معينة من سرطان الرئة (سرطان الرئة ذو<br />الخلايا غير الصغيرة)، سرطان البروستاتا، سرطان المعدة، سرطان الرأس والرقبة:<br />لعلاج حالات سرطان الثدي المتقدم؛ يُستخدم دوسيتاكسيل إما بمفرده أو مع دوكسوروبيسين، أو تراستوزوماب أو كابيسيتابين. <br />لعلاج حالات سرطان الثدي المبكر سواء كان مصاح بًا بتضخم العقد الليمفاوية أم لا؛ يُستخدم دوسيتاكسيل مع دوكسوروبيسين <br />وسيكلوفوسفاميد.<br />لعلاج حالات سرطان الرئة؛ يُستخدم دوسيتاكسيل إما بمفرده أو مع سيسبلاتين. <br />لعلاج حالات سرطان البروستاتا؛ يُستخدم دوسيتاكسيل مع بريدنيسون أو بريدنيسولون. <br />لعلاج حالات سرطان القولون النقيلي؛ يُستخدم دوسيتاكسيل مع سيسبلاتين و 5- فلوريوراسيل. <br />لعلاج حالات سرطان الرأس والرقبة؛ يُستخدم دوسيتاكسيل مع سيسبلاتين و 5- فلوريوراسيل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحظر استخدام دوسيتاكسيل أكورد في الحالات التالية:<br />إذا كنت تعاني من حساسية (فرط الحساسية) تجاه دوسيتاكسيل أو أيٍّ مكون من المكونات الأخرى لدواء دوسيتاكسيل أكورد. <br />إذا كنت تعاني من انخفاض شديد في عدد كريات الدم البيضاء. <br />إذا كنت تعاني من مرض كبدي شديد. <br />تحذيرات واحتياطات<br />ستخضع قبل أي جرعة من دوسيتاكسيل أكورد، إلى فحوصات للدم للتأكد من أن لديك كميه كافيه من خلايا الدم وللتأكد من أن وظائف الكبد مناسبة<br />لتلقي دوسيتاكسيل أكورد. في حالة وجود خلل بخلايا الدم البيضاء، قد تتعرض للإصابة بحمى أو حالات عدوى مقترنة.<br />إذا كنت تعاني من مشاكل في الرؤية، فأخبر طبيبك المعالج، الصيدلي أو الممرض التابعين للمستشفى. توجه فورًا لفحص العينين والرؤية إذا<br />واجهتك أي مشاكل في الرؤية، خاصة في حالة عدم وضوح الرؤية.<br />يُرجى إبلاغ طبيبك المعالج، الصيدلي أو الممرض التابعين للمستشفى على الفور، إذا أصبت بمشاكل رئوية حادة أو متفاقمة (حمى، ضيق تنفس أو<br />سعال). قد يوقف طبيبك المعالج العلاج الخاص بك فورًا.<br />سيطلب منك تناول علاج تحضيري من الكورتيكوستيرويدات التي يتم تناولها عن طريق الفم مثل ديكساميثازون، يوم واحد قبل إعطائك<br />دوسيتاكسيل أكورد ويستمر لمدة يوم أو يومين بعد ذلك لتقليل بعض الآثار الجانبية والتي قد تحدث بعد استخدام دوسيتاكسيل أكورد مثل تفاعلات<br />الحساسية واحتباس السوائل (تورم في اليدين، القدمين، الساقين أو زيادة الوزن).<br />قد يتم إعطائك أدوية أخرى أثناء فترة العلاج ، و ذلك للحفاظ على عدد خلايا الدم.<br />يحتوي دوسيتاكسيل أكورد على الكحول. استشر طبيبك المعالج إذا كنت تعاني من إدمان الكحول أو اعتلال في وظائف الكبد. انظر أيضًا قسم<br />&quot;يحتوي دوسيتاكسيل أكورد على الإيثانول (كحول)&quot; أدناه.</p><p>تناول أدوية أخرى مع دوسيتاكسيل أكورد<br />يُرجى إبلاغ طبيبك المعالج أو الصيدلي التابع للمستشفى إذا كنت تتناول أو قد تناولت مؤخرًا أية أدوية أخرى، بما في ذلك الأدوية التي حصلت<br />عليها دون وصفة طبية. ذلك لأن دوسيتاكسيل أكورد أو أي دواء آخر قد لا يمنحك المفعول المرجو وقد تكون معرضً ا للإصابة بآثار جانبية.<br />الحمل والرَّضاعة الطبيعية والخصوبة<br />استشر طبيبك المعالج قبل تناول أي دواء.<br />يحظر استخدام دوسيتاكسيل أكورد إذا كنتِ حاملًا، إلا إذا أوصاكِ الطبيب المعالج لك بذلك.<br />يجب عليكِ تجنب الحمل خلال فترة العلاج بهذا الدواء، وعليكِ أيضًا استخدام وسيلة منع حمل فعالة خلال فترة العلاج وذلك لأن دوسيتاكسيل أكورد<br />قد يضر بالجنين. إذا حدث حمل أثناء فترة علاجكِ ، فيجب علي ك إبلاغ طبيبك المعالج على الفور.<br />يرجى منك التوقف عن الرضاعة الطبيعية أثناء فترة العلاج بدواء دوسيتاكسيل.<br />يوصى المرضى من الرجال الذين يتم علاجهم بدواء دوسيتاكسيل أكورد بعدم المشاركة في الإنجاب خلال فترة العلاج وبعد العلاج لفترة تصل إلى<br />6 أشهر، وعليهم طلب المشورة بشأن حفظ الحيوانات المنوية قبل بدء العلاج نظرًا لإحتمالية تغير الخصوبة بسبب العلاج بدوسيتاكسيل.</p><p>القيادة واستخدام الآلات<br />قد تؤدي كمية الكحول في هذا الدواء إلى ضعف قدرتك على القيادة أو تشغيل الآلات. قد تعاني من الآثار الجانبية لهذا الدواء والتي قد تضعف<br />قدرتك على القيادة أو استخدام الأدوات أو تشغيل الآلات (انظر قسم 4 &quot;الآثار الجانبية المحتملة&quot;). إذا حدث ذلك، فتجنب القيادة أو استخدام أي<br />أدوات أو آلات قبل استشارة طبيبك المعالج، الممرض أو الصيدلي التابعين للمستشفى.<br />يحتوي دوسيتاكسيل أكورد على الإيثانول (الكحول)، يحتوي هذا الدواء على 50 ٪ من الإيثانول (الكحول) مما يعني:<br />أ ) يحتوي فيال واحد بحجم 1 ملليلتر من المحلول المركز على ما يصل إلى 0.395 ملغم ( 0.5 ملليلتر) من الإيثانول، أي ما يعادل 10 ملليلتر<br />من البيرة أو 4 ملليلتر من الخمر.<br />ب ) يحتوي فيال واحد من واحد بحجم 4 ملليلتر من المحلول المركز على ما يصل إلى 1.58 ملغم ( 2 ملليلتر) من الإيثانول، أي ما يعادل 40<br />ملليلتر من البيرة أو 17 ملليلتر من الخمر.<br />ج ) يحتوي فيال واحد بحجم 8 ملليلتر من المحلول المركز على ما يصل إلى 3.16 ملغم ( 4 ملليلتر) من الإيثانول، أي ما يعادل 80 ملليلتر من<br />البيرة أو 33 ملليلتر من الخمر.<br />هذا الدواء ضارللمرضى الذين يعانون من إدمان الكحول. ويجب الوضع في الاعتبار إذا كنتِ حاملًا أو إذا كنتِ مرضع ا بالإضافة إلى الأطفال<br />وشرائح المرضى الأكثر عرضة للخطر مثل المرضى المصابين بمرض كبدي أو صرع.<br />قد تغير كمية الكحول في هذا الدواء من تأثير الأدوية الأخرى.<br />قد تؤدي كمية الكحول في هذا الدواء إلى ضعف قدرتك على القيادة أو تشغيل الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>سيتم إعطاء دوسيتاكسيل أكورد عن طريق أخصائي الرعاية الصحية.<br />الجرعات الموصى بها<br />تعتمد الجرعة على وزنك وعلى حالتك الصحية العامة. سيقوم الطبيب المعالج لك بتقدير مساحة سطح جسمك بالمتر المربع (م 2)، وسيحدد الجرعة<br />الواجب إعطائها.<br />كيفية إعطاء الدواء<br />يُعطى دوسيتاكسيل أكورد عن طريق التسريب في أحد الأوردة (عن طريق الحقن الوريدي). وسوف يستمر التسريب إلى ساعة واحدة تقريب ا أثناء<br />تواجدكِ في المستشفى.<br />تكرار إعطاء الدواء<br />يجب إعطائك الجرعة الخاصة بك مرة كل 3 أسابيع.<br />قد يُغير طبيبك المعالج الجرعة ومرات تكرارها بناءً على نتائج اختبارات الدم وحالتك الصحية العامة واستجابتك للعلاج بدوسيتاكسيل أكورد.<br />يرجى على وجه الخصوص إبلاغ طبيبك المعالج في حالة الإصابة بالإسهال، تقرحات الفم، الشعور بتنميل أو شكشكة مثل وخز الدبابيس والإبر،<br />الحمى، و ينبغي إعطاء أي نتائج لاختبارات الدم إلى طبيبك المعالج. تساعد هذه المعلومات طبيبك المعالج أن يقرر ما إذا كان هناك حاجة لتقليل<br />الجرعة. إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدواء، فاستشر طبيبك المعالج، الصيدلي أو الممرض التابعين للمستشفى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>يمكن أن يُسبب هذا الدَّواء، مثله مثل كافة الأدوية، آثارًا جانبية على الرغم من عدم حدوثها لدى جميع المرضى.<br />سوف يناقش معك طبيبك المعالج هذه الأثار الجانبية المحتملة وسوف يشرح المخاطر والفوائد المحتملة لعلاجك.</p><p>الآثار الجانبية التي تم الإبلاغ عنها بشكل أكثر شيوعًا مع دوسيتاكسيل وحده هي: انخفاض عدد خلايا الدم الحمراء أو خلايا الدم البيضاء، تساقط<br />الشعر، غثيان، قيء، تقرحات في الفم، إسهال وتعب.<br />من الممكن زيادة شدة الآثار الجانبية لدوسيتاكسيل عندما يكون مصاح بًا مع أدوية العلاج الكيميائي الأخرى.<br />أثناء التسريب الوريدي في المستشفى، قد تحدث التفاعلات التحسسية التالية (قد تؤثر على أكثر من مريض واحد من كل 10 مرضى):<br />احمرار، تفاعلات جلدية، حكة <br />ضيق في الصدر، صعوبة في التنفس <br />حمى أو رعشة <br />ألم بالظهر <br />انخفاض ضغط الدم <br />قد تحدث تفاعلات أكثر حدة.<br />إذا كنت تعاني من تفاعل تحسسي تجاه باكليتاكسيل، فربما تواجه تفاعل تحسسي تجاه دوسيتاكسيل أيضً ا ، والذي يمكن أن يكون أكثر حدة.<br />أثناء العلاج، سوف يراقب الفريق الطبي في المستشفى حالتك الصحية عن كثب. أخبرهم على الفور إذا لاحظت أيًا من هذه التأثيرات.<br />قد يحدث ما يلي أثناء التسريب الوريدي بدواء دوسيتاكسيل، وقد يختلف معدل التكرار مع مجموعات الأدوية التي تستخدمها:<br />دا (قد تُؤثر على أكثر من مريض واحد من بين كل 10 مرضى): 􀌒 أثار جانبية شائعة ج<br />حالات عدوى، انخفاض في عدد خلايا الدم الحمراء (أنيميا) أو انخفاض في عدد خلايا الدَّم البيضاء (وهي مهمة لمنع الإصابة بحالات <br />العدوى) وانخفاض عدد الصفائح الدموية<br />حمى: إذا أُصبت بحمى، يجب عليك إخبار طبيبك المعالج على الفور <br />تفاعلات حساسية كما وضح أعلاه <br />فقدان الشهية <br />أَرَق <br />شعور بتنميل أو بشكشكة ، وخز الدبابيس أو الإبر أو ألم في المفاصل أو العضلات <br />صداع <br />اضطراب في حاسة التذوق <br />التهاب العين أو زيادة معدل الإدماع في العين <br />تورم ناتج عن التصريف الليمفاوي الخاطئ <br />ضيق النفس <br />رشح الأنف، التهاب الحلق والأنف، سعال</p><p>نزيف بالأنف <br />قرح بالفم <br />اضطرابات بالمعدة يتضمن ذلك غثيان، قيء وإسهال، إمساك <br />ألم بالبطن <br />عسر الهضم <br />تساقط الشعر (في معظم الحالات يجب أن يعود نمو الشعر الطبيعي) <br />احمرار وتورم كف اليد أو باطن القدم مما قد يتسبب في تقشير جلد القدمين (قد يحدث ذلك أيضًا في الذراعين، الوجه أو الجسم) <br />تغير لون الأظافر، وقد تنفصل الأظافر <br />ألام ووجع في العضلات، ألم في الظهر، ألم في العظام <br />عدم انتظام الدورة الشهرية أو انقطاعها <br />تورم اليدين ، القدمين، الساقين <br />تعب أو أعراض شبيهة بأعراض الإنفلونزا <br />زيادة الوزن أو فقدان الوزن.</p><p>آثار جانبية شائعة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل ١٠ مرضى):<br />سُلَاق فموي (داء المبيضات الفموي) <br />جفاف <br />دوخة <br />ضعف السمع <br />انخفاض ضغط الدم، عدم انتظام أو تسارع نبضات القلب <br />فشل القلب <br />التهاب المريء <br />جفاف الفم <br />صعوبة أو ألم أثناء البلع <br />نزيف <br />ارتفاع في انزيمات الكبد (ولذلك يجب عمل اختبارات دم بانتظام) <br />آثار جانبية غير شائعة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل ١٠٠ مريض):<br />إغماء <br />قد تحدث تفاعلات جلدية في موضع الحقن، التهاب الوريد أو تورم <br />التهاب القولون،الأمعاء الدقيقة، ثقب بالأمعاء</p><p>جلطات دموية.</p><p>آثار جانبية نادرة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل ١٠٠٠ مريض):<br />التهاب القولون والأمعاء الدقيقة والذي يمكن أن يكون قاتل (معدل تكراره غير معروف)؛ ثقب بالأمعاء. <br />آثار جانبية غير معروف معدل تكرارها (لا يمكن تقديرها من واقع البيانات المتاحة):<br />مرض الرئة الخلالي (التهاب الرئتين المؤدي إلى السعال وصعوبة التنفس. قد يظهر التهاب الرئتين أيضًا عند العلاج بدوسيتاكسيل بالتازمن <br />مع العلاج الإشعاعي)<br />التهاب رئوي (عدوى بالرئة) <br />تليف رئوي (تمزق وزيادة سُمك الرئتين، مصاحبين بضيق التنفس). <br />عدم وضوح الرؤية نتيجة تورم الشبكية داخل العين (تورم كيسي في بقعة الشبكية). <br />انخفاض في نسبة الصوديوم، البوتاسيوم، المغنيسيوم و/أو الكالسيوم في الدم (اضطرابات توازن الإلكتروليت). <br />عدم انتظام ضربات القلب البطيني أو سرعة ضربات القلب البطيني (يظهر مثل ضربات قلب غير منتظمة و/أو سرعة ضربات القلب، <br />ضيق شديد في التنفس، دوخة و/أو إغماء). قد تكون بعض هذه الأعراض خطيرة . إذا حدثت، يجب ان تبلغ طبيبك المعالج فورًا.<br />تفاعلات في موضع الحقن السابق ، في نفس مكان التفاعل السابق. <br />إذا أصبح أيٌّ من الآثار الجانبية خطيرًا أو إذا لاحظت أيَّ آثار جانبية غير مدرجة بهذه النَّشرة، ف يُرجى إبلاغ طبيبك المعالج أو الصيدلي و الممرض<br />التابعين للمستشفى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيدًا عن مرأى ومتناول الأطفال.<br />يحفظ في درجة حرارة بحيث لا تتعدى 25 &deg;م. يُحفظ الفيال في العبوة الخارجية لحمايته من الضوء.<br />يجب عدم استخدام هذا الدواء بعد انتهاء تاريخ الصلاحية الموضح على العبوة. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.<br />استخدم الفيال مباشرة بعد فتحه. إذا لم يتم استخدامه فورًا، تكون فترة وظروف التخزين أثناء الاستخدام مسئولية المُستخدِم .<br />من الناحية الميكروبيولوجية، يجب أن يتم التخفيف في ظروف تعقيم مُحكمة.</p><p>استخدم الدواء مباشرة بعد إضافته إلى كيس التسريب. إذا لم يستخدم على الفور، تكون فترة وظروف التخزين أثناء و قبل الاستخدام مسئولية<br />المُستخدِم وفي المعتاد يجب ألا تزيد عن 6 ساعات في درجة حرارة أقل من 25 &deg;م بما في ذلك ساعة التسريب الوريدي.<br />تم إثبات الاستقرار الفيزيائي والكيميائي أثناء الاستخدام لمحلول التسريب الذي تم إعداده على النحو الموصى به في أكياس غير محتوية على أي<br />نوع من مادة البولي فينيل كلوريد لمدة تصل إلى 48 ساعة عند حفظه في درجة حرارة تتراوح بين 2&deg; م إلى 8&deg; م.<br />ينبغي إعداد محلول التسريب على النحو الموصى به. لا تترك محلول التسريب في جهاز التسريب لأكثر من 8 ساعات عند تخزينه في درجة<br />حرارة 25 &deg; م.<br />محلول دوسيتاكسيل للتسريب الوريدي هو محلول فائق التشبع، لذلك قد تتبلور بمرور الوقت. إذا ظهرت البلورات، يجب عدم استخدام المحلول و<br />كما يجب التخلص منه.<br />يجب عدم التخلص من الأدوية عن طريق مياه الصرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بكِ عن كيفية التَّخلص من الأدوية التي لم<br />تعد بحاجة إليها. تُساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي دوسيتاكسيل. يحتوي كل ملليتر من محلول مركز للترسيب الوريدي على 20 ملغم دوسيتاكسيل.<br />فيال 1 ملليتر من المحلول المركز تحتوي علي 20 ملغم من دوسيتاكسيل.<br />فيال 4 ملليتر من المحلول المركز تحتوي علي 80 ملغم من دوسيتاكسيل.<br />فيال 8 ملليتر من المحلول المركز تحتوي علي 160 ملغم من دوسيتاكسيل.<br />المواد الأخرى هي بولي سوربات 80 ، إيثانول لا مائي وحمض الستريك اللا مائي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>الشكل الصيدلاني لدوسيتاكسيل أكورد ومحتويات العبوة<br />دوسيتاكسيل أكورد محلول مركز للترسيب الوريدي عبارة عن محلول شفاف يميل لونه من الأصفر الشاحب إلى الأصفر البني.<br />حجم العبوات:<br />1 فيال 1 ملليتر من المحلول المركز ( 20 ملغم / 1 ملليتر)<br />1 فيال 4 ملليتر من المحلول المركز ( 80 ملغم / 4 ملليتر)<br />1 فيال 8 ملليتر من المحلول المركز ( 160 ملغم / 8 ملليتر)</p><p>قد لا تتوفر جميع أحجام العبوات في الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>حامل التصريح بالتسويق<br />أكورد هيلثكير ليمتد<br />المملكة المتحدة ،HA1 4HF سيج هاوس، 319 بينر رود، نورث هارو، ميدلسيكس<br />+44 208 863 هاتف: 1427<br />+44 208 863 فاكس: 1426<br />mena-info@accord-healthcare.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آخر اعتماد لهذه النشرة بتاريخ 2018/12
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Docetaxel Accord 80mg/4ml concentrate for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml of concentrate contains 20mg Docetaxel.
One vial of 4ml of concentrate contains 80mg of Docetaxel.
Excipient with known effect:
Each vial of concentrate contains 2ml of ethanol anhydrous (1.58g).
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion (sterile concentrate).
The concentrate is a clear pale yellow to brownish-yellow solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Breast cancer<br />Docetaxel Accord in combination with Doxorubicin and Cyclophosphamide is indicated for the adjuvant treatment of patients with:<br />&bull; operable node-positive breast cancer<br />&bull; operable node-negative breast cancer.</p><p>For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer (see section 5.1).<br />Docetaxel Accord in combination with Doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.<br />Docetaxel Accord monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an Anthracycline or an alkylating agent.<br />Docetaxel Accord in combination with Trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express HER2 and who previously have not received chemotherapy for metastatic disease.<br />Docetaxel Accord in combination with Capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an Anthracycline.</p><p>Non small cell lung cancer<br />Docetaxel Accord is indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer after failure of prior chemotherapy.<br />Docetaxel Accord in combination with Cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non small cell lung cancer, in patients who have not previously received chemotherapy for this condition.<br />Prostate cancer<br />Docetaxel Accord in combination with Prednisone or Prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.<br />Gastric adenocarcinoma<br />Docetaxel Accord in combination with Cisplatin and 5-Fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.<br />Head and neck cancer<br />Docetaxel Accord in combination with Cisplatin and 5-Fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The use of Docetaxel should be confined to units specialized in the administration of cytotoxic chemotherapy and it should only be administered under the supervision of a physician qualified in the use of anticancer chemotherapy (see section 6.6).<br />Recommended dose<br />For breast, non small cell lung, gastric, and head and neck cancers, premedication consisting of an oral corticosteroid, such as Dexamethasone 16mg per day (e.g. 8mg twice daily) for 3 days starting 1 day prior to Docetaxel administration, unless contraindicated, can be used (see section 4.4). Prophylactic G-CSF may be used to mitigate the risk of haematological toxicities.<br />For prostate cancer, given the concurrent use of Prednisone or Prednisolone the recommended premedication regimen is oral Dexamethasone 8mg, 12 hours, 3 hours and 1-hour before the Docetaxel<br />infusion (see section 4.4).<br />Docetaxel is administered as a one-hour infusion every three weeks.</p><p>Breast cancer<br />In the adjuvant treatment of operable node-positive and node-negative breast cancer, the recommended dose of Docetaxel is 75mg/m2 administered 1-hour after Doxorubicin 50mg/m2 and Cyclophosphamide 500mg/m2 every 3 weeks for 6 cycles (TAC regimen) (see also Dose adjustments during treatment). For the treatment of patients with locally advanced or metastatic breast cancer, the recommended dose of Docetaxel is 100mg/m2 in monotherapy. In first-line treatment, Docetaxel 75mg/m2 is given in combination therapy with Doxorubicin (50mg/m2).<br />In combination with Trastuzumab the recommended dose of Docetaxel is 100mg/m2 every three weeks, with Trastuzumab administered weekly. In the pivotal study the initial Docetaxel infusion was started the day following the first dose of Trastuzumab. The subsequent Docetaxel doses were administered immediately after completion of the Trastuzumab infusion, if the preceding dose of Trastuzumab was well tolerated. For Trastuzumab dose and administration, see Trastuzumab summary of product characteristics.<br />In combination with Capecitabine, the recommended dose of Docetaxel is 75mg/m2 every three weeks, combined with Capecitabine at 1250mg/m2 twice daily (within 30 minutes after a meal) for 2 weeks followed by a 1-week rest period. For Capecitabine dose calculation according to body surface area, see Capecitabine summary of product characteristics.<br />Non small cell lung cancer<br />In chemotherapy na&iuml;ve patients treated for non small cell lung cancer, the recommended dose regimen is Docetaxel 75mg/m2 immediately followed by Cisplatin 75mg/m2 over 30-60 minutes. For treatment after failure of prior platinum-based chemotherapy, the recommended dose is 75mg/m2 as a single agent.<br />Prostate cancer<br />The recommended dose of Docetaxel is 75mg/m2. Prednisone or Prednisolone 5mg orally twice daily is administered continuously (see section 5.1).</p><p>Gastric adenocarcinoma<br />The recommended dose of Docetaxel is 75mg/m2 as a 1-hour infusion, followed by Cisplatin 75mg/m2, as a 1- to 3-hour infusion (both on day 1 only), followed by 5-Fluorouracil 750mg/m2 per day given as a 24-hour continuous infusion for 5 days, starting at the end of the Cisplatin infusion. Treatment is repeated every three weeks. Patients must receive premedication with antiemetics and appropriate hydration for Cisplatin administration. Prophylactic G-CSF should be used to mitigate the risk of haematological toxicities (see also Dose adjustments during treatment).<br />Head and neck cancer<br />Patients must receive premedication with antiemetics and appropriate hydration (prior to and after Cisplatin administration). Prophylactic G-CSF may be used to mitigate the risk of haematological toxicities. All patients on the Docetaxel-containing arm of the TAX 323 and TAX 324 studies, received prophylactic antibiotics.<br />&bull; Induction chemotherapy followed by radiotherapy (TAX 323)<br />For the induction treatment of inoperable locally advanced squamous cell carcinoma of the head and neck (SCCHN), the recommended dose of Docetaxel is 75mg/m2 as a 1-hour infusion followed by Cisplatin 75mg/m2 over 1-hour, on day one, followed by 5-Fluorouracil as a continuous infusion at 750mg/m2 per day for five days. This regimen is administered every 3 weeks for 4 cycles. Following chemotherapy, patients should receive radiotherapy.<br />&bull; Induction chemotherapy followed by chemoradiotherapy TAX 324)<br />For the induction treatment of patients with locally advanced (technically unresectable, low probability of surgical cure, and aiming at organ preservation) squamous cell carcinoma of the head</p><p>and neck (SCCHN), the recommended dose of Docetaxel is 75mg/m2 as a 1-hour intravenous infusion on day 1, followed by Cisplatin 100mg/m2 administered as a 30-minute to 3-hour infusion, followed by 5-Fluorouracil 1000mg/m2/day as a continuous infusion from day 1 to day 4. This regimen is administered every 3 weeks for 3 cycles. Following chemotherapy, patients should receive chemoradiotherapy.<br />For Cisplatin and 5-Fluorouracil dose modifications, see the corresponding summary of product characteristics.<br />Dose adjustments during treatment<br />General<br />Docetaxel should be administered when the neutrophil count is &ge; 1,500 cells/mm3. In patients who experienced either febrile neutropenia, neutrophil count &lt; 500 cells/mm3 for more than one week, severe or cumulative cutaneous reactions or severe peripheral neuropathy during Docetaxel therapy, the dose of Docetaxel should be reduced from 100mg/m2 to 75mg/m2 and/or from 75 to 60mg/m2. If the patient continues to experience these reactions at 60mg/m2, the treatment should be discontinued<br />Adjuvant therapy for breast cancer<br />Primary G-CSF prophylaxis should be considered in patients who receive Docetaxel, Doxorubicin and Cyclophosphamide (TAC) adjuvant therapy for breast cancer. Patients who experience febrile neutropenia and/or neutropenic infection should have their Docetaxel dose reduced to 60mg/m2 in all subsequent cycles (see sections 4.4 and 4.8). Patients who experience Grade 3 or 4 stomatitis should have their dose decreased to 60mg/m2.<br />In combination with Cisplatin<br />For patients who are dosed initially at Docetaxel 75mg/m2 in combination with Cisplatin and whose nadir of platelet count during the previous course of therapy is &lt; 25,000 cells/mm3, or in patients who experience febrile neutropenia, or in patients with serious non-haematologic toxicities, the Docetaxel dose in subsequent cycles should be reduced to 65mg/m2. For Cisplatin dose adjustments, see the corresponding summary of product characteristics.&nbsp;Cisplatin and 5-Fluorouracil (5-FU):</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Toxicity </strong></p></td><td style="vertical-align:top"><p><strong>Dose adjustment </strong></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea grade 3</p></td><td style="vertical-align:top"><p>First episode: reduce 5-FU dose by 20%.</p><p>Second episode: then reduce Docetaxel dose by 20%.</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea grade 4</p></td><td style="vertical-align:top"><p>First episode: reduce Docetaxel and 5-FU doses by 20%.</p><p>Second episode: discontinue treatment.</p></td></tr><tr><td style="vertical-align:top"><p>Stomatitis/mucositis grade 3</p></td><td style="vertical-align:top"><p>First episode: reduce 5-FU dose by 20%.</p><p>Second episode: stop 5-FU only, at all subsequent cycles.</p><p>Third episode: reduce Docetaxel dose by 20%.</p></td></tr><tr><td style="vertical-align:top"><p>Stomatitis/mucositis grade 4</p></td><td style="vertical-align:top"><p>First episode: stop 5-FU only, at all subsequent cycles.</p><p>Second episode: reduce Docetaxel dose by 20%.</p></td></tr></tbody></table><p>For Cisplatin and 5-Fluorouracil dose adjustments, see the corresponding summary of product characteristics.<br />In the pivotal SCCHN studies patients who experienced complicated neutropenia (including prolonged neutropenia, febrile neutropenia, or infection), it was recommended to use G-CSF to provide prophylactic coverage (eg, day 6-15) in all subsequent cycles.<br />Special populations<br />Patients with hepatic impairment<br />Based on pharmacokinetic data with Docetaxel at 100mg/m2 as single agent, patients who have both elevations of transaminase (ALT and/or AST) greater than 1.5 times the upper limit of the normal range (ULN) and Alkaline Phosphatase greater than 2.5 times the ULN, the recommended dose of Docetaxel is 75mg/m2 (see sections 4.4 and 5.2). For those patients with serum bilirubin &gt; ULN and/or ALT and AST &gt; 3.5 times the ULN associated with Alkaline Phosphatase &gt; 6 times the ULN, no dose-reduction can be recommended and Docetaxel should not be used unless strictly indicated.<br />In combination with Cisplatin and 5-Fluorouracil for the treatment of patients with gastric adenocarcinoma, the pivotal clinical study excluded patients with ALT and/or AST &gt; 1.5 &times; ULN associated with Alkaline Phosphatase &gt; 2.5 &times; ULN, and Bilirubin &gt; 1 x ULN; for these patients, no dose-reductions<br />can be recommended and Docetaxel should not be used unless strictly indicated. No data are available in patients with hepatic impairment treated by Docetaxel in combination in the other indications.<br />Paediatric population<br />The safety and efficacy of Docetaxel in nasopharyngeal carcinoma in children aged 1 month to less than 18 years have not yet been established.<br />There is no relevant use of Docetaxel in the paediatric population in the indications breast cancer, non small cell lung cancer, prostate cancer, gastric carcinoma and head and neck cancer, not including type II and III less differentiated nasopharyngeal carcinoma.<br />Older people<br />Based on a population pharmacokinetic analysis, there are no special instructions for use in the older people. In combination with Capecitabine, for patients 60 years of age or more, a starting dose reduction of Capecitabine to 75% is recommended (see Capecitabine summary of product characteristics).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Docetaxel must not be used in patients with baseline neutrophil count of < 1,500 cells/mm3.
Docetaxel must not be used in patients with severe liver impairment since there is no data available (see sections 4.2 and 4.4).
Contraindications for other medicinal products also apply, when combined with Docetaxel.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For breast and non small cell lung cancers, premedication consisting of an oral corticosteroid, such as Dexamethasone 16mg per day (e.g. 8mg twice daily) for 3 days starting 1 day prior to Docetaxel administration, unless contraindicated, can reduce the incidence and severity of fluid retention as well as the severity of hypersensitivity reactions. For prostate cancer, the premedication is oral Dexamethasone 8mg, 12 hours, 3 hours and 1-hour before the Docetaxel infusion (see section 4.2).</p><p>Haematology<br />Neutropenia is the most frequent adverse reaction of Docetaxel. Neutrophil nadirs occurred at a median of 7 days but this interval may be shorter in heavily pre-treated patients. Frequent monitoring of complete blood counts should be conducted on all patients receiving Docetaxel. Patients should be retreated with Docetaxel when neutrophils recover to a level &ge; 1,500 cells/mm3 (see section 4.2)<br />In the case of severe neutropenia (&lt; 500 cells/mm3 for seven days or more) during a course of Docetaxel therapy, a reduction in dose for subsequent courses of therapy or the use of appropriate symptomatic measures are recommended (see section 4.2).<br />In patients treated with Docetaxel in combination with Cisplatin and 5-Fluorouracil (TCF), febrile neutropenia and neutropenic infection occurred at lower rates when patients received prophylactic G-CSF. Patients treated with TCF should receive prophylactic G-CSF to mitigate the risk of complicated neutropenia (febrile neutropenia, prolonged neutropenia or neutropenic infection). Patients receiving TCF should be closely monitored (see sections 4.2 and 4.8).<br />In patients treated with Docetaxel in combination with Doxorubicin and Cyclophosphamide (TAC), febrile neutropenia and/or neutropenic infection occurred at lower rates when patients received primary G-CSF prophylaxis. Primary G-CSF prophylaxis should be considered in patients who receive adjuvant therapy with TAC for breast cancer to mitigate the risk of complicated neutropenia (febrile neutropenia, prolonged neutropenia or neutropenic infection). Patients receiving TAC should be closely monitored (see sections 4.2 and 4.8).</p><p>Gastrointestinal reactions<br />Caution is recommended for patients with neutropenia, particularly at risk for developing gastrointestinal complications. Although majority of cases occurred during the first or second cycle of Docetaxel containing regimen, enterocolitis could develop at any time, and could lead to death as early as on the first day of onset. Patients should be closely monitored for early manifestations of serious gastrointestinal toxicity (see sections 4.2, 4.4 Haematology, and 4.8).</p><p>Hypersensitivity reactions<br />Patients should be observed closely for hypersensitivity reactions especially during the first and second<br />infusions. Hypersensitivity reactions may occur within a few minutes following the initiation of the infusion of Docetaxel, thus facilities for the treatment of hypotension and bronchospasm should be available. If hypersensitivity reactions occur, minor symptoms such as flushing or localized cutaneous reactions do not require interruption of therapy. However, severe reactions, such as severe hypotension, bronchospasm or generalized rash/erythema require immediate discontinuation of Docetaxel and appropriate therapy. Patients who have developed severe hypersensitivity reactions should not be re-challenged with Docetaxel.<br />Cutaneous reactions<br />Localized skin erythema of the extremities (palms of the hands and soles of the feet) with oedema followed by desquamation has been observed. Severe symptoms such as eruptions followed by&nbsp;desquamation which lead to interruption or discontinuation of Docetaxel treatment were reported (see section 4.2).<br />Fluid retention<br />Patients with severe fluid retention such as pleural effusion, pericardial effusion and ascites should be monitored closely.<br />Respiratory disorders<br />Acute respiratory distress syndrome, interstitial pneumonia/pneumonitis, interstitial lung disease, pulmonary fibrosis and respiratory failure have been reported and may be associated with fatal outcome. Cases of radiation pneumonitis have been reported in patients receiving concomitant radiotherapy.<br />If new or worsening pulmonary symptoms develop, patients should be closely monitored, promptly investigated, and appropriately treated. Interruption of Docetaxel therapy is recommended until diagnosis is available. Early use of supportive care measures may help improve the condition. The benefit of resuming Docetaxel treatment must be carefully evaluated.</p><p>Patients with liver impairment<br />In patients treated with Docetaxel at 100mg/m2 as single agent who have serum Transaminase levels (ALT and/or AST) greater than 1.5 times the ULN concurrent with serum Alkaline Phosphatase levels greater than 2.5 times the ULN, there is a higher risk of developing severe adverse reactions such as toxic deaths including sepsis and gastrointestinal haemorrhage which can be fatal, febrile neutropenia, infections, thrombocytopenia, stomatitis and asthenia. Therefore, the recommended dose of Docetaxel in those patients with elevated liver function test (LFTs) is 75mg/m2 and LFTs should be measured at baseline and before each cycle (see section 4.2).<br />For patients with serum bilirubin levels &gt; ULN and/or ALT and AST &gt; 3.5 times the ULN concurrent with serum Alkaline Phosphatase levels &gt; 6 times the ULN, no dose-reduction can be recommended and Docetaxel should not be used unless strictly indicated.<br />In combination with Cisplatin and 5-Fluorouracil for the treatment of patients with gastric adenocarcinoma, the pivotal clinical study excluded patients with ALT and/or AST &gt; 1.5 &times; ULN associated with Alkaline Phosphatase &gt; 2.5 &times; ULN, and Bilirubin &gt; 1 x ULN; for these patients, no dose-reductions can be recommended and Docetaxel should not be used unless strictly indicated. No data are available in patients with hepatic impairment treated by Docetaxel in combination in the other indications.</p><p>Patients with renal impairment<br />There are no data available in patients with severely impaired renal function treated with Docetaxel.<br />Nervous system<br />The development of severe peripheral neurotoxicity requires a reduction of dose (see section 4.2).<br />Cardiac toxicity<br />Heart failure has been observed in patients receiving Docetaxel in combination with Trastuzumab, particularly following Anthracycline (Doxorubicin or Epirubicin) -containing chemotherapy. This may be moderate to severe and has been associated with death (see section 4.8).<br />When patients are candidates for treatment with Docetaxel in combination with Trastuzumab, they should undergo baseline cardiac assessment. Cardiac function should be further monitored during treatment (e.g. every three months) to help identify patients who may develop cardiac dysfunction. For more details see summary of product characteristics of Trastuzumab.<br />Ventricular arrhythmia including ventricular tachycardia (sometimes fatal) has been reported in patients treated with docetaxel in combination regimens including Doxorubicin, 5-Fluorouracil and/ or&nbsp;Cyclophosphamide (see Section 4.8).<br />Baseline cardiac assessment is recommended.<br />Eye disorders<br />Cystoid macular oedema (CMO) has been reported in patients treated with Docetaxel. Patients with impaired vision should undergo a prompt and complete ophthalmologic examination. In case CMO is diagnosed, Docetaxel treatment should be discontinued and appropriate treatment initiated (see section 4.8).<br />Others<br />Contraceptive measures must be taken by both men and women during treatment and for men at least 6 months after cessation of therapy (see section 4.6).<br />The concomitant use of Docetaxel with strong CYP3A4 inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin, Indinavir, Nefazodone, Nelfinavir, Ritonavir, Saquinavir, Telithromycin and Voriconazole) should be avoided (see section 4.5).</p><p>Additional cautions for use in adjuvant treatment of breast cancer<br />Complicated neutropenia<br />For patients who experience complicated neutropenia (prolonged neutropenia, febrile neutropenia or infection), G-CSF and dose reduction should be considered (see section 4.2).<br />Gastrointestinal reactions<br />Symptoms such as early abdominal pain and tenderness, fever, diarrhoea, with or without neutropenia, may be early manifestations of serious gastrointestinal toxicity and should be evaluated and treated promptly.<br />Congestive heart failure (CHF)<br />Patients should be monitored for symptoms of congestive heart failure during therapy and during the follow up period. In patients treated with the TAC regimen for node-positive breast cancer, the risk of CHF has been shown to be higher during the first year after treatment (see sections 4.8 and 5.1).<br />Leukaemia<br />In the Docetaxel, Doxorubicin and Cyclophosphamide (TAC) treated patients, the risk of delayed myelodysplasia or myeloid leukaemia requires haematological follow up.<br />Patients with 4+ nodes<br />As the benefit observed in patient with 4+ nodes was not statistically significant on disease-free survival (DFS) and overall survival (OS), the positive benefit/risk ratio for TAC in patients with 4+ nodes was not fully demonstrated at the final analysis (see section 5.1).<br />Older people<br />There are limited data available in patients &gt; 70 years of age on Docetaxel use in combination with Doxorubicin and Cyclophosphamide.<br />Of the 333 patients treated with Docetaxel every three weeks in a prostate cancer study, 209 patients were 65 years of age or greater and 68 patients were older than 75 years. In patients treated with Docetaxel every three weeks, the incidence of related nail changes occurred at a rate &ge; 10% higher in patients who were 65 years of age or greater compared to younger patients. The incidence of related fever, diarrhoea, anorexia, and peripheral oedema occurred at rates &ge; 10% higher in patients who were&nbsp;75 years of age or greater versus less than 65 years.<br />Among the 300 (221 patients in the phase III part of the study and 79 patients in the phase II part) patients treated with Docetaxel in combination with Cisplatin and 5-Fluorouracil in the gastric cancer study, 74 were 65 years of age or older and 4 patients were 75 years of age or older. The incidence of serious adverse events was higher in older people compared to younger patients. The incidence of the following adverse events (all grades): lethargy, stomatitis, neutropenic infection occurred at rates &ge; 10% higher in patients who were 65 years of age or older compared to younger patients. Older people treated with TCF should be closely monitored.<br />Excipients<br />This medicinal product contains 50 vol% ethanol (alcohol), i.e. up to 1.58g (2ml) per vial, equivalent to 40ml of beer or 17ml wine per vial.<br />Harmful for those suffering from alcoholism.<br />To be taken into account in pregnant or breastfeeding women, children and high-risk groups such as patients with liver disease, or epilepsy.<br />The amount of alcohol in this medicinal product may alter the effects of other medicinal products.<br />The amount of alcohol in this medicinal product may impair the patients ability to drive or use machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In vitro studies have shown that the metabolism of Docetaxel may be modified by the concomitant administration of compounds which induce, inhibit or are metabolized by (and thus may inhibit the enzyme competitively) Cytochrome P450-3A such as Ciclosporine, Terfenadine, Ketoconazole, Erythromycin and Troleandomycin. As a result, caution should be exercised when treating patients with these medicinal products as concomitant therapy since there is a potential for a significant interaction.<br />In case of combination with CYP3A4 inhibitors, the occurrence of Docetaxel adverse reactions may increase, as a result of reduced metabolism. If the concomitant use of a strong CYP3A4 inhibitor (e.g., Ketoconazole, Itraconazole, Clarithromycin, Indinavir, Nefazodone, Nelfinavir, Ritonavir, Saquinavir, Telithromycin and Voriconazole) cannot be avoided, a close clinical surveillance is warranted and a dose-adjustment of Docetaxel may be suitable during the treatment with the strong CYP3A4 inhibitor (see section 4.4). In a pharmacokinetic study with 7 patients, the coadministration of Docetaxel with the strong CYP3A4 inhibitor Ketoconazole leads to a significant decrease in Docetaxel clearance by 49%.<br />Docetaxel is highly protein-bound (&gt; 95%). Although the possible in vivo interaction of Docetaxel with concomitantly administered medicinal product has not been investigated formally, in vitro interactions with tightly protein-bound agents such as Erythromycin, Diphenhydramine, Propranolol, Propafenone, Phenytoin, Salicylate, Sulfamethoxazole and Sodium Valproate did not affect protein binding of Docetaxel. In addition, Dexamethasone did not affect protein binding of Docetaxel. Docetaxel did not influence the binding of Digitoxin.<br />The pharmacokinetics of Docetaxel, Doxorubicin and Cyclophosphamide were not influenced by their coadministration. Limited data from a single uncontrolled study were suggestive of an interaction between Docetaxel and Carboplatin. When combined to Docetaxel, the clearance of Carboplatin was about 50% higher than values previously reported for Carboplatin monotherapy.<br />Docetaxel pharmacokinetics in the presence of Prednisone was studied in patients with metastatic prostate cancer. Docetaxel is metabolised by CYP3A4 and Prednisone is known to induce CYP3A4. No statistically significant effect of Prednisone on the pharmacokinetics of Docetaxel was observed.</p><p>Clinical cases consistent with an increase in Docetaxel toxicity were reported when it was combined with Ritonavir. The mechanism behind this interaction is a CYP3A4 inhibition, the main isoenzyme involved in Docetaxel metabolism by Ritonavir. Based on extrapolation from a pharmacokinetic study with Ketoconazole in 7 patients, consider a 50% Docetaxel dose reduction if patients require coadministration of a strong CYP3A4 inhibitor such as azole antifungals, Ritonavir and some macrolides (Clarithromycin, Telithromycin).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />There is no information on the use of Docetaxel in pregnant women. Docetaxel has been shown to be both embryotoxic and foetotoxic in rabbits and rats, and to reduce fertility in rats. As with other cytotoxic medicinal products, Docetaxel may cause foetal harm when administered to pregnant women. Therefore, Docetaxel must not be used during pregnancy unless clearly indicated.<br />Women of childbearing age receiving Docetaxel should be advised to avoid becoming pregnant, and to inform the treating physician immediately should this occur.<br />Breastfeeding<br />Docetaxel is a lipophilic substance but it is not known whether it is excreted in human milk. Consequently, because of the potential for adverse reactions in nursing infants, breastfeeding must be discontinued for the duration of Docetaxel therapy.<br />Contraception in males and females<br />An effective method of contraception should be used during treatment.<br />Fertility<br />In non clinical studies, Docetaxel has genotoxic effects and may alter male fertility (see section 5.3). Therefore, men being treated with Docetaxel are advised not to father a child during and up to 6 months after treatment and to seek advice on conservation of sperm prior to treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. The amount of alcohol in this medicinal product and the side effects of the product may impair the ability to drive or use machines (see sections 4.4 and 4.8). Therefore, patients should be warned of the potential impact of the amount of alcohol and the side effects of this medicinal product on the ability to drive or use machines, and be advised not to drive or use machines if they experience these side effects during treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>summery of&nbsp;the safety profile for all indications<br />The adverse reactions considered to be possibly or probably related to the administration of Docetaxel have been obtained in:<br />&bull; 1312 and 121 patients who received 100mg/m2 and 75mg/m2 of Docetaxel as a single agent respectively.<br />&bull; 258 patients who received Docetaxel in combination with Doxorubicin.<br />&bull; 406 patients who received Docetaxel in combination with Cisplatin.<br />&bull; 92 patients treated with Docetaxel in combination with Trastuzumab.<br />&bull; 255 patients who received Docetaxel in combination with Capecitabine.<br />&bull; 332 patients who received Docetaxel in combination with Prednisone or Prednisolone (clinically important treatment related adverse events are presented).<br />&bull; 1276 patients (744 and 532 in TAX 316 and GEICAM 9805 respectively) who received Docetaxel in&nbsp;combination with Doxorubicin and Cyclophosphamide (clinically important treatment related adverse events are presented).</p><p>&bull; 300 gastric adenocarcinoma patients (221 patients in the phase III part of the study and 79 patients in the phase II part) who received Docetaxel in combination with Cisplatin and 5-Fluorouracil (clinically important treatment related adverse events are presented).<br />&bull; 174 and 251 head and neck cancer patients who received Docetaxel in combination with Cisplatin and 5-Fluorouracil (clinically important treatment related adverse events are presented).</p><p>grade 4 = G4), the COSTART and the MedDRA terms. Frequencies are defined as: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from available data).<br />Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.<br />The most commonly reported adverse reactions of Docetaxel alone are: neutropenia (which was reversible and not cumulative; the median day to nadir was 7 days and the median duration of severe neutropenia (&lt; 500 cells/mm3) was 7 days), anaemia, alopecia, nausea, vomiting, stomatitis, diarrhoea and asthenia. The severity of adverse events of Docetaxel may be increased when Docetaxel is given in combination with other chemotherapeutic agents.<br />For combination with Trastuzumab, adverse events (all grades) reported in &ge; 10% are displayed. There was an increased incidence of SAEs (40% vs. 31%) and Grade 4 AEs (34% vs. 23%) in the Trastuzumab combination arm compared to Docetaxel monotherapy.<br />For combination with Capecitabine, the most frequent treatment related undesirable effects (&ge; 5%) reported in a phase III study in breast cancer patients failing Anthracycline treatment are presented (see Capecitabine summary of product characteristics).<br />The following adverse reactions are frequently observed with Docetaxel:</p><p>Immune system disorders<br />Hypersensitivity reactions have generally occurred within a few minutes following the start of the infusion of Docetaxel and were usually mild to moderate. The most frequently reported symptoms were flushing, rash with or without pruritus, chest tightness, back pain, dyspnoea and fever or chills. Severe reactions were characterised by hypotension and/or bronchospasm or generalized rash/erythema (see section 4.4).</p><p>Nervous system disorders<br />The development of severe peripheral neurotoxicity requires a reduction of dose (see sections 4.2 and 4.4). Mild to moderate neurosensory signs are characterised by paresthesia, dysesthesia or pain including burning. Neuromotor events are mainly characterised by weakness.</p><p>Skin and subcutaneous tissue disorders<br />Reversible cutaneous reactions have been observed and were generally considered as mild to moderate. Reactions were characterized by a rash including localized eruptions mainly on the feet and hands (including severe hand and foot syndrome), but also on the arms, face or thorax, and frequently associated with pruritus. Eruptions generally occurred within one week after the Docetaxel infusion. Less frequently, severe symptoms such as eruptions followed by desquamation which rarely lead to interruption or discontinuation of Docetaxel treatment were reported (see sections 4.2 and 4.4). Severe nail disorders are characterized by hypo- or hyperpigmentation and sometimes pain and onycholysis.<br />General disorders and administration site conditions<br />Infusion site reactions were generally mild and consisted of hyper pigmentation, inflammation, redness or dryness of the skin, phlebitis or extravasation and swelling of the vein.<br />Fluid retention includes events such as peripheral oedema and less frequently pleural effusion,</p><p>pericardial effusion, ascites and weight gain. The peripheral oedema usually starts at the lower extremities and may become generalized with a weight gain of 3 kg or more. Fluid retention is cumulative in incidence and severity (see section 4.4).<br />Tabulated list of adverse reactions in breast cancer for Docetaxel 100mg/m2 single agent</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA system organ classes </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Very common adverse </strong></p><p><strong>reactions </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Common adverse reactions </strong></p></td><td style="vertical-align:top"><p><strong>Uncommon adverse reactions </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Infections and infestations</p></td><td colspan="2" style="vertical-align:top"><p>Infections (G3/4: 5.7%;</p><p>including sepsis and pneumonia, fatal in 1.7%)</p></td><td colspan="2" style="vertical-align:top"><p>Infection associated with G4 neutropenia (G3/4: 4.6%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td colspan="2" style="vertical-align:top"><p>Neutropenia (G4: 76.4%);</p><p>Anaemia (G3/4: 8.9%);</p><p>Febrile neutropenia</p></td><td colspan="2" style="vertical-align:top"><p>Thrombocytopenia (G4: 0.2%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Immune system disorders</p></td><td colspan="3" style="vertical-align:top"><p>Hypersensitivity (G3/4: 5.3%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td colspan="3" style="vertical-align:top"><p>Anorexia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Nervous system disorders</p></td><td colspan="3" style="vertical-align:top"><p>Peripheral sensory neuropathy (G3: 4.1%);</p><p>Peripheral motor neuropathy (G3/4: 4%);</p><p>Dysgeusia (severe: 0.07%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Cardiac disorders</p></td><td colspan="2" style="vertical-align:top"><p>Arrhythmia (G3/4: 0.7%)</p></td><td colspan="2" style="vertical-align:top"><p>Cardiac failure</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Vascular disorders</p></td><td colspan="3" style="vertical-align:top"><p>Hypotension;</p><p>Hypertension;</p><p>Haemorrhage</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td colspan="3" style="vertical-align:top"><p>Dyspnoea (severe: 2.7%)</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td colspan="2" style="vertical-align:top"><p>Stomatitis (G3/4: 5.3%);</p><p>Diarrhoea (G3/4: 4%);</p><p>Nausea (G3/4: 4%);</p><p>Vomiting (G3/4: 3%)</p></td><td colspan="2" style="vertical-align:top"><p>Constipation (severe: 0.2%);</p><p>Abdominal pain (severe: 1%);</p><p>Gastrointestinal haemorrhage (severe: 0.3%)</p></td><td style="vertical-align:top"><p>Oesophagitis (severe: 0.4%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td colspan="3" style="vertical-align:top"><p>Alopecia;</p><p>Skin reaction (G3/4: 5.9%);</p><p>Nail disorders (severe: 2.6%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td colspan="2" style="vertical-align:top"><p>Myalgia (severe: 1.4%)</p></td><td colspan="2" style="vertical-align:top"><p>Arthralgia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td colspan="2" style="vertical-align:top"><p>Fluid retention (severe: 6.5%);</p><p>Asthenia (severe: 11.2%);</p><p>Pain</p></td><td colspan="2" style="vertical-align:top"><p>Infusion site reaction;</p><p>Non-cardiac chest pain (severe: 0.4%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Investigations</p></td><td colspan="3" style="vertical-align:top"><p>G3/4 Blood bilirubin increased (&lt; 5%);</p><p>G3/4 Blood Alkaline Phosphatase increased (&lt; 4%);</p><p>G3/4 AST increased (&lt; 3%);</p><p>G3/4 ALT increased (&lt; 2%)</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>Description of selected adverse reactions in breast cancer for Docetaxel 100mg/m2 single agent</p><p>Blood and lymphatic system disorders<br />Rare: bleeding episodes associated with grade 3/4 thrombocytopenia.</p><p>Nervous system disorders<br />Reversibility data are available among 35.3% of patients who developed neurotoxicity following Docetaxel treatment at 100mg/m&sup2; as single agent. The events were spontaneously reversible within 3 months.<br />Skin and subcutaneous tissue disorders<br />Very rare: one case of alopecia non-reversible at the end of the study. 73% of the cutaneous reactions were reversible within 21 days.<br />General disorders and administration site conditions<br />The median cumulative dose to treatment discontinuation was more than 1,000mg/m2 and the median time to fluid retention reversibility was 16.4 weeks (range 0 to 42 weeks). The onset of moderate and severe retention is delayed (median cumulative dose: 818.9mg/m2) in patients with premedication compared with patients without premedication (median cumulative dose: 489.7mg/m2); however, it has been reported in some patients during the early courses of therapy.<br />Tabulated list of adverse reactions in breast cancer for Docetaxel 75mg/m2 single agent</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA system organ classes </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Very common adverse reactions </strong></p></td><td style="vertical-align:top"><p><strong>Common adverse reactions </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Infections and infestations</p></td><td colspan="2" style="vertical-align:top"><p>Infections (G3/4: 5%)</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td colspan="2" style="vertical-align:top"><p>Neutropenia (G4: 54.2%);</p><p>Anaemia (G3/4: 10.8%);</p><p>Thrombocytopenia (G4: 1.7%)</p></td><td style="vertical-align:top"><p>Febrile neutropenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Immune system disorders</p></td><td colspan="2" style="vertical-align:top"><p>Hypersensitivity (no severe)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td colspan="2" style="vertical-align:top"><p>Anorexia</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td colspan="2" style="vertical-align:top"><p>Peripheral sensory neuropathy (G3/4: 0.8%)</p></td><td style="vertical-align:top"><p>Peripheral motor neuropathy (G3/4: 2.5%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Cardiac disorders</p></td><td colspan="2" style="vertical-align:top"><p>Arrhythmia (no severe)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Vascular disorders</p></td><td colspan="2" style="vertical-align:top"><p>Hypotension</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td colspan="2" style="vertical-align:top"><p>Nausea (G3/4: 3.3%);</p><p>Stomatitis (G3/4: 1.7%);</p><p>Vomiting (G3/4: 0.8%);</p><p>Diarrhoea (G3/4: 1.7%)</p></td><td style="vertical-align:top"><p>Constipation</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td colspan="2" style="vertical-align:top"><p>Alopecia;</p><p>Skin reaction (G3/4: 0.8%)</p></td><td style="vertical-align:top"><p>Nail disorders (severe: 0.8%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td colspan="2" style="vertical-align:top"><p>Myalgia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td colspan="2" style="vertical-align:top"><p>Asthenia (severe: 12.4%);</p><p>Fluid retention (severe: 0.8%);</p><p>Pain</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Investigations</p></td><td colspan="2" style="vertical-align:top"><p>G3/4 Blood bilirubin increased (&lt; 2%)</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>Tabulated list of adverse reactions in breast cancer for Docetaxel 75mg/m2 in combination with Doxorubicin</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA system </strong></p><p><strong>organ classes </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Very common adverse </strong></p><p><strong>reactions </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Common adverse </strong></p><p><strong>reactions </strong></p></td><td style="vertical-align:top"><p><strong>Uncommon adverse </strong></p><p><strong>reactions </strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Infections and infestations</p></td><td colspan="3" style="vertical-align:top"><p>Infection (G3/4: 7.8%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td colspan="3" style="vertical-align:top"><p>Neutropenia (G4: 91.7%);</p><p>Anaemia (G3/4: 9.4%);</p><p>Febrile neutropenia;</p><p>Thrombocytopenia (G4: 0.8%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Immune system disorders</p></td><td colspan="3" style="vertical-align:top"><p>Hypersensitivity (G3/4: 1.2%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td colspan="3" style="vertical-align:top"><p>Anorexia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Nervous system disorders</p></td><td colspan="2" style="vertical-align:top"><p>Peripheral sensory neuropathy (G3: 0.4%)</p></td><td colspan="2" style="vertical-align:top"><p>Peripheral motor neuropathy (G3/4: 0.4%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Cardiac disorders</p></td><td colspan="3" style="vertical-align:top"><p>Cardiac failure;</p><p>Arrhythmia (no severe)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Vascular disorders</p></td><td colspan="3" style="vertical-align:top"><p>Hypotension</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td colspan="3" style="vertical-align:top"><p>Nausea (G3/4: 5%);</p><p>Stomatitis (G3/4: 7.8%);</p><p>Diarrhoea (G3/4: 6.2%);</p><p>Vomiting (G3/4: 5%);</p><p>Constipation</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td colspan="3" style="vertical-align:top"><p>Alopecia;</p><p>Nail disorders (severe: 0.4%);</p><p>Skin reaction (no severe)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td colspan="3" style="vertical-align:top"><p>Myalgia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td colspan="2" style="vertical-align:top"><p>Asthenia (severe: 8.1%);</p><p>Fluid retention (severe: 1.2%);</p><p>Pain</p></td><td colspan="2" style="vertical-align:top"><p>Infusion site reaction</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Investigations</p></td><td colspan="2" style="vertical-align:top"><p>G3/4 Blood bilirubin increased (&lt; 2.5%);</p><p>G3/4 Blood Alkaline Phosphatase increased (&lt; 2.5%)</p></td><td colspan="2" style="vertical-align:top"><p>G3/4 AST increased (&lt; 1%);</p><p>G3/4 ALT increased (&lt; 1%)</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>Tabulated list of adverse reactions in breast cancer for Docetaxel 75mg/m2 in combination with Cisplatin</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA system </strong></p><p><strong>organ classes </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Very common adverse </strong></p><p><strong>reactions </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Common adverse </strong></p><p><strong>reactions </strong></p></td><td style="vertical-align:top"><p><strong>Uncommon adverse </strong></p><p><strong>reactions </strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Infections and infestations</p></td><td colspan="3" style="vertical-align:top"><p>Infection (G3/4: 5.7%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td colspan="2" style="vertical-align:top"><p>Neutropenia (G4: 51.5%);</p><p>Anaemia (G3/4: 6.9%);</p><p>Thrombocytopenia (G4: 0.5%)</p></td><td colspan="2" style="vertical-align:top"><p>Febrile neutropenia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Immune system disorders</p></td><td colspan="3" style="vertical-align:top"><p>Hypersensitivity (G3/4:</p><p>2.5%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td colspan="3" style="vertical-align:top"><p>Anorexia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Nervous system disorders</p></td><td colspan="3" style="vertical-align:top"><p>Peripheral sensory neuropathy (G3: 3.7%);</p><p>Peripheral motor neuropathy (G3/4: 2%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Cardiac disorders</p></td><td colspan="2" style="vertical-align:top"><p>Arrhythmia (G3/4: 0.7%)</p></td><td colspan="2" style="vertical-align:top"><p>Cardiac failure</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Vascular disorders</p></td><td colspan="3" style="vertical-align:top"><p>Hypotension (G3/4: 0.7%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td colspan="2" style="vertical-align:top"><p>Nausea (G3/4: 9.6%);</p><p>Vomiting (G3/4: 7.6%);</p><p>Diarrhoea (G3/4: 6.4%);</p><p>Stomatitis (G3/4: 2%)</p></td><td colspan="2" style="vertical-align:top"><p>Constipation</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td colspan="3" style="vertical-align:top"><p>Alopecia;</p><p>Nail disorders (severe: 0.7%);</p><p>Skin reaction (G3/4: 0.2%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td colspan="3" style="vertical-align:top"><p>Myalgia (severe: 0.5%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td colspan="2" style="vertical-align:top"><p>Asthenia (severe: 9.9%);</p><p>Fluid retention (severe: 0.7%);</p><p>Fever (G3/4: 1.2%)</p></td><td colspan="2" style="vertical-align:top"><p>Infusion site reaction;</p><p>Pain</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Investigations</p></td><td colspan="2" style="vertical-align:top"><p>G3/4 Blood bilirubin increased (2.1%);</p><p>G3/4 ALT increased (1.3%)</p></td><td colspan="2" style="vertical-align:top"><p>G3/4 AST increased (0.5%);</p><p>G3/4 Blood Alkaline Phosphatase increased (0.3%)</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>Tabulated list of adverse reactions in breast cancer for Docetaxel 100mg/m2 in combination with Trastuzumab</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA system organ classes </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Very common adverse </strong></p><p><strong>reactions </strong></p></td><td style="vertical-align:top"><p><strong>Common adverse reactions </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td colspan="2" style="vertical-align:top"><p>Neutropenia (G3/4: 32%);</p><p>Febrile neutropenia (includes neutropenia associated with fever and antibiotic use) or neutropenic sepsis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td colspan="2" style="vertical-align:top"><p>Anorexia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Psychiatric disorders</p></td><td colspan="2" style="vertical-align:top"><p>Insomnia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Nervous system disorders</p></td><td colspan="2" style="vertical-align:top"><p>Paresthesia; Headache;</p><p>Dysgeusia; hypoesthesia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Eye disorders</p></td><td colspan="2" style="vertical-align:top"><p>Lacrimation increased;</p><p>Conjunctivitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Cardiac disorders</p></td><td colspan="2" style="vertical-align:top"><p>Cardiac failure</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Vascular disorders</p></td><td colspan="2" style="vertical-align:top"><p>Lymphoedema</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td colspan="2" style="vertical-align:top"><p>Epistaxis; Pharyngolaryngeal pain; Nasopharyngitis; Dyspnoea;</p><p>Cough; Rhinorrhoea</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td colspan="2" style="vertical-align:top"><p>Nausea; Diarrhoea; Vomiting;</p><p>Constipation; Stomatitis;</p><p>Dyspepsia; Abdominal pain</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td colspan="2" style="vertical-align:top"><p>Alopecia; Erythema; Rash; Nail disorders</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td colspan="2" style="vertical-align:top"><p>Myalgia; Arthralgia; Pain in extremity; Bone pain; Back pain</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td colspan="2" style="vertical-align:top"><p>Asthenia; Oedema peripheral;</p><p>Pyrexia; Fatigue; Mucosal inflammation; Pain; Influenza like illness; Chest pain; Chills</p></td><td style="vertical-align:top"><p>Lethargy</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Investigations</p></td><td colspan="2" style="vertical-align:top"><p>Weight increased</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>Description of selected adverse reactions in breast cancer for Docetaxel 100mg/m2 in combination with Trastuzumab<br />Blood and lymphatic system disorders<br />Very common: Haematological toxicity was increased in patients receiving Trastuzumab and Docetaxel, compared with Docetaxel alone (32% grade 3/4 neutropenia versus 22%, using NCI-CTC criteria). Note that this is likely to be an underestimate since Docetaxel alone at a dose of 100mg/m2 is known to result in neutropenia in 97% of patients, 76% grade 4, based on nadir blood counts. The incidence of febrile neutropenia/neutropenic sepsis was also increased in patients treated with Herceptin plus Docetaxel (23% versus 17% for patients treated with Docetaxel alone).<br />Cardiac disorders<br />Symptomatic cardiac failure was reported in 2.2% of the patients who received Docetaxel plus Trastuzumab compared to 0% of patients given Docetaxel alone. In the Docetaxel plus Trastuzumab arm, 64% had received a prior Anthracycline as adjuvant therapy compared with 55% in the Docetaxel arm alone.</p><p>Tabulated list of adverse reactions in breast cancer for Docetaxel 75mg/m2 in combination with Capecitabine</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA system organ classes </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Very common adverse </strong></p><p><strong>reactions </strong></p></td><td style="vertical-align:top"><p><strong>Common adverse reactions </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Infections and infestations</p></td><td colspan="2" style="vertical-align:top"><p>Oral candidiasis (G3/4: &lt; 1%)</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td colspan="2" style="vertical-align:top"><p>Neutropenia (G3/4: 63%);</p><p>Anaemia (G3/4: 10%)</p></td><td style="vertical-align:top"><p>Thrombocytopenia (G3/4: 3%)</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td colspan="2" style="vertical-align:top"><p>Anorexia (G3/4: 1%);</p><p>Decreased appetite</p></td><td style="vertical-align:top"><p>Dehydration (G3/4: 2%)</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td colspan="2" style="vertical-align:top"><p>Dysgeusia (G3/4: &lt; 1%);</p><p>Paraesthesia (G3/4: &lt; 1%)</p></td><td style="vertical-align:top"><p>Dizziness;</p><p>Headache (G3/4: &lt; 1%);</p><p>Neuropathy peripheral</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Eye disorders</p></td><td colspan="2" style="vertical-align:top"><p>Lacrimation increased</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td colspan="2" style="vertical-align:top"><p>Pharyngolaryngeal pain (G3/4: 2%)</p></td><td style="vertical-align:top"><p>Dyspnoea (G3/4: 1%);</p><p>Cough (G3/4: &lt; 1%);</p><p>Epistaxis (G3/4: &lt; 1%)</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td colspan="2" style="vertical-align:top"><p>Stomatitis (G3/4: 18%);</p><p>Diarrhoea (G3/4: 14%);</p><p>Nausea (G3/4: 6%);</p><p>Vomiting (G3/4: 4%); Constipation (G3/4: 1%);</p><p>Abdominal pain (G3/4: 2%);</p><p>Dyspepsia</p></td><td style="vertical-align:top"><p>Abdominal pain upper;</p><p>Dry mouth</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td colspan="2" style="vertical-align:top"><p>Hand-foot syndrome (G3/4: 24%);</p><p>Alopecia (G3/4: 6%);</p><p>Nail disorders (G3/4: 2%)</p></td><td style="vertical-align:top"><p>Dermatitis;</p><p>Rash erythematous (G3/4: &lt; 1%);</p><p>Nail discolouration;</p><p>Onycholysis (G3/4: 1%)</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td colspan="2" style="vertical-align:top"><p>Myalgia (G3/4: 2%);</p><p>Arthralgia (G3/4: 1%)</p></td><td style="vertical-align:top"><p>Pain in extremity (G3/4: &lt; 1%);</p><p>Back pain (G3/4: 1%)</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td colspan="2" style="vertical-align:top"><p>Asthenia (G3/4: 3%);</p><p>Pyrexia (G3/4: 1%);</p><p>Fatigue/weakness (G3/4: 5%);</p><p>Oedema peripheral (G3/4: 1%)</p></td><td style="vertical-align:top"><p>Lethargy;</p><p>Pain</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Investigations</p></td><td colspan="2" style="vertical-align:top"><p>Weight decreased;</p><p>G3/4 Blood bilirubin increased (9%)</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>Tabulated list of adverse reactions in breast cancer for Docetaxel 75mg/m2 in combination with Prednisone or Prednisolone</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA system organ classes </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Very common adverse </strong></p><p><strong>reactions </strong></p></td><td style="vertical-align:top"><p><strong>Common adverse reactions </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Infections and infestations</p></td><td colspan="2" style="vertical-align:top"><p>Infection (G3/4: 3.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td colspan="2" style="vertical-align:top"><p>Neutropenia (G3/4: 32%);</p><p>Anaemia (G3/4: 4.9%)</p></td><td style="vertical-align:top"><p>Thrombocytopenia (G3/4: 0.6%);</p><p>Febrile neutropenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Immune system disorders</p></td><td colspan="2" style="vertical-align:top"><p>Hypersensitivity (G3/4: 0.6%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td colspan="2" style="vertical-align:top"><p>Anorexia (G3/4: 0.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td colspan="2" style="vertical-align:top"><p>Peripheral sensory neuropathy (G3/4: 1.2%);</p><p>Dysgeusia (G3/4: 0%)</p></td><td style="vertical-align:top"><p>Peripheral motor neuropathy (G3/4: 0%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Eye disorders</p></td><td colspan="2" style="vertical-align:top"><p>Lacrimation increased (G3/4: 0.6%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Cardiac disorders</p></td><td colspan="2" style="vertical-align:top"><p>Cardiac left ventricular function decrease (G3/4: 0.3%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td colspan="2" style="vertical-align:top"><p>Epistaxis (G3/4: 0%);</p><p>Dyspnoea (G3/4: 0.6%);</p><p>Cough (G3/4: 0%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td colspan="2" style="vertical-align:top"><p>Nausea (G3/4: 2.4%);</p><p>Diarrhoea (G3/4: 1.2%);</p><p>Stomatitis/Pharyngitis (G3/4: 0.9%);</p><p>Vomiting (G3/4: 1.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td colspan="2" style="vertical-align:top"><p>Alopecia;</p><p>Nail disorders (no severe)</p></td><td style="vertical-align:top"><p>Exfoliative rash (G3/4: 0.3%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Musculoskeletal and connective bone disorders</p></td><td colspan="2" style="vertical-align:top"><p>Arthralgia (G3/4: 0.3%);</p><p>Myalgia (G3/4: 0.3%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td colspan="2" style="vertical-align:top"><p>Fatigue (G3/4: 3.9%);</p><p>Fluid retention (severe: 0.6%)</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>Tabulated list of adverse reactions in breast cancer for adjuvant therapy with Docetaxel 75mg/m2 in combination with Doxorubicin and Cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer - pooled data</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA System </strong></p><p><strong>Organ classes </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Very common adverse reactions </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Common adverse reactions </strong></p></td><td style="vertical-align:top"><p><strong>Uncommon adverse reactions </strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Infections and infestations</p></td><td colspan="3" style="vertical-align:top"><p>Infection (G3/4: 2.4%);</p><p>Neutropenic infection (G3/4: 2.6%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td colspan="3" style="vertical-align:top"><p>Anaemia (G3/4: 3%);</p><p>Neutropenia (G3/4: 59.2%); Thrombocytopenia (G3/4: 1.6%);</p><p>Febrile neutropenia (G3/4: NA)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Immune system disorders</p></td><td colspan="3" style="vertical-align:top"><p>Hypersensitivity (G3/4: 0.6%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td colspan="3" style="vertical-align:top"><p>Anorexia (G3/4: 1.5%)</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td colspan="2" style="vertical-align:top"><p>Dysgeusia (G3/4: 0.6%);</p><p>Peripheral sensory neuropathy (G3/4: &lt;0.1%)</p></td><td colspan="2" style="vertical-align:top"><p>Peripheral motor neuropathy (G3/4: 0%)</p></td><td style="vertical-align:top"><p>Syncope (G3/4: 0%);</p><p>Neurotoxicity (G3/4: 0%);</p><p>Somnolence (G3/4: 0%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Eye disorders</p></td><td colspan="2" style="vertical-align:top"><p>Conjunctivitis (G3/4: &lt;0.1%)</p></td><td colspan="2" style="vertical-align:top"><p>Lacrimation increased (G3/4: &lt;0.1%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Cardiac disorders</p></td><td colspan="3" style="vertical-align:top"><p>Arrhythmia (G3/4: 0.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td colspan="2" style="vertical-align:top"><p>Hot flush (G3/4: 0.5%)</p></td><td colspan="2" style="vertical-align:top"><p>Hypotension (G3/4: 0%);</p><p>Phlebitis (G3/4: 0%)</p></td><td style="vertical-align:top"><p>Lymphoedema (G3/4: 0%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td colspan="3" style="vertical-align:top"><p>Cough (G3/4: 0%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td colspan="2" style="vertical-align:top"><p>Nausea (G3/4: 5.0%);</p><p>Stomatitis (G3/4: 6.0%);</p><p>Vomiting (G3/4: 4.2%);</p><p>Diarrhoea (G3/4: 3.4%);</p><p>Constipation (G3/4: 0.5%)</p></td><td colspan="2" style="vertical-align:top"><p>Abdominal pain (G3/4: 0.4%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td colspan="3" style="vertical-align:top"><p>Alopecia ( persisting: &lt;3%);</p><p>Skin disorder (G3/4: 0.6%);</p><p>Nail disorders (G3/4: 0.4%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td colspan="3" style="vertical-align:top"><p>Myalgia (G3/4: 0.7%);</p><p>Arthralgia (G3/4: 0.2%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td colspan="3" style="vertical-align:top"><p>Amenorrhoea (G3/4: NA)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td colspan="3" style="vertical-align:top"><p>Asthenia (G3/4: 10.0%);</p><p>Pyrexia (G3/4: NA);</p><p>Oedema peripheral (G3/4: 0.2%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Investigations</p></td><td colspan="3" style="vertical-align:top"><p>Weight increased (G3/4: 0%);</p><p>Weight decreased (G3/4;0.2%)</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>Description of selected adverse reactions for adjuvant therapy with Docetaxel 75mg/m&sup2; in combination with Doxorubicin and Cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer<br />Nervous system disorders<br />In study TAX316 peripheral sensory neuropathy started during the treatment period and persisted into the follow-up period in 84 patients (11.3%) in TAC arm and 15 patients (2 %) in FAC arm. At the end of the follow-up period (median follow-up time of 8 years), peripheral sensory neuropathy was observed to be ongoing in 10 patients (1.3%) in TAC arm, and in 2 patients (0.3%) in FAC arm.<br />In GEICAM 9805 study peripheral sensory neuropathy that started during the treatment period persisted into the follow-up period in 10 patients (1.9%) in TAC arm and 4 patients (0.8 %) in FAC arm. At the end of the follow-up period (median follow-up time of 10 years and 5 months), peripheral sensory neuropathy was observed to be ongoing in 3 patients (0.6%) in TAC arm, and in 1 patient (0.2%) in FAC arm.</p><p>Cardiac disorders<br />In study TAX316, 26 patients (3.5%) in the TAC arm and 17 patients (2.3%) in the FAC arm experienced congestive heart failure. All except one patient in each arm were diagnosed with CHF more than 30 days after the treatment period. Two patients in the TAC arm and 4 patients in the FAC arm died because of cardiac failure.<br />In GEICAM 9805 study, 3 patients (0.6 %) in TAC arm and 3 patients (0.6 %) in FAC arm developed congestive heart failure during the follow-up period. At the end of the follow-up period (actual median follow-up time of 10 years and 5 months), no patients had CHF in TAC arm and 1 patient in TAC arm died because of dilated cardiomyopathy, and CHF was observed to be ongoing in 1 patient (0.2%) in FAC arm.<br />Skin and subcutaneous tissue disorders<br />In study TAX316, alopecia persisting into the follow-up period after the end of chemotherapy was reported in 687 of 744 TAC patients (92.3%) and 645 of 736 FAC patients (87.6%).<br />At the end of the follow-up period (actual median follow-up time of 8 years), alopecia was observed to be ongoing in 29 TAC patients (3.9%) and 16 FAC patients (2.2%).</p><p>In GEICAM 9805 study alopecia that started during the treatment period and persisted into the follow-up period was observed to be ongoing in 49 patients (9.2 %) in TAC arm and 35 patients (6.7 %) in FAC arm. Alopecia related to study drug started or worsened during the follow-up period in 42 patients (7.9 %) in TAC arm and 30 patients (5.8 %) in FAC arm. At the end of the follow-up period (median follow-up time of 10 years and 5 months), alopecia was observed to be ongoing in 3 patients (0.6%) in TAC arm, and in 1 patient (0.2%) in FAC arm.<br />Reproductive system and breast disorders<br />In TAX316 amenorrhoea that started during the treatment period and persisted into the follow-up period after the end of chemotherapy was reported in 202 of 744 TAC patients (27.2%) and 125 of 736 FAC patients (17.0%). Amenorrhea was observed to be ongoing at the end of the follow-up period (median follow-up time of 8 years) in 121 of 744 TAC patients (16.3%) and 86 FAC patients (11.7%).<br />In GEICAM 9805 study amenorrhoea that started during the treatment period and persisted into the follow-up period was observed to be ongoing in 18 patients (3.4 %) in TAC arm and 5 patients (1.0 %) in FAC arm. At the end of the follow-up period (median follow-up time of 10 years and 5 months), amenorrhoea was observed to be ongoing in 7 patients (1.3%) in TAC arm, and in 4 patients (0.8%) in FAC arm.</p><p>General disorders and administration site conditions<br />In study TAX316 peripheral oedema that started during the treatment period and persisted into the follow-up period after the end of chemotherapy was observed in 119 of 744 TAC patients (16.0%) and 23 of 736 FAC patients (3.1%). At the end of the follow-up period (actual median follow-up time of 8 years), peripheral oedema was ongoing in19 TAC patients (2.6%) and 4 FAC patients (0.5%).</p><p>In study TAX316 lymphoedema that started during the treatment period and persisted into the follow-up period after the end of chemotherapy was reported in 11 of 744 TAC patients (1.5%) and 1 of 736 FAC patients (0.1%). At the end of the follow-up period (actual median follow-up time of 8 years), lymphoedema was observed to be ongoing in 6 TAC patients (0.8%) and 1 FAC patient (0.1%).<br />In study TAX316 asthenia that started during the treatment period and persisted into the follow-up period after the end of chemotherapy was reported in 236 of 744 TAC patients (31.7%) and 180 of 736 FAC patients (24.5%). At the end of the follow-up period (actual median follow-up time of 8 years), asthenia was observed to be ongoing in 29 TAC patients (3.9%) and 16 FAC patients (2.2%).</p><p>In study GEICAM 9805 peripheral oedema that started during the treatment period persisted into the follow-up period in 4 patients (0.8%) in TAC arm and in 2 patients (0.4%) in FAC arm. At the end of the follow-up period (median follow-up time of 10 years and 5 months), no patients (0%) in TAC arm had peripheral oedema and it was observed to be ongoing in 1 patient (0.2%) in FAC arm. Lymphoedema that started during the treatment period persisted into the follow-up period in 5 patients (0.9%) in TAC arm and 2 patients (0.4 %) in FAC arm. At the end of the follow-up period, lymphoedema was observed to be ongoing in 4 patients (0.8%) in TAC arm, and in 1 patient (0.2%) in FAC arm.<br />Asthenia that started during the treatment period and persisted into the follow-up period was observed to be ongoing in 12 patients (2.3 %) in TAC arm and 4 patients (0.8 %) in FAC arm. At the end of the follow-up period, asthenia was observed to be ongoing in 2 patients (0.4%) in TAC arm, and in 2 patients (0.4%) in FAC arm.</p><p>Acute leukaemia / Myelodysplastic syndrome<br />After 10 years of follow up in study TAX316, acute leukaemia was reported in 3 of 744 TAC patients (0.4%) and in 1 of 736 FAC patients (0.1%). One TAC patient (0.1%) and 1 FAC patient (0.1%) died due to AML during the follow-up period (median follow-up time of 8 years). Myelodysplastic syndrome was reported in 2 of 744 TAC patients (0.3%) and in 1 of 736 FAC patients (0.1%). After 10 years of follow-up in GEICAM 9805 study acute leukaemia occurred in 1 of 532 (0.2%) patients in TAC arm No cases were reported in patients in FAC arm No patient was diagnosed with myelodysplastic syndrome in either treatment groups.<br />Neutropenic complications<br />Table below shows that the incidence of Grade 4 neutropenia, febrile neutropenia and neutropenic infection was decreased in patients who received primary G-CSF prophylaxis after it was made mandatory in the TAC arm-GEICAM study.</p><p>Neutropenic complications in patients receiving TAC with or without primary G-CSF prophylaxis (GEICAM 9805)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Without primary </strong></p><p><strong>G-CSF prophylaxis </strong></p><p><strong>(n = 111) </strong></p><p><strong>n (%) </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>With primary </strong></p><p><strong>G-CSF prophylaxis </strong></p><p><strong>(n = 421) </strong></p><p><strong>n (%) </strong></p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia (Grade 4)</p></td><td colspan="2" style="vertical-align:top"><p>104 (93.7)</p></td><td style="vertical-align:top"><p>135 (32.1)</p></td></tr><tr><td style="vertical-align:top"><p>Febrile neutropenia</p></td><td colspan="2" style="vertical-align:top"><p>28 (25.2)</p></td><td style="vertical-align:top"><p>23 (5.5)</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenic infection</p></td><td colspan="2" style="vertical-align:top"><p>14 (12.6)</p></td><td style="vertical-align:top"><p>21 (5.0)</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenic infection</p><p>(Grade 3-4)</p></td><td colspan="2" style="vertical-align:top"><p>2 (1.8)</p></td><td style="vertical-align:top"><p>5 (1.2)</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>Tabulated list of adverse reactions in gastric adenocarcinoma cancer for Docetaxel 75mg/m2 in combination with Cisplatin and 5-Fluorouracil</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA system organ classes </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Very common adverse </strong></p><p><strong>reactions </strong></p></td><td style="vertical-align:top"><p><strong>Common adverse reactions </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Infections and infestations</p></td><td colspan="2" style="vertical-align:top"><p>Neutropenic infection;</p><p>Infection (G3/4: 11.7%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td colspan="2" style="vertical-align:top"><p>Anaemia (G3/4: 20.9%);</p><p>Neutropenia (G3/4: 83.2%);</p><p>Thrombocytopenia (G3/4: 8.8%);</p><p>Febrile neutropenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Immune system disorders</p></td><td colspan="2" style="vertical-align:top"><p>Hypersensitivity (G3/4: 1.7%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td colspan="2" style="vertical-align:top"><p>Anorexia (G3/4: 11.7%)</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td colspan="2" style="vertical-align:top"><p>Peripheral sensory neuropathy (G3/4: 8.7%)</p></td><td style="vertical-align:top"><p>Dizziness (G3/4: 2.3%);</p><p>Peripheral motor neuropathy (G3/4: 1.3%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Eye disorders</p></td><td colspan="2" style="vertical-align:top"><p>Lacrimation increased (G3/4:</p><p>0%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td colspan="2" style="vertical-align:top"><p>Hearing impaired (G3/4: 0%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Cardiac disorders</p></td><td colspan="2" style="vertical-align:top"><p>Arrhythmia (G3/4: 1.0%)</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td colspan="2" style="vertical-align:top"><p>Diarrhoea (G3/4: 19.7%);</p><p>Nausea (G3/4: 16%);</p><p>Stomatitis (G3/4: 23.7%);</p><p>Vomiting (G3/4: 14.3%)</p></td><td style="vertical-align:top"><p>Constipation (G3/4: 1.0%);</p><p>Gastrointestinal pain (G3/4: 1.0%);</p><p>Oesophagitis/dysphagia/odynophagia (G3/4: 0.7%)</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td colspan="2" style="vertical-align:top"><p>Alopecia (G3/4: 4.0%)</p></td><td style="vertical-align:top"><p>Rash pruritus (G3/4: 0.7%);</p><p>Nail disorders (G3/4: 0.7%);</p><p>Skin exfoliation (G3/4: 0%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td colspan="2" style="vertical-align:top"><p>Lethargy (G3/4: 19.0%);</p><p>Fever (G3/4: 2.3%);</p><p>Fluid retention (severe/life- threatening: 1%)</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>Description of selected adverse reactions in gastric adenocarcinoma cancer for Docetaxel 75mg/m2 in combination with Cisplatin and 5-Fluorouracil<br />Blood and lymphatic system disorders<br />Febrile neutropenia and neutropenic infection occurred in 17.2% and 13.5% of patients respectively, regardless of G-CSF use. G-CSF was used for secondary prophylaxis in 19.3% of patients (10.7% of the cycles). Febrile neutropenia and neutropenic infection occurred respectively in 12.1% and 3.4% of patients when patients received prophylactic G-CSF, in 15.6% and 12.9% of patients without prophylactic G-CSF (see section 4.2).<br />Tabulated list of adverse reactions in head and neck cancer for Docetaxel 75mg/m2 in combination with Cisplatin and 5-Fluorouracil<br />&bull; Induction chemotherapy followed by radiotherapy (TAX 323)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA system </strong></p><p><strong>organ classes </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Very common adverse </strong></p><p><strong>reactions </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Common adverse </strong></p><p><strong>reactions </strong></p></td><td style="vertical-align:top"><p><strong>Uncommon adverse </strong></p><p><strong>reactions </strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Infections and infestations</p></td><td colspan="3" style="vertical-align:top"><p>Infection (G3/4: 6.3%); Neutropenic infection</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</p></td><td colspan="3" style="vertical-align:top"><p>Cancer pain (G3/4: 0.6%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td colspan="2" style="vertical-align:top"><p>Neutropenia (G3/4: 76.3%);</p><p>Anaemia (G3/4: 9.2%);</p><p>Thrombocytopenia (G3/4: 5.2%)</p></td><td colspan="2" style="vertical-align:top"><p>Febrile neutropenia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Immune system disorders</p></td><td colspan="3" style="vertical-align:top"><p>Hypersensitivity (no severe)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td colspan="3" style="vertical-align:top"><p>Anorexia (G3/4: 0.6%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Nervous system disorders</p></td><td colspan="2" style="vertical-align:top"><p>Dysgeusia/Parosmia;</p><p>Peripheral sensory neuropathy (G3/4: 0.6%)</p></td><td colspan="2" style="vertical-align:top"><p>Dizziness</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Eye disorders</p></td><td colspan="3" style="vertical-align:top"><p>Lacrimation increased;</p><p>Conjunctivitis</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td colspan="3" style="vertical-align:top"><p>Hearing impaired</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Cardiac disorders</p></td><td colspan="2" style="vertical-align:top"><p>Myocardial ischemia (G3/4:1.7%)</p></td><td colspan="2" style="vertical-align:top"><p>Arrhythmia (G3/4: 0.6%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Vascular disorders</p></td><td colspan="3" style="vertical-align:top"><p>Venous disorder (G3/4: 0.6%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td colspan="2" style="vertical-align:top"><p>Nausea (G3/4: 0.6%);</p><p>Stomatitis (G3/4: 4.0%);</p><p>Diarrhoea (G3/4: 2.9%);</p><p>Vomiting (G3/4: 0.6%)</p></td><td colspan="2" style="vertical-align:top"><p>Constipation;</p><p>Esophagitis/dysphagia/ odynophagia (G3/4: 0.6%);</p><p>Abdominal pain;</p><p>Dyspepsia;</p><p>Gastrointestinal haemorrhage (G3/4: 0.6%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td colspan="2" style="vertical-align:top"><p>Alopecia (G3/4: 10.9%)</p></td><td colspan="2" style="vertical-align:top"><p>Rash pruritic;</p><p>Dry skin;</p><p>Skin exfoliative (G3/4: 0.6%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td colspan="3" style="vertical-align:top"><p>Myalgia (G3/4: 0.6%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td colspan="3" style="vertical-align:top"><p>Lethargy (G3/4: 3.4%);</p><p>Pyrexia (G3/4: 0.6%);</p><p>Fluid retention;</p><p>Oedema</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Investigations</p></td><td colspan="3" style="vertical-align:top"><p>Weight increased</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&bull; Induction chemotherapy followed by chemoradiotherapy (TAX 324)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA system organ classes </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Very common adverse reactions </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Common adverse reactions </strong></p></td><td style="vertical-align:top"><p><strong>Uncommon adverse reactions </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Infections and infestations</p></td><td colspan="2" style="vertical-align:top"><p>Infection (G3/4: 3.6%)</p></td><td colspan="2" style="vertical-align:top"><p>Neutropenic infection</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</p></td><td colspan="3" style="vertical-align:top"><p>Cancer pain (G3/4: 1.2%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td colspan="3" style="vertical-align:top"><p>Neutropenia (G3/4: 83.5%);</p><p>Anaemia (G3/4: 12.4%);</p><p>Thrombocytopenia (G3/4: 4.0%);</p><p>Febrile neutropenia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Immune system disorders</p></td><td colspan="3" style="vertical-align:top"><p>Hypersensitivity</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td colspan="3" style="vertical-align:top"><p>Anorexia (G3/4: 12.0%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Nervous system disorders</p></td><td colspan="2" style="vertical-align:top"><p>Dysgeusia/Parosmia (G3/4: 0.4%);</p><p>Peripheral sensory neuropathy (G3/4: 1.2%)</p></td><td colspan="2" style="vertical-align:top"><p>Dizziness (G3/4: 2.0%);</p><p>Peripheral motor neuropathy (G3/4: 0.4%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Eye disorders</p></td><td colspan="2" style="vertical-align:top"><p>Lacrimation increased</p></td><td colspan="2" style="vertical-align:top"><p>Conjunctivitis</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td colspan="3" style="vertical-align:top"><p>Hearing impaired (G3/4: 1.2%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Cardiac disorders</p></td><td colspan="2" style="vertical-align:top"><p>Arrhythmia (G3/4: 2.0%)</p></td><td colspan="2" style="vertical-align:top"><p>Ischemia myocardial</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Vascular disorders</p></td><td colspan="3" style="vertical-align:top"><p>Venous disorder</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td colspan="2" style="vertical-align:top"><p>Nausea (G3/4: 13.9%);</p><p>Stomatitis (G3/4: 20.7%);</p><p>Vomiting (G3/4: 8.4%);</p><p>Diarrhoea (G3/4: 6.8%);</p><p>Esophagitis/dysphagia/ odynophagia (G3/4: 12.0%);</p><p>Constipation (G3/4: 0.4%)</p></td><td colspan="2" style="vertical-align:top"><p>Dyspepsia (G3/4: 0.8%);</p><p>Gastrointestinal pain (G3/4: 1.2%);</p><p>Gastrointestinal haemorrhage (G3/4: 0.4%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td colspan="2" style="vertical-align:top"><p>Alopecia (G3/4: 4.0%);</p><p>Rash pruritic</p></td><td colspan="2" style="vertical-align:top"><p>Dry skin;</p><p>Desquamation</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Musculoskeletal, connective tissue bone disorders</p></td><td colspan="3" style="vertical-align:top"><p>Myalgia (G3/4: 0.4%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td colspan="3" style="vertical-align:top"><p>Lethargy (G3/4: 4.0%);</p><p>Pyrexia (G3/4: 3.6%);</p><p>Fluid retention (G3/4: 1.2%);</p><p>Oedema (G3/4: 1.2%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Investigations</p></td><td colspan="2" style="vertical-align:top"><p>Weight decreased</p></td><td colspan="2" style="vertical-align:top"><p>Weight increased</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>Post-marketing experience<br />Neoplasms benign, malignant and unspecified (incl cysts and polyps)<br />Cases of acute myeloid leukaemia and myelodysplastic syndrome have been reported in association with Docetaxel when used in combination with other chemotherapy agents and/or radiotherapy.</p><p>Blood and lymphatic system disorders<br />Bone marrow suppression and other haematologic adverse reactions have been reported. Disseminated intravascular coagulation (DIC), often in association with sepsis or multiorgan failure, has been reported.<br />Immune system disorders<br />Some cases of anaphylactic shock, sometimes fatal, have been reported.<br />Hypersensitivity reactions (frequency not known) have been reported with Docetaxel in patients who previously experienced hypersensitivity reactions to Paclitaxel.<br />Nervous system disorders<br />Rare cases of convulsion or transient loss of consciousness have been observed with Docetaxel administration. These reactions sometimes appear during the infusion of the medicinal product.<br />Eye disorders<br />Very rare cases of transient visual disturbances (flashes, flashing lights, scotomata) typically occurring during infusion of the medicinal product and in association with hypersensitivity reactions have been reported. These were reversible upon discontinuation of the infusion. Cases of lacrimation with or without conjunctivitis, as cases of lacrimal duct obstruction resulting in excessive tearing have been rarely reported. Cases of cystoid macular oedema (CMO) have been reported in patients treated with Docetaxel.<br />Ear and labyrinth disorders<br />Rare cases of ototoxicity, hearing impaired and/or hearing loss have been reported.<br />Cardiac disorders<br />Rare cases of myocardial infarction have been reported.</p><p>Ventricular arrhythmia including ventricular tachycardia (frequency not known), sometimes fatal, has been reported in patients treated with Docetaxel in combination regimens including Doxorubicin, 5-Fluorouracil and/ or Cyclophosphamide.<br />Vascular disorders<br />Venous thromboembolic events have rarely been reported.</p><p>Respiratory, thoracic and mediastinal disorders<br />Acute respiratory distress syndrome and cases of interstitial pneumonia/ pneumonitis, interstitial lung<br />disease, pulmonary fibrosis and respiratory failure sometimes fatal have rarely been reported. Rare cases of radiation pneumonitis have been reported in patients receiving concomitant radiotherapy.<br />Gastrointestinal disorders<br />Rare occurrences of dehydration as a consequence of gastrointestinal events, gastrointestinal perforation, colitis ischaemic, colitis and neutropenic enterocolitis have been reported. Rare cases of ileus and intestinal obstruction have been reported.<br />Hepatobiliary disorders<br />Very rare cases of hepatitis, sometimes fatal primarily in patients with pre-existing liver disorders, have been reported.<br />Skin and subcutaneous tissue disorders<br />Very rare cases of cutaneous lupus erythematosus and bullous eruptions such as erythema multiforme,</p><p>Stevens-Johnson syndrome, toxic epidermal necrolysis, have been reported with Docetaxel. In some cases concomitant factors may have contributed to the development of these effects. Sclerodermal-like changes usually preceded by peripheral lymphoedema have been reported with Docetaxel. Cases of persisting alopecia have been reported.<br />Renal and urinary disorders<br />Renal insufficiency and renal failure have been reported. In about 20% of these cases there were no risk factors for acute renal failure such as concomitant nephrotoxic medicinal products and gastrointestinal disorders.<br />General disorders and administration site conditions<br />Radiation recall phenomena have rarely been reported.<br />Fluid retention has not been accompanied by acute episodes of oliguria or hypotension. Dehydration and pulmonary oedema have rarely been reported.<br />Metabolism and nutrition disorders<br />Cases of hyponatraemia have been reported, mostly associated with dehydration, vomiting and pneumonia. Hypokalaemia, hypomagnesaemia, and hypocalcaemia were observed, usually in association with gastrointestinal disorders and in particular with diarrhoea.<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.<br />To report any side effect(s) in Saudi Arabia, please contact:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There were a few reports of overdose. There is no known antidote for Docetaxel overdose. In case of overdose, the patient should be kept in a specialized unit and vital functions closely monitored. In cases of overdose, exacerbation of adverse events may be expected. The primary anticipated complications of overdose would consist of bone marrow suppression, peripheral neurotoxicity and mucositis. Patients should receive therapeutic G-CSF as soon as possible after discovery of overdose. Other appropriate symptomatic measures should be taken, as needed.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group<br />Taxanes, ATC Code: L01CD02</p><p>Mechanism of action</p><p>Docetaxel is an antineoplastic agent which acts by promoting the assembly of tubulin into stable microtubules and inhibits their disassembly which leads to a marked decrease of free tubulin. The binding of Docetaxel to microtubules does not alter the number of protofilaments.<br />Docetaxel has been shown in vitro to disrupt the microtubular network in cells which is essential for vital mitotic and interphase cellular functions.<br />Pharmacodynamic effects<br />Docetaxel was found to be cytotoxic in vitro against various murine and human tumour cell lines and against freshly excised human tumour cells in clonogenic assays. Docetaxel achieves high intracellular concentrations with a long cell residence time. In addition, Docetaxel was found to be active on some but not all cell lines over expressing the p-glycoprotein which is encoded by the multidrug resistance gene. In vivo, Docetaxel is schedule independent and has a broad spectrum of experimental antitumour activity against advanced murine and human grafted tumours.<br />Clinical efficacy and safety<br />Breast cancer<br />Docetaxel in combination with Doxorubicin and Cyclophosphamide: adjuvant therapy</p><p>Patients with operable node-positive breast cancer (TAX 316)<br />Data from a multicentre open label randomized study support the use of Docetaxel for the adjuvant treatment of patients with operable node-positive breast cancer and KPS &ge; 80%, between 18 and 70 years of age. After stratification according to the number of positive lymph nodes (1-3, 4+), 1491 patients were randomized to receive either Docetaxel 75mg/m2 administered 1-hour after Doxorubicin 50mg/m2 and Cyclophosphamide 500mg/m2 (TAC arm), or Doxorubicin 50mg/m2 followed by Fluorouracil 500mg/m2 and Cyclophosphamide 500mg/m2 (FAC arm). Both regimens were administered once every 3 weeks for 6 cycles. Docetaxel was administered as a 1-hour infusion, all other medicinal products were given as intravenous bolus on day one. G-CSF was administered as secondary prophylaxis to patients who experienced complicated neutropenia (febrile neutropenia, prolonged neutropenia, or infection). Patients on the TAC arm received antibiotic prophylaxis with Ciprofloxacin 500mg orally twice daily for 10 days starting on day 5 of each cycle, or equivalent. In both arms, after the last cycle of chemotherapy, patients with positive estrogen and/or progesterone receptors received Tamoxifen 20mg daily for up to 5 years. Adjuvant radiation therapy was prescribed according to guidelines in place at participating institutions and was given to 69% of patients who received TAC and 72% of patients who received FAC. Two interim analyses and one final analysis were performed. The first interim analysis was planned 3 years after the date when half of study enrollment was done. The second interim analysis was done after 400 DFS events had been recorded overall, which led to a median follow up of 55 months. The final analysis was performed when all patients had reached their 10-year follow up visit (unless they had a DFS event or were lost to follow up before). Disease-free survival (DFS) was the primary efficacy endpoint and Overall survival (OS) was the secondary efficacy endpoint.</p><p>Patients with operable node-positive breast cancer (TAX 316)<br />Data from a multicentre open label randomized study support the use of Docetaxel for the adjuvant treatment of patients with operable node-positive breast cancer and KPS &ge; 80%, between 18 and 70 years of age. After stratification according to the number of positive lymph nodes (1-3, 4+), 1491 patients were randomized to receive either Docetaxel 75mg/m2 administered 1-hour after Doxorubicin 50mg/m2 and Cyclophosphamide 500mg/m2 (TAC arm), or Doxorubicin 50mg/m2 followed by Fluorouracil 500mg/m2 and Cyclophosphamide 500mg/m2 (FAC arm). Both regimens were administered once every 3 weeks for 6 cycles. Docetaxel was administered as a 1-hour infusion, all other medicinal products were given as intravenous bolus on day one. G-CSF was administered as secondary prophylaxis to patients who experienced complicated neutropenia (febrile neutropenia, prolonged neutropenia, or infection). Patients on the TAC arm received antibiotic prophylaxis with Ciprofloxacin 500mg orally twice daily for 10 days starting on day 5 of each cycle, or equivalent. In both arms, after the last cycle of chemotherapy, patients with positive estrogen and/or progesterone receptors received Tamoxifen 20mg daily for up to 5 years. Adjuvant radiation therapy was prescribed according to guidelines in place at participating institutions and was given to 69% of patients who received TAC and 72% of patients who received FAC. Two interim analyses and one final analysis were performed. The first interim analysis was planned 3 years after the date when half of study enrollment was done. The second interim analysis was done after 400 DFS events had been recorded overall, which led to a median follow up of 55 months. The final analysis was performed when all patients had reached their 10-year follow up visit (unless they had a DFS event or were lost to follow up before). Disease-free survival (DFS) was the primary efficacy endpoint and Overall survival (OS) was the secondary efficacy endpoint.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Disease</strong>-<strong>free survival </strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Overall survival </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Patient subset </strong></p></td><td style="vertical-align:top"><p><strong>Number of </strong></p><p><strong>patients </strong></p></td><td style="vertical-align:top"><p><strong>Hazard </strong></p><p><strong>ratio* </strong></p></td><td style="vertical-align:top"><p><strong>95% CI </strong></p></td><td style="vertical-align:top"><p><strong>p = </strong></p></td><td style="vertical-align:top"><p><strong>Hazard </strong></p><p><strong>ratio* </strong></p></td><td style="vertical-align:top"><p><strong>95% CI </strong></p></td><td style="vertical-align:top"><p><strong>p = </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>No of positive </strong></p><p><strong>nodes </strong></p><p>Overall</p><p>1-3</p><p>4+</p></td><td style="vertical-align:top"><p>745</p><p>467</p><p>278</p></td><td style="vertical-align:top"><p>0.80</p><p>0.72</p><p>0.87</p></td><td style="vertical-align:top"><p>0.68-0.93</p><p>0.58-0.91</p><p>0.70-1.09</p></td><td style="vertical-align:top"><p>0.0043</p><p>0.0047</p><p>0.2290</p></td><td style="vertical-align:top"><p>0.74</p><p>0.62</p><p>0.87</p></td><td style="vertical-align:top"><p>0.61-0.90</p><p>0.46-0.82</p><p>0.67-1.12</p></td><td style="vertical-align:top"><p>0.0020</p><p>0.0008</p><p>0.2746</p></td></tr></tbody></table><p>*a hazard ratio of less than 1 indicates that TAC is associated with a longer disease-free survival and overall survival compared to FAC</p><p>Patients with operable node-negative breast cancer eligible to receive chemotherapy (GEICAM 9805)<br />Data from a multicentre open label randomized trial support the use of Docetaxel for the adjuvant treatment of patients with operable node-negative breast cancer eligible to receive chemotherapy.<br />1060 patients were randomized to receive either Docetaxel 75mg/m2 administered 1-hour after Doxorubicin 50mg/m2 and Cyclophosphamide 500mg/m2 (539 patients in TAC arm), or Doxorubicin 50mg/m2 followed by Fluorouracil 500mg/m2 and Cyclophosphamide 500mg/m2 (521 patients in FAC arm), as adjuvant treatment of operable node-negative breast cancer patients with high risk of relapse according to 1998 St. Gallen criteria (tumour size &gt;2 cm and/or negative ER and PR and/or high histological/nuclear grade (grade 2 to 3) and /or age &lt;35 years).). Both regimens were administered once every 3 weeks for 6 cycles. Docetaxel was administered as a 1-hour infusion, all other medicinal products were given intravenously on day 1 every three weeks. Primary prophylactic G-CSF was made mandatory in TAC arm after 230 patients were randomized. The incidence of Grade 4 neutropenia, febrile neutropenia and neutropenic infection was decreased in patients who received primary G-CSF prophylaxis (see section 4.8). In both arms, after the last cycle of chemotherapy, patients with ER+ and/or PgR+ tumours received Tamoxifen 20mg once a day for up to 5 years. Adjuvant radiation therapy was administered according to guidelines in place at participating institutions and was given to 57.3% of patients who received TAC and 51.2% of patients who received FAC.<br />Median duration of follow up was 77 months. Significantly longer disease-free survival for the TAC arm compared to the FAC arm was demonstrated. TAC-treated patients had a 32% reduction in the risk of relapse compared to those treated with FAC (hazard ratio = 0.68, 95% CI (0.49-0.93), p = 0.01). Overall survival (OS) was also longer in the TAC arm with TAC-treated patients having a 24% reduction in the risk of death compared to FAC (hazard ratio = 0.76, 95% CI (0.46-1.26, p = 0.29). However, the distribution of OS was not significantly different between the 2 groups.<br />TAC-treated patient subsets according to prospectively defined major prognostic factors were analyzed (see table below):<br />Subset Analyses-Adjuvant Therapy in Patients with Node-negative Breast Cancer Study<br />(Intent-to-Treat Analysis)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Patient subset </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Number of patients in TAC group </strong></p></td><td style="vertical-align:top"><p><strong>Disease</strong>-<strong>Free Survival </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hazard ratio* </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>95% CI </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall </strong></p></td><td style="vertical-align:top"><p>539</p></td><td style="vertical-align:top"><p>0.68</p></td><td style="vertical-align:top"><p>0.49-0.93</p></td></tr><tr><td style="vertical-align:top"><p><strong>Age category 1 </strong></p><p>&lt;50 years</p><p>&ge;50 years</p></td><td style="vertical-align:top"><p>260</p><p>279</p></td><td style="vertical-align:top"><p>0.67</p><p>0.67</p></td><td style="vertical-align:top"><p>0.43-1.05</p><p>0.43-1.05</p></td></tr><tr><td style="vertical-align:top"><p><strong>Age category 2 </strong></p><p>&lt;35 years</p><p>&ge;35 years</p></td><td style="vertical-align:top"><p>42</p><p>497</p></td><td style="vertical-align:top"><p>0.31</p><p>0.73</p></td><td style="vertical-align:top"><p>0.11-0.89</p><p>0.52-1.01</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Hormonal receptor status </strong></p><p>Negative</p><p>Positive</p></td><td style="vertical-align:top"><p>195</p><p>344</p></td><td style="vertical-align:top"><p>0.7</p><p>0.62</p></td><td style="vertical-align:top"><p>0.45-1.1</p><p>0.4-0.97</p></td></tr><tr><td style="vertical-align:top"><p><strong>Tumour size </strong></p><p>&le; 2 cm</p><p>&gt;2 cm</p></td><td style="vertical-align:top"><p>285</p><p>254</p></td><td style="vertical-align:top"><p>0.69</p><p>0.68</p></td><td style="vertical-align:top"><p>0.43-1.1</p><p>0.45-1.04</p></td></tr><tr><td style="vertical-align:top"><p><strong>Histological grade </strong></p><p>Grade1 (includes grade not assessed)</p><p>Grade 2</p><p>Grade 3</p></td><td style="vertical-align:top"><p>64</p><p>216</p><p>259</p></td><td style="vertical-align:top"><p>0.79</p><p>0.77</p><p>0.59</p></td><td style="vertical-align:top"><p>0.24-2.6</p><p>0.46-1.3</p><p>0.39-0.9</p></td></tr><tr><td style="vertical-align:top"><p><strong>Menopausal status </strong></p><p>Pre-Menopausal</p><p>Post-Menopausal</p></td><td style="vertical-align:top"><p>285</p><p>254</p></td><td style="vertical-align:top"><p>0.64</p><p>0.72</p></td><td style="vertical-align:top"><p>0.40-1</p><p>0.47-1.12</p></td></tr></tbody></table><p>*a hazard ratio (TAC/FAC) of less than 1 indicates that TAC is associated with a longer disease-free survival compared to FAC.<br />Exploratory subgroup analyses for disease-free survival for patients who meet the 2009 St. Gallen chemotherapy criteria &ndash; (ITT population) were performed and presented here below:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Subgroups </strong></p></td><td style="vertical-align:top"><p><strong>TAC </strong></p><p>(n=539)</p></td><td style="vertical-align:top"><p><strong>FAC </strong></p><p>(n=521)</p></td><td style="vertical-align:top"><p><strong>Hazard ratio </strong></p><p><strong>(TAC/FAC) </strong></p><p>(95% CI)</p></td><td style="vertical-align:top"><p><strong>p-value </strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Meeting relative indication</p><p>for chemotherapy a</p></td></tr><tr><td style="vertical-align:top"><p>No</p></td><td style="vertical-align:top"><p>18/214</p><p>(8.4%)</p></td><td style="vertical-align:top"><p>26/227</p><p>(11.5%)</p></td><td style="vertical-align:top"><p>0.796 (0.434 - 1.459)</p></td><td style="vertical-align:top"><p>0.4593</p></td></tr><tr><td style="vertical-align:top"><p>Yes</p></td><td style="vertical-align:top"><p>48/325</p><p>(14.8%)</p></td><td style="vertical-align:top"><p>69/294</p><p>(23.5%)</p></td><td style="vertical-align:top"><p>0.606 (0.42 - 0.877)</p></td><td style="vertical-align:top"><p>0.0072</p></td></tr></tbody></table><p>TAC = Docetaxel, Doxorubicin and Cyclophosphamide<br />FAC = 5-Fluorouracil, Doxorubicin and Cyclophosphamide<br />CI = confidence interval; ER = estrogen receptor<br />PR = progesterone receptor<br />a ER/PR-negative or Grade 3 or tumour size &gt;5 cm<br />The estimated hazard ratio was using Cox proportional hazard model with treatment group as the factor.<br />Docetaxel as single agent<br />Two randomized phase III comparative studies, involving a total of 326 alkylating or 392 Anthracycline failure metastatic breast cancer patients, have been performed with Docetaxel at the recommended dose and regimen of 100mg/m2 every 3 weeks.<br />In alkylating-failure patients, Docetaxel was compared to Doxorubicin (75mg/m2 every 3 weeks). Without affecting overall survival time (Docetaxel 15 months vs. Doxorubicin 14 months, p = 0.38) or time to progression (Docetaxel 27 weeks vs. Doxorubicin 23 weeks, p = 0.54), Docetaxel increased response rate (52% vs. 37%, p = 0.01) and shortened time to response (12 weeks vs. 23 weeks, p = 0.007). Three Docetaxel patients (2%) discontinued the treatment due to fluid retention, whereas 15 Doxorubicin patients (9%) discontinued due to cardiac toxicity (three cases of fatal congestive heart failure).</p><p>In Anthracycline-failure patients, Docetaxel was compared to the combination of Mitomycin C and Vinblastine (12mg/m2 every 6 weeks and 6mg/m2 every 3 weeks). Docetaxel increased response rate (33% vs. 12%, p &lt; 0.0001), prolonged time to progression (19 weeks vs. 11 weeks, p = 0.0004) and prolonged overall survival (11 months vs. 9 months, p = 0.01).<br />During these two phase III studies, the safety profile of Docetaxel was consistent with the safety profile observed in phase II studies (see section 4.8).<br />An open-label, multicentre, randomized phase III study was conducted to compare Docetaxel monotherapy and Paclitaxel in the treatment of advanced breast cancer in patients whose previous therapy should have included an Anthracycline. A total of 449 patients were randomized to receive either Docetaxel monotherapy 100mg/m2 as a 1-hour infusion or Paclitaxel 175mg/m2 as a 3 hour infusion. Both regimens were administered every 3 weeks.<br />Without affecting the primary endpoint, overall response rate (32% vs 25%, p = 0.10), Docetaxel prolonged median time to progression (24.6 weeks vs 15.6 weeks; p &lt; 0.01) and median survival (15.3 months vs 12.7 months; p = 0.03).<br />More grade 3/4 adverse events were observed for Docetaxel monotherapy (55.4%) compared to paclitaxel (23.0%).<br />Docetaxel in combination with Doxorubicin<br />One large randomized phase III study, involving 429 previously untreated patients with metastatic disease, has been performed with Doxorubicin (50mg/m2) in combination with Docetaxel (75mg/m2) (AT arm) versus Doxorubicin (60mg/m2) in combination with Cyclophosphamide (600mg/m2) (AC arm). Both regimens were administered on day 1 every 3 weeks.<br />&bull; Time to progression (TTP) was significantly longer in the AT arm versus AC arm, p = 0.0138. The median TTP was 37.3 weeks (95% CI: 33.4 - 42.1) in AT arm and 31.9 weeks (95% CI: 27.4-36.0) in AC arm.<br />&bull; Overall response rate (ORR) was significantly higher in the AT arm versus AC arm, p = 0.009. The ORR was 59.3% (95% CI: 52.8 - 65.9) in AT arm versus 46.5% (95% CI: 39.8 - 53.2) in AC arm.</p><p>In this study, AT arm showed a higher incidence of severe neutropenia (90% versus 68.6%), febrile neutropenia (33.3% versus 10%), infection (8% versus 2.4%), diarrhoea (7.5% versus 1.4%), asthenia (8.5% versus 2.4%), and pain (2.8% versus 0%) than AC arm. On the other hand, AC arm showed a higher incidence of severe anaemia (15.8% versus 8.5%) than AT arm, and, in addition, a higher incidence of severe cardiac toxicity: congestive heart failure (3.8% versus 2.8%), absolute LVEF decrease &ge; 20% (13.1% versus 6.1%), absolute LVEF decrease &ge; 30% (6.2% versus 1.1%). Toxic deaths occurred in 1 patient in the AT arm (congestive heart failure) and in 4 patients in the AC arm (1 due to septic shock and 3 due to congestive heart failure).<br />In both arms, quality of life measured by the EORTC questionnaire was comparable and stable during treatment and follow up.</p><p>Docetaxel in combination with Trastuzumab<br />Docetaxel in combination with Trastuzumab was studied for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2, and who previously had not received chemotherapy for metastatic disease. One hundred eighty six patients were randomized to receive Docetaxel (100mg/m2) with or without Trastuzumab; 60% of patients received prior Anthracycline-based adjuvant chemotherapy. Docetaxel plus Trastuzumab was efficacious in patients whether or not they had received prior adjuvant Anthracycline. The main test method used to determine HER2 positivity in this pivotal study was immunohistochemistry (IHC). A minority of patients were tested using fluorescence in-situ hybridization (FISH). In this study, 87% of patients had disease that was IHC 3+, and 95% of patients entered had disease that was IHC 3+ and/or FISH positive. Efficacy results are summarized in the following table:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Parameter</p></td><td style="vertical-align:top"><p>Docetaxel plus Trastuzumab1</p><p>n = 92</p></td><td style="vertical-align:top"><p>Docetaxel1</p><p>n = 94</p></td></tr><tr><td style="vertical-align:top"><p>Response rate</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>61%</p><p>(50-71)</p></td><td style="vertical-align:top"><p>34%</p><p>(25-45)</p></td></tr><tr><td style="vertical-align:top"><p>Median duration of response</p><p>(months)</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>11.4</p><p>(9.2-15.0)</p></td><td style="vertical-align:top"><p>5.1</p><p>(4.4-6.2)</p></td></tr><tr><td style="vertical-align:top"><p>Median TTP (months)</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>10.6</p><p>(7.6-12.9)</p></td><td style="vertical-align:top"><p>5.7</p><p>(5.0-6.5)</p></td></tr><tr><td style="vertical-align:top"><p>Median survival (months)</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>30.52</p><p>(26.8-ne)</p></td><td style="vertical-align:top"><p>22.12</p><p>(17.6-28.9)</p></td></tr></tbody></table><p>TTP = time to progression; &ldquo;ne&rdquo; indicates that it could not be estimated or it was not yet reached.<br />1Full analysis set (intent-to-treat)<br />2Estimated median survival</p><p>Docetaxel in combination with Capecitabine<br />Data from one multicentre, randomized, controlled phase III clinical study support the use of Docetaxel in combination with Capecitabine for treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy, including an Anthracycline. In this study, 255 patients were randomized to treatment with Docetaxel (75mg/m2 as a 1-hour intravenous infusion every 3 weeks) and Capecitabine (1250mg/m2 twice daily for 2 weeks followed by 1-week rest period). 256 patients were randomized to treatment with Docetaxel alone (100mg/m2 as a 1-hour intravenous infusion every 3 weeks). Survival was superior in the Docetaxel + Capecitabine combination arm (p = 0.0126). Median survival was 442 days (Docetaxel + Capecitabine) vs. 352 days (Docetaxel alone). The overall objective response rates in the all- randomized population (investigator assessment) were 41.6% (Docetaxel + Capecitabine) vs. 29.7% (Docetaxel alone); p = 0.0058. Time to progressive disease was superior in the Docetaxel + Capecitabine combination arm (p &lt; 0.0001). The median time to progression was 186 days (Docetaxel + Capecitabine) vs. 128 days (Docetaxel alone).</p><p>Non small cell lung cancer<br />Patients previously treated with chemotherapy with or without radiotherapy<br />In a phase III study, in previously treated patients, time to progression (12.3 weeks versus 7 weeks) and overall survival were significantly longer for Docetaxel at 75mg/m2 compared to Best Supportive Care. The 1-year survival rate was also significantly longer in Docetaxel (40%) versus BSC (16%). There was less use of morphinic analgesic (p &lt; 0.01), non-morphinic analgesics (p &lt; 0.01), other disease-related medicinal products (p = 0.06) and radiotherapy (p &lt; 0.01) in patients treated with Docetaxel at 75mg/m2 compared to those with BSC.<br />The overall response rate was 6.8% in the evaluable patients, and the median duration of response was 26.1 weeks.</p><p>Docetaxel in combination with platinum agents in chemotherapy-na&iuml;ve patients<br />In a phase III study, 1218 patients with unresectable stage IIIB or IV NSCLC, with KPS of 70% or greater, and who did not receive previous chemotherapy for this condition, were randomized to either Docetaxel (T) 75mg/m2 as a 1-hour infusion immediately followed by Cisplatin (Cis) 75mg/m2 over 30-60 minutes every 3 weeks (TCis), Docetaxel 75mg/m2 as a 1-hour infusion in combination with Carboplatin (AUC 6mg/ml.min) over 30-60 minutes every 3 weeks, or Vinorelbine (V) 25mg/m2 administered over 6-10 minutes on days 1, 8, 15, 22 followed by Cisplatin 100mg/m2 administered on day 1 of cycles repeated every 4 weeks (VCis).<br />Survival data, median time to progression and response rates for two arms of the study are illustrated in the following table:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>TCis</p><p>n = 408</p></td><td colspan="2" style="vertical-align:top"><p>VCis</p><p>n = 404</p></td><td style="vertical-align:top"><p>Statistical analysis</p></td></tr><tr><td style="vertical-align:top"><p>Overall survival</p><p>(Primary end-point):</p><p>Median survival (months)</p><p>1-year Survival (%)</p><p>2-year Survival (%)</p></td><td style="vertical-align:top"><p>11.3</p><p>46</p><p>21</p></td><td style="vertical-align:top"><p>10.1</p><p>41</p><p>14</p></td><td style="vertical-align:top"><p>Hazard Ratio: 1.122</p><p>[97.2% CI: 0.937; 1.342]* Treatment difference: 5.4%</p><p>[95% CI: -1.1; 12.0]</p><p>Treatment difference: 6.2%</p><p>[95% CI: 0.2; 12.3]</p></td></tr><tr><td style="vertical-align:top"><p>Median time to progression</p><p>(weeks):</p></td><td style="vertical-align:top"><p>22.0</p></td><td style="vertical-align:top"><p>23.0</p></td><td style="vertical-align:top"><p>Hazard Ratio: 1.032</p><p>[95% CI: 0.876; 1.216]</p></td></tr><tr><td style="vertical-align:top"><p>Overall response rate (%):</p></td><td style="vertical-align:top"><p>31.6</p></td><td style="vertical-align:top"><p>24.5</p></td><td style="vertical-align:top"><p>Treatment difference: 7.1%</p><p>[95% CI: 0.7; 13.5]</p></td></tr></tbody></table><p>*: Corrected for multiple comparisons and adjusted for stratification factors (stage of disease and region of treatment), based on evaluable patient population.<br />Secondary end-points included change of pain, global rating of quality of life by EuroQoL-5D, Lung Cancer Symptom Scale, and changes in Karnosfky performance status. Results on these end-points were supportive of the primary end-points results.<br />For Docetaxel/Carboplatin combination, neither equivalent nor non-inferior efficacy could be proven compared to the reference treatment combination VCis.<br />Prostate cancer<br />The safety and efficacy of Docetaxel in combination with Prednisone or Prednisolone in patients with hormone refractory metastatic prostate cancer were evaluated in a randomized multicentre phase III study. A total of 1006 patients with KPS &ge; 60 were randomized to the following treatment groups:<br />&bull; Docetaxel 75mg/m2 every 3 weeks for 10 cycles.<br />&bull; Docetaxel 30mg/m2 administered weekly for the first 5 weeks in a 6 week cycle for 5 cycles.<br />&bull; Mitoxantrone 12mg/m2 every 3 weeks for 10 cycles.<br />All 3 regimens were administered in combination with prednisone or prednisolone 5 mg twice daily, continuously.<br />Patients who received Docetaxel every three weeks demonstrated significantly longer overall survival compared to those treated with Mitoxantrone. The increase in survival seen in the Docetaxel weekly arm was not statistically significant compared to the Mitoxantrone control arm. Efficacy endpoints for the Docetaxel arms versus the control arm are summarized in the following table:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Endpoint</p></td><td style="vertical-align:top"><p>Docetaxel</p><p>every 3 weeks</p></td><td style="vertical-align:top"><p>Docetaxel</p><p>every week</p></td><td style="vertical-align:top"><p>Mitoxantrone</p><p>every 3 weeks</p></td></tr><tr><td style="vertical-align:top"><p>Number of patients</p><p>Median survival (months)</p><p>95% CI</p><p>Hazard ratio</p><p>95% CI</p><p>p-value&dagger;*</p></td><td style="vertical-align:top"><p>335</p><p>18.9</p><p>(17.0-21.2)</p><p>0.761</p><p>(0.619-0.936)</p><p>0.0094</p></td><td style="vertical-align:top"><p>334</p><p>17.4</p><p>(15.7-19.0)</p><p>0.912</p><p>(0.747-1.113)</p><p>0.3624</p></td><td style="vertical-align:top"><p>337</p><p>16.5</p><p>(14.4-18.6)</p><p>--</p><p>--</p><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Number of patients</p><p>PSA** response rate (%)</p></td><td style="vertical-align:top"><p>291</p><p>45.4</p></td><td style="vertical-align:top"><p>282</p><p>47.9</p></td><td style="vertical-align:top"><p>300</p><p>31.7</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>95% CI</p><p>p-value*</p></td><td style="vertical-align:top"><p>(39.5-51.3)</p><p>0.0005</p></td><td style="vertical-align:top"><p>(41.9-53.9)</p><p>&lt;0.0001</p></td><td style="vertical-align:top"><p>(26.4-37.3)</p><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Number of patients</p><p>Pain response rate (%)</p><p>95% CI</p><p>p-value*</p></td><td style="vertical-align:top"><p>153</p><p>34.6</p><p>(27.1-42.7)</p><p>0.0107</p></td><td style="vertical-align:top"><p>154</p><p>31.2</p><p>(24.0-39.1)</p><p>0.0798</p></td><td style="vertical-align:top"><p>157</p><p>21.7</p><p>(15.5-28.9)</p><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Number of patients</p><p>Tumour response rate (%)</p><p>95% CI</p><p>p-value*</p></td><td style="vertical-align:top"><p>141</p><p>12.1</p><p>(7.2-18.6)</p><p>0.1112</p></td><td style="vertical-align:top"><p>134</p><p>8.2</p><p>(4.2-14.2)</p><p>0.5853</p></td><td style="vertical-align:top"><p>137</p><p>6.6</p><p>(3.0-12.1)</p></td></tr></tbody></table><p>Stratified log rank test<br />*Threshold for statistical significance = 0.0175<br />**PSA: Prostate-Specific Antigen</p><p>Given the fact that Docetaxel every week presented a slightly better safety profile than Docetaxel every 3 weeks, it is possible that certain patients may benefit from Docetaxel every week.<br />No statistical differences were observed between treatment groups for Global Quality of Life.<br />Gastric adenocarcinoma<br />A multicentre, open-label, randomized study was conducted to evaluate the safety and efficacy of Docetaxel for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who had not received prior chemotherapy for metastatic disease. A total of 445 patients with KPS &gt; 70 were treated with either Docetaxel (T) (75mg/m2 on day 1) in combination with Cisplatin (C) (75mg/m2 on day 1) and 5-Fluorouracil (F) (750mg/m2 per day for 5 days) or Cisplatin (100mg/m2 on day 1) and 5-Fluorouracil (1000mg/m2 per day for 5 days). The length of a treatment cycle was 3 weeks for the TCF arm and 4 weeks for the CF arm. The median number of cycles administered per patient was 6 (with a range of 1-16) for the TCF arm compared to 4 (with a range of 1-12) for the CF arm. Time to progression (TTP) was the primary endpoint. The risk reduction of progression was 32.1% and was associated with a significantly longer TTP (p = 0.0004) in favour of the TCF arm. Overall survival was also significantly longer (p = 0.0201) in favour of the TCF arm with a risk reduction of mortality of 22.7%. Efficacy results are summarized in the following table:<br />Efficacy of Docetaxel in the treatment of patients with gastric adenocarcinoma</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint </strong></p></td><td style="vertical-align:top"><p><strong>TCF </strong></p><p>n = 221</p></td><td style="vertical-align:top"><p><strong>CF </strong></p><p>n = 224</p></td></tr><tr><td style="vertical-align:top"><p>Median TTP (months)</p><p>(95% CI)</p><p>Hazard ratio</p><p>(95% CI)</p><p>*p-value</p></td><td style="vertical-align:top"><p>5.6</p><p>(4.86-5.91)</p></td><td style="vertical-align:top"><p>3.7</p><p>(3.45-4.47)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>1.473</p><p>(1.189-1.825)</p><p>0.0004</p></td></tr><tr><td style="vertical-align:top"><p>Median survival (months)</p><p>(95% CI)</p><p>2-year estimate (%)</p><p>Hazard ratio</p><p>(95% CI)</p><p>*p-value</p></td><td style="vertical-align:top"><p>9.2</p><p>(8.38-10.58)</p><p>18.4</p></td><td style="vertical-align:top"><p>8.6</p><p>(7.16-9.46)</p><p>8.8</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>1.293</p><p>(1.041-1.606)</p><p>0.0201</p></td></tr><tr><td style="vertical-align:top"><p>Overall response rate (CR+PR) (%)</p><p>p-value</p></td><td style="vertical-align:top"><p>36.7</p></td><td style="vertical-align:top"><p>25.4</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>0.0106</p></td></tr><tr><td style="vertical-align:top"><p>Progressive disease as best overall response (%)</p></td><td style="vertical-align:top"><p>16.7</p></td><td style="vertical-align:top"><p>25.9</p></td></tr></tbody></table><p>*Unstratified logrank test</p><p>Subgroup analyses across age, gender and race consistently favoured the TCF arm compared to the CF arm.<br />A survival update analysis conducted with a median follow up time of 41.6 months no longer showed a statistically significant difference although always in favour of the TCF regimen and showed that the benefit of TCF over CF is clearly observed between 18 and 30 months of follow up.<br />Overall, quality of life (QoL) and clinical benefit results consistently indicated improvement in favour of the TCF arm. Patients treated with TCF had a longer time to 5% definitive deterioration of global health status on the QLQ-C30 questionnaire (p = 0.0121) and a longer time to definitive worsening of Karnofsky performance status (p = 0.0088) compared to patients treated with CF.<br />Head and neck cancer<br />&bull; Induction chemotherapy followed by radiotherapy (TAX323)<br />The safety and efficacy of Docetaxel in the induction treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) was evaluated in a phase III, multicentre, open-label, randomized study (TAX323). In this study, 358 patients with inoperable locally advanced SCCHN, and WHO performance status 0 or 1, were randomized to one of two treatment arms. Patients on the Docetaxel arm received Docetaxel (T) 75mg/m2 followed by Cisplatin (P) 75mg/m2 followed by 5-Fluorouracil (F) 750mg/m2 per day as a continuous infusion for 5 days. This regimen was administered every three weeks for 4 cycles in case at least a minor response (&ge; 25% reduction in bidimensionally measured tumour size) was observed after 2 cycles. At the end of chemotherapy, with a minimal interval of 4 weeks and a maximal interval of 7 weeks, patients whose disease did not progress received radiotherapy (RT) according to institutional guidelines for 7 weeks (TPF/RT). Patients on the comparator arm received Cisplatin (P) 100mg/m2 followed by 5-Fluorouracil (F) 1000mg/m2 per day for 5 days. This regimen was administered every three weeks for 4 cycles in case at least a minor response (&ge; 25% reduction in bidimensionally measured tumour size) was observed after 2 cycles. At the end of chemotherapy, with a minimal interval of 4 weeks and a maximal interval of 7 weeks, patients whose disease did not progress received radiotherapy (RT) according to institutional guidelines for 7 weeks (PF/RT). Locoregional therapy with radiation was delivered either with a conventional fraction (1.8 Gy - 2.0 Gy once a day, 5 days per week for a total dose of 66 to 70 Gy), or accelerated/hyperfractionated regimens of radiation therapy (twice a day, with a minimum interfraction interval of 6 hours, 5 days per week). A total of 70 Gy was recommended for accelerated regimens and 74 Gy for hyperfractionated schemes. Surgical resection was allowed following chemotherapy, before or after radiotherapy. Patients on the TPF arm received antibiotic prophylaxis with Ciprofloxacin 500mg orally twice daily for 10 days starting on day 5 of each cycle, or equivalent.</p><p>The primary endpoint in this study, progression-free survival (PFS), was significantly longer in the TPF arm compared to the PF arm, p = 0.0042 (median PFS: 11.4 vs. 8.3 months respectively) with an overall median follow up time of 33.7 months. Median overall survival was also significantly longer in favour of the TPF arm compared to the PF arm (median OS: 18.6 vs. 14.5 months respectively) with a 28% risk reduction of mortality, p = 0.0128. Efficacy results are presented in the table below:</p><p>Efficacy of Docetaxel in the induction treatment of patients with inoperable locally advanced SCCHN (Intent-to-Treat Analysis)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint </strong></p></td><td style="vertical-align:top"><p><strong>Docetaxel + </strong></p><p><strong>Cis + 5</strong>-<strong>FU </strong></p><p><strong>n = 177 </strong></p></td><td style="vertical-align:top"><p><strong>Cis + 5</strong>-<strong>FU </strong></p><p><strong>n = 181 </strong></p></td></tr><tr><td style="vertical-align:top"><p>Median progression free survival (months)</p><p>(95% CI)</p><p>Adjusted hazard ratio</p><p>(95% CI)</p><p>*p-value</p></td><td style="vertical-align:top"><p>11.4</p><p>(10.1-14.0)</p></td><td style="vertical-align:top"><p>8.3</p><p>(7.4-9.1)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>0.70</p><p>(0.55-0.89)</p><p>0.0042</p></td></tr><tr><td style="vertical-align:top"><p>Median survival (months)</p><p>(95% CI)</p><p>Hazard ratio</p><p>(95% CI)</p><p>**p-value</p></td><td style="vertical-align:top"><p>18.6</p><p>(15.7-24.0)</p></td><td style="vertical-align:top"><p>14.5</p><p>(11.6-18.7)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>0.72</p><p>(0.56-0.93)</p><p>0.0128</p></td></tr><tr><td style="vertical-align:top"><p>Best overall response to chemotherapy (%)</p><p>(95% CI)</p><p>***p-value</p></td><td style="vertical-align:top"><p>67.8</p><p>(60.4-74.6)</p></td><td style="vertical-align:top"><p>53.6</p><p>(46.0-61.0)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>0.006</p></td></tr><tr><td style="vertical-align:top"><p>Best overall response to study treatment</p><p>[chemotherapy +/- radiotherapy] (%)</p><p>(95% CI)</p><p>***p-value</p></td><td style="vertical-align:top"><p>72.3</p><p>(65.1-78.8)</p></td><td style="vertical-align:top"><p>58.6</p><p>(51.0-65.8)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>0.006</p></td></tr><tr><td style="vertical-align:top"><p>Median duration of response to chemotherapy &plusmn;</p><p>radiotherapy (months)</p><p>(95% CI)</p><p>Hazard ratio</p><p>(95% CI)</p><p>**p-value</p></td><td style="vertical-align:top"><p>n = 128</p><p>15.7</p><p>(13.4-24.6)</p></td><td style="vertical-align:top"><p>n = 106</p><p>11.7</p><p>(10.2-17.4)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>0.72</p><p>(0.52-0.99)</p><p>0.0457</p></td></tr></tbody></table><p>A hazard ratio of less than 1 favours Docetaxel + Cisplatin + 5-FU<br />*Cox model (adjustment for Primary tumour site, T and N clinical stages and PSWHO)<br />**Logrank test<br />*** Chi-square test<br />Quality of life parameters<br />Patients treated with TPF experienced significantly less deterioration of their Global health score compared to those treated with PF (p = 0.01, using the EORTC QLQ-C30 scale).<br />Clinical benefit parameters<br />The performance status scale, for head and neck (PSS-HN) subscales designed to measure understandability of speech, ability to eat in public, and normalcy of diet, was significantly in favour of TPF as compared to PF.<br />Median time to first deterioration of WHO performance status was significantly longer in the TPF arm compared to PF. Pain intensity score improved during treatment in both groups indicating adequate pain management.<br />&bull; Induction chemotherapy followed by chemoradiotherapy (TAX324)<br />The safety and efficacy of Docetaxel in the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) was evaluated in a randomized, multicentre open-label, phase III study (TAX324). In this study, 501 patients, with locally advanced SCCHN, and a WHO performance status of 0 or 1, were randomized to one of two arms. The study population comprised patients with technically unresectable disease, patients with low probability of surgical cure</p><p>and patients aiming at organ preservation. The efficacy and safety evaluation solely addressed survival endpoints and the success of organ preservation was not formally addressed. Patients on the Docetaxel arm received Docetaxel (T) 75mg/m&sup2; by intravenous infusion on day 1 followed by Cisplatin (P) 100mg/m&sup2; administered as a 30-minute to three-hour intravenous infusion, followed by the continuous intravenous infusion of 5-Fluorouracil (F) 1000mg/m&sup2;/day from day 1 to day 4. The cycles were repeated every 3 weeks for 3 cycles. All patients who did not have progressive disease were to receive chemoradiotherapy (CRT) as per protocol (TPF/CRT). Patients on the comparator arm received Cisplatin (P) 100mg/m&sup2; as a 30-minute to three-hour intravenous infusion on day 1 followed by the continuous intravenous infusion of 5-Fluorouracil (F) 1000mg/m&sup2;/day from day 1 to day 5. The cycles were repeated every 3 weeks for 3 cycles. All patients who did not have progressive disease were to receive CRT as per protocol (PF/CRT).<br />Patients in both treatment arms were to receive 7 weeks of CRT following induction chemotherapy with a minimum interval of 3 weeks and no later than 8 weeks after start of the last cycle (day 22 to day 56 of last cycle). During radiotherapy, Carboplatin (AUC 1.5) was given weekly as a one-hour intravenous infusion for a maximum of 7 doses. Radiation was delivered with megavoltage equipment using once daily fractionation (2 Gy per day, 5 days per week for 7 weeks, for a total dose of 70-72 Gy). Surgery on the primary site of disease and/or neck could be considered at anytime following completion of CRT. All patients on the Docetaxel-containing arm of the study received prophylactic antibiotics. The primary efficacy endpoint in this study, overall survival (OS) was significantly longer (log-rank test, p = 0.0058) with the Docetaxel-containing regimen compared to PF (median OS: 70.6 versus 30.1 months respectively), with a 30% risk reduction in mortality compared to PF (hazard ratio (HR) = 0.70, 95% confidence interval (CI) = 0.54-0.90) with an overall median follow up time of 41.9 months. The secondary endpoint, PFS, demonstrated a 29% risk reduction of progression or death and a 22 month improvement in median PFS (35.5 months for TPF and 13.1 for PF). This was also statistically significant with an HR of 0.71; 95% CI 0.56-0.90; log-rank test p = 0.004. Efficacy results are presented in the table below:<br />Efficacy of Docetaxel in the induction treatment of patients with locally advanced SCCHN (Intent-to-Treat Analysis)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint </strong></p></td><td style="vertical-align:top"><p><strong>Docetaxel + Cis + 5</strong>-<strong>FU </strong></p><p><strong>n = 255 </strong></p></td><td style="vertical-align:top"><p><strong>Cis + 5</strong>-<strong>FU </strong></p><p><strong>n = 246 </strong></p></td></tr><tr><td style="vertical-align:top"><p>Median overall survival (months)</p><p>(95% CI)</p><p>Hazard ratio:</p><p>(95% CI)</p><p>*p-value</p></td><td style="vertical-align:top"><p>70.6</p><p>(49.0-NA)</p></td><td style="vertical-align:top"><p>30.1</p><p>(20.9-51.5)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>0.70</p><p>(0.54-0.90)</p><p>0.0058</p></td></tr><tr><td style="vertical-align:top"><p>Median PFS (months)</p><p>(95% CI)</p><p>Hazard ratio:</p><p>(95% CI)</p><p>**p-value</p></td><td style="vertical-align:top"><p>35.5</p><p>(19.3-NA)</p></td><td style="vertical-align:top"><p>13.1</p><p>(10.6 - 20.2)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>0.71</p><p>(0.56 - 0.90)</p><p>0.004</p></td></tr><tr><td style="vertical-align:top"><p>Best overall response (CR + PR) to chemotherapy (%)</p><p>(95% CI)</p><p>***p-value</p></td><td style="vertical-align:top"><p>71.8</p><p>(65.8-77.2)</p></td><td style="vertical-align:top"><p>64.2</p><p>(57.9-70.2)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>0.070</p></td></tr><tr><td style="vertical-align:top"><p>Best overall response (CR + PR) to study</p><p>treatment [chemotherapy +/- chemoradiotherapy] (%)</p><p>(95%CI)</p><p>***p-value</p></td><td style="vertical-align:top"><p>76.5</p><p>(70.8-81.5)</p></td><td style="vertical-align:top"><p>71.5</p><p>(65.5-77.1)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>0.209</p></td></tr></tbody></table><p>hazard ratio of less than 1 favours Docetaxel + Cisplatin + Fluorouracil<br />*un-adjusted log-rank test<br />**un-adjusted log-rank test, not adjusted for multiple comparisons<br />***Chi square test, not adjusted for multiple comparisons<br />NA-not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />The pharmacokinetics of Docetaxel have been evaluated in cancer patients after administration of 20-115mg/m2 in phase I studies. The kinetic profile of Docetaxel is dose independent and consistent with a three-compartment pharmacokinetic model with half-lives for the &alpha;, &beta; and &gamma; phases of 4 min, 36 min and 11.1 h, respectively. The late phase is due, in part, to a relatively slow efflux of Docetaxel from the peripheral compartment.</p><p>Distribution<br />Following the administration of a 100mg/m2 dose given as a one-hour infusion a mean peak plasma level of 3.7&mu;g/ml was obtained with a corresponding AUC of 4.6 h.&mu;g/ml. Mean values for total body clearance and steady-state volume of distribution were 21 l/h/m2 and 113 l, respectively. Inter individual variation in total body clearance was approximately 50%. Docetaxel is more than 95% bound to plasma proteins.</p><p>Elimination<br />A study of 14C-Docetaxel has been conducted in three cancer patients. Docetaxel was eliminated in both the urine and faeces following cytochrome P450-mediated oxidative metabolism of the tert-butyl ester group, within seven days, the urinary and faecal excretion accounted for about 6% and 75% of the administered radioactivity, respectively. About 80% of the radioactivity recovered in faeces is excreted during the first 48 hours as one major inactive metabolite and 3 minor inactive metabolites and very low amounts of unchanged medicinal product.</p><p>Special populations<br />Age and gender<br />A population pharmacokinetic analysis has been performed with Docetaxel in 577 patients. Pharmacokinetic parameters estimated by the model were very close to those estimated from phase I studies. The pharmacokinetics of Docetaxel were not altered by the age or sex of the patient.</p><p>Hepatic impairment<br />In a small number of patients (n = 23) with clinical chemistry data suggestive of mild to moderate liver function impairment (ALT, AST &ge; 1.5 times the ULN associated with Alkaline Phosphatase &ge; 2.5 times the ULN), total clearance was lowered by 27% on average (see section 4.2).</p><p>Fluid retention<br />Docetaxel clearance was not modified in patients with mild to moderate fluid retention and there are no data available in patients with severe fluid retention.<br />Combination therapy<br />Doxorubicin<br />When used in combination, Docetaxel does not influence the clearance of Doxorubicin and the plasma levels of Doxorubicinol (a Doxorubicin metabolite). The pharmacokinetics of Docetaxel, Doxorubicin and Cyclophosphamide were not influenced by their coadministration.<br />Capecitabine<br />Phase I study evaluating the effect of Capecitabine on the pharmacokinetics of Docetaxel and vice versa</p><p>showed no effect by Capecitabine on the pharmacokinetics of Docetaxel (Cmax and AUC) and no effect by Docetaxel on the pharmacokinetics of a relevant Capecitabine metabolite 5&rsquo;-DFUR.<br />Cisplatin<br />Clearance of Docetaxel in combination therapy with Cisplatin was similar to that observed following monotherapy. The pharmacokinetic profile of Cisplatin administered shortly after Docetaxel infusion is similar to that observed with Cisplatin alone.<br />Cisplatin and 5-Fluorouracil<br />The combined administration of Docetaxel, Cisplatin and 5-Fluorouracil in 12 patients with solid tumours had no influence on the pharmacokinetics of each individual medicinal product.<br />Prednisone and Dexamethasone<br />The effect of Prednisone on the pharmacokinetics of Docetaxel administered with standard Dexamethasone premedication has been studied in 42 patients.<br />Prednisone<br />No effect of Prednisone on the pharmacokinetics of Docetaxel was observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The carcinogenic potential of Docetaxel has not been studied.<br />Docetaxel has been shown to be mutagenic in the in vitro micronucleus and chromosome aberration test in CHO-K1 cells and in the in vivo micronucleus test in the mouse. However, it did not induce mutagenicity in the Ames test or the CHO/HGPRT gene mutation assay. These results are consistent with the pharmacological activity of Docetaxel.<br />Undesirable effects on the test is observed in rodent toxicity studies suggest that Docetaxel may impair male fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>6.1 List of excipients<br />Polysorbate 80<br />Ethanol anhydrous<br />Citric acid anhydrous</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial
24 months
After opening of the vial
Each vial is for single use and should be used immediately after opening. If not used immediately, in-use storage times and conditions are the responsibility of the user.
Once added to the infusion bag
From a microbiological point of view, dilution must take place in controlled and aseptic conditions and the medicinal product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.
Once added as recommended into the infusion bag, the Docetaxel infusion solution, if stored below 25°C, is stable for 6 hours. It should be used within 6 hours (including the one-hour infusion intravenous administration). The infusion solution must not be coupled to the infusion set for more than 8 h at 25°C.
In addition, physical and chemical in-use stability of the infusion solution prepared as recommended has been demonstrated in non-PVC bags up to 48 hours when stored between 2° to 8°C.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25&deg;C.<br />Store in the original package in order to protect from light.<br />For storage conditions of the diluted medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clear glass (type I) vial with fluorotec plus (ethylene tetrafluoroethylene film) rubber stopper and aluminium seal and a red flip-off cap, containing 4ml of concentrate.<br />Each box contains one vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Docetaxel is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing Docetaxel Accord solutions. The use of gloves is recommended.<br />If Docetaxel Accord concentrate or infusion solution should come into contact with skin, wash immediately and thoroughly with soap and water. If Docetaxel Accord concentrate or infusion solution should come into contact with mucous membranes, wash immediately and thoroughly with water.<br />Preparation for the intravenous administration<br />Preparation of the infusion solution<br />DO NOT use other Docetaxel medicinal products consisting of 2 vials (concentrate and solvent)<br />with this medicinal product which contains only 1 vial of concentrate. Docetaxel Accord 80mg/4 ml concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution.<br />Each vial is of single use and should be used immediately.<br />If the vials are stored under refrigeration, allow the required number of boxes of Docetaxel Accord concentrate for solution for infusion to stand below 25&deg;C for 5 minutes before use. More than one vial of Docetaxel Accord concentrate for solution for infusion may be necessary to obtain the required dose for the patient.<br />Aseptically withdraw the required amount of Docetaxel Accord concentrate for solution for infusion using a calibrated syringe.<br />In Docetaxel Accord 80mg/4ml vial the concentration of Docetaxel is 20mg/ml.<br />The required volume of Docetaxel Accord concentrate for solution for infusion must be injected via a single injection (one shot) into a 250ml infusion bag containing either 5% glucose solution or sodium chloride 9mg/ml (0.9%) solution for infusion.</p><p>If a dose greater than 190mg of Docetaxel is required, use a larger volume of the infusion vehicle so that a concentration of 0.74mg/ml Docetaxel is not exceeded.<br />Mix the infusion bag manually using a rocking motion.<br />The infusion bag solution should be used within 6 hours below 25&deg;C including the one-hour infusion to the patient.<br />As with all parenteral products, Docetaxel Accord infusion solution should be visually inspected prior to use, solutions containing a precipitate should be discarded.<br />Docetaxel infusion solution is supersaturated and may therefore crystallize over time. If crystals appear, the solution must no longer be used and shall be discarded.<br />Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Accord Healthcare Limited
Sage House, 319 Pinner Road, North Harrow, Middlesex HA1 4HF, United Kingdom
Tel: +44 208 863 1427
Fax: +44 208 863 1426
E-mail: mena-info@accord-healthcare.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                12/2018 (SA)
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="data:image/png; base64,iVBORw0KGgoAAAANSUhEUgAACSMAAAZ2CAIAAADVZbb1AAAKQ2lDQ1BJQ0MgUHJvZmlsZQAAeJydU3dYk/cWPt/3ZQ9WQtjwsZdsgQAiI6wIyBBZohCSAGGEEBJAxYWIClYUFRGcSFXEgtUKSJ2I4qAouGdBiohai1VcOO4f3Ke1fXrv7e371/u855zn/M55zw&#x2B;AERImkeaiagA5UoU8Otgfj09IxMm9gAIVSOAEIBDmy8JnBcUAAPADeXh&#x2B;dLA//AGvbwACAHDVLiQSx&#x2B;H/g7pQJlcAIJEA4CIS5wsBkFIAyC5UyBQAyBgAsFOzZAoAlAAAbHl8QiIAqg0A7PRJPgUA2KmT3BcA2KIcqQgAjQEAmShHJAJAuwBgVYFSLALAwgCgrEAiLgTArgGAWbYyRwKAvQUAdo5YkA9AYACAmUIszAAgOAIAQx4TzQMgTAOgMNK/4KlfcIW4SAEAwMuVzZdL0jMUuJXQGnfy8ODiIeLCbLFCYRcpEGYJ5CKcl5sjE0jnA0zODAAAGvnRwf44P5Dn5uTh5mbnbO/0xaL&#x2B;a/BvIj4h8d/&#x2B;vIwCBAAQTs/v2l/l5dYDcMcBsHW/a6lbANpWAGjf&#x2B;V0z2wmgWgrQevmLeTj8QB6eoVDIPB0cCgsL7SViob0w44s&#x2B;/zPhb&#x2B;CLfvb8QB7&#x2B;23rwAHGaQJmtwKOD/XFhbnauUo7nywRCMW735yP&#x2B;x4V//Y4p0eI0sVwsFYrxWIm4UCJNx3m5UpFEIcmV4hLpfzLxH5b9CZN3DQCshk/ATrYHtctswH7uAQKLDljSdgBAfvMtjBoLkQAQZzQyefcAAJO/&#x2B;Y9AKwEAzZek4wAAvOgYXKiUF0zGCAAARKCBKrBBBwzBFKzADpzBHbzAFwJhBkRADCTAPBBCBuSAHAqhGJZBGVTAOtgEtbADGqARmuEQtMExOA3n4BJcgetwFwZgGJ7CGLyGCQRByAgTYSE6iBFijtgizggXmY4EImFINJKApCDpiBRRIsXIcqQCqUJqkV1II/ItchQ5jVxA&#x2B;pDbyCAyivyKvEcxlIGyUQPUAnVAuagfGorGoHPRdDQPXYCWomvRGrQePYC2oqfRS&#x2B;h1dAB9io5jgNExDmaM2WFcjIdFYIlYGibHFmPlWDVWjzVjHVg3dhUbwJ5h7wgkAouAE&#x2B;wIXoQQwmyCkJBHWExYQ6gl7CO0EroIVwmDhDHCJyKTqE&#x2B;0JXoS&#x2B;cR4YjqxkFhGrCbuIR4hniVeJw4TX5NIJA7JkuROCiElkDJJC0lrSNtILaRTpD7SEGmcTCbrkG3J3uQIsoCsIJeRt5APkE&#x2B;S&#x2B;8nD5LcUOsWI4kwJoiRSpJQSSjVlP&#x2B;UEpZ8yQpmgqlHNqZ7UCKqIOp9aSW2gdlAvU4epEzR1miXNmxZDy6Qto9XQmmlnafdoL&#x2B;l0ugndgx5Fl9CX0mvoB&#x2B;nn6YP0dwwNhg2Dx0hiKBlrGXsZpxi3GS&#x2B;ZTKYF05eZyFQw1zIbmWeYD5hvVVgq9ip8FZHKEpU6lVaVfpXnqlRVc1U/1XmqC1SrVQ&#x2B;rXlZ9pkZVs1DjqQnUFqvVqR1Vu6k2rs5Sd1KPUM9RX6O&#x2B;X/2C&#x2B;mMNsoaFRqCGSKNUY7fGGY0hFsYyZfFYQtZyVgPrLGuYTWJbsvnsTHYF&#x2B;xt2L3tMU0NzqmasZpFmneZxzQEOxrHg8DnZnErOIc4NznstAy0/LbHWaq1mrX6tN9p62r7aYu1y7Rbt69rvdXCdQJ0snfU6bTr3dQm6NrpRuoW623XP6j7TY&#x2B;t56Qn1yvUO6d3RR/Vt9KP1F&#x2B;rv1u/RHzcwNAg2kBlsMThj8MyQY&#x2B;hrmGm40fCE4agRy2i6kcRoo9FJoye4Ju6HZ&#x2B;M1eBc&#x2B;ZqxvHGKsNN5l3Gs8YWJpMtukxKTF5L4pzZRrmma60bTTdMzMyCzcrNisyeyOOdWca55hvtm82/yNhaVFnMVKizaLx5balnzLBZZNlvesmFY&#x2B;VnlW9VbXrEnWXOss623WV2xQG1ebDJs6m8u2qK2brcR2m23fFOIUjynSKfVTbtox7PzsCuya7AbtOfZh9iX2bfbPHcwcEh3WO3Q7fHJ0dcx2bHC866ThNMOpxKnD6VdnG2ehc53zNRemS5DLEpd2lxdTbaeKp26fesuV5RruutK10/Wjm7ub3K3ZbdTdzD3Ffav7TS6bG8ldwz3vQfTw91jicczjnaebp8LzkOcvXnZeWV77vR5Ps5wmntYwbcjbxFvgvct7YDo&#x2B;PWX6zukDPsY&#x2B;Ap96n4e&#x2B;pr4i3z2&#x2B;I37Wfpl&#x2B;B/ye&#x2B;zv6y/2P&#x2B;L/hefIW8U4FYAHBAeUBvYEagbMDawMfBJkEpQc1BY0FuwYvDD4VQgwJDVkfcpNvwBfyG/ljM9xnLJrRFcoInRVaG/owzCZMHtYRjobPCN8Qfm&#x2B;m&#x2B;UzpzLYIiOBHbIi4H2kZmRf5fRQpKjKqLupRtFN0cXT3LNas5Fn7Z72O8Y&#x2B;pjLk722q2cnZnrGpsUmxj7Ju4gLiquIF4h/hF8ZcSdBMkCe2J5MTYxD2J43MC52yaM5zkmlSWdGOu5dyiuRfm6c7Lnnc8WTVZkHw4hZgSl7I/5YMgQlAvGE/lp25NHRPyhJuFT0W&#x2B;oo2iUbG3uEo8kuadVpX2ON07fUP6aIZPRnXGMwlPUit5kRmSuSPzTVZE1t6sz9lx2S05lJyUnKNSDWmWtCvXMLcot09mKyuTDeR55m3KG5OHyvfkI/lz89sVbIVM0aO0Uq5QDhZML6greFsYW3i4SL1IWtQz32b&#x2B;6vkjC4IWfL2QsFC4sLPYuHhZ8eAiv0W7FiOLUxd3LjFdUrpkeGnw0n3LaMuylv1Q4lhSVfJqedzyjlKD0qWlQyuCVzSVqZTJy26u9Fq5YxVhlWRV72qX1VtWfyoXlV&#x2B;scKyorviwRrjm4ldOX9V89Xlt2treSrfK7etI66Trbqz3Wb&#x2B;vSr1qQdXQhvANrRvxjeUbX21K3nShemr1js20zcrNAzVhNe1bzLas2/KhNqP2ep1/XctW/a2rt77ZJtrWv913e/MOgx0VO97vlOy8tSt4V2u9RX31btLugt2PGmIbur/mft24R3dPxZ6Pe6V7B/ZF7&#x2B;tqdG9s3K&#x2B;/v7IJbVI2jR5IOnDlm4Bv2pvtmne1cFoqDsJB5cEn36Z8e&#x2B;NQ6KHOw9zDzd&#x2B;Zf7f1COtIeSvSOr91rC2jbaA9ob3v6IyjnR1eHUe&#x2B;t/9&#x2B;7zHjY3XHNY9XnqCdKD3x&#x2B;eSCk&#x2B;OnZKeenU4/PdSZ3Hn3TPyZa11RXb1nQ8&#x2B;ePxd07ky3X/fJ897nj13wvHD0Ivdi2yW3S609rj1HfnD94UivW2/rZffL7Vc8rnT0Tes70e/Tf/pqwNVz1/jXLl2feb3vxuwbt24m3Ry4Jbr1&#x2B;Hb27Rd3Cu5M3F16j3iv/L7a/eoH&#x2B;g/qf7T&#x2B;sWXAbeD4YMBgz8NZD&#x2B;8OCYee/pT/04fh0kfMR9UjRiONj50fHxsNGr3yZM6T4aeypxPPyn5W/3nrc6vn3/3i&#x2B;0vPWPzY8Av5i8&#x2B;/rnmp83Lvq6mvOscjxx&#x2B;8znk98ab8rc7bfe&#x2B;477rfx70fmSj8QP5Q89H6Y8en0E/3Pud8/vwv94Tz&#x2B;5fBhlYAAAAJcEhZcwAAHsMAAB7DAbyXl9oAACAASURBVHic7N3Pyu3Ieehh2Q4xuYscciZp30HAYEKTkYcZNWQcPMkk13EmmZiMDX0D8cg0wdBw7iDtSQ7JXQQfCH0G8hFy6c8qvSpJVaXnoQd7f3stLS19u7&#x2B;lrZ&#x2B;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&#x2B;//u///v2DewIAAAAA/fnB999///Q&#x2B;AABnzYtaPu0NAAAAAM5Q2gCgMTtRLb&#x2B;cbW1EewMAAACAfEobANSrSFSr8LUAAAAAoA9KGwBUoc7QZegbAAAAAOxQ2gDgbnVGtUxN7zwAAAAAlKW0AcCF3tCl3vAeAQAAAGCV0gYAZQhOc6adBAAAAOANlDYAOGanqA1K0jYlEgAAAID&#x2B;KG0AsElUu5qhbwAAAAA0TWkDgGEw4qoavhEAAAAANERpA&#x2B;B1tJy2&#x2B;H4BAAAAUC2lDYCeiTS9Mu0kAAAAADVQ2gDohKg2&#x2B;df/9dvVr//1P/7s1v24l78AAAAAANxPaQOgPZrKZCuqZeq7vQ2GvgEAAABwMaUNgKqJapOTUS3Ta9vb8L6/UQAAAACcp7QBUIWd/jG8L4HcE9UyaW8AAAAAsEVpA&#x2B;Buolqiqq6W6bX57YV/PwEAAADYobQBcCGjhRItRrVMr21vw1v/MgMAAAAwKG0AlKJDJDqOapm6b2&#x2B;DoW8AAAAAr6e0AXCYqJYQ1TJpbwAAAAB0RmkDYI&#x2B;olhDVynpzexve&#x2B;j8RAAAAQE&#x2B;UNgD&#x2B;QA9Y0tXu94b2Nhj6BgAAANALpQ3gdXaK2vDiC/2iWrVe3t6GF/9fCQAAAFA/pQ2gZ6LaKlGtddrba//nBQAAAKiN0gbQCVFtlaj2Ei9pb4NpJwEAAAAqo7QBtMdIl1WiGnPa2/DuHwgAAAAA91DaAKrmGnommY1V7&#x2B;ltCUPfAAAAAO6htAHUYieq/de33w3D8Kd/9Rc37k7DVLc3e21a&#x2B;0i2BwAAALiC0gbwgI9RLYfwlkl465iudob2BgAAAHCe0gZwrSJRLYfwlk97a5SudgPTTgIAAAAcorQBFLZ6nbpsVMukvWUS3uqkq1XC0DcAAACAHUobQHm3jWM7RHjLp73dTFRrjqFvAAAAACOlDaC8H/3ox//17Xd/9tMvPj5SeGuC8FaWrtYlQ98AAACAd1LaAMobS1vyReGtJ9pbPl3ttbQ3AAAA4A2UNoDyVktbQnjrifA20dXYZ9pJAAAAoDNKG0B5OaUtIbx15iXtTVfjPEPfAAAAgKYpbQDlBUpbQnjrTAfhTVTjNtobAAAA0BClDaC886UtUXl4G7S34ypvb511tX/62T/Pf/sPv/37p/aEMPkNAAAAqJPSBlBe8dKWEN7682x4a7qrJRVt31ZjGzeiwLVFewMAAABqoLQBlHd1aUsIb126rr013dUyHcpvc2Jb67bym/YGAAAAXERpAyjv5tKWEN66FA5vb&#x2B;hqqzJj2/4ot5xHUjlD3wAAAIBLKW0A5T1b2hLCW6&#x2B;W7a2DqLaax8omrsBwN3NOdkZ7AwAAAApS2gDKq6q0JYQ3npUfunJGm10X4cYtnxwYR0NMOwkAAADEKG0A5dVc2hLCG48Lr6k2XJC4rkhrhr41ytA3AAAAIIfSBlBeQ6UtUX94G7S32&#x2B;XEp/MZ6UziunnOyWnLRxuh2NYBQ98AAACAhNIGUF67pS0hvL3ZVr66c0LF4muq7Twg39Ze7Wx5vwX&#x2B;08/&#x2B;WYRrl6FvAAAA8HJKG0B53ZS2hPD2KmcmdZxcF5CS3bs5AX4UboQFiyBP0d4AAADgVZQ2gPJ6LW0J4e2d6ilw&#x2B;XtydFm1i8a9JS0tn&#x2B;rWAdNOAgAAQK&#x2B;UNoDyXlLaEsLbexxNXDePNltdUy1/N8ruTKKeTsnjDH0DAACAPihtAOW9s7QlhLe3qbMhlVpTbf8pYXUetDPuPHpdMvQNAAAAmqO0AZSntC0Jb69VJCYNNy75lmm&#x2B;Mtz9Ea6ecBUYsGgtukMMfQMAAIDKKW0A5SltHzUR3gbtrZDAtI13Tji5MwzrwTXVtubArM3WinThfnl6jzq3DG96GwAAADxLaQMoT2k7Snh7p8rnTqx892LuGU&#x2B;2c&#x2B;gyS2ptx&#x2B;1BO2PaBpkNAAAAKqC0AZSntJ0kvL1cqTFwZWtN/dNgLs27WrL/y90oO4pu3JquFrCf1kbjD8A/&#x2B;&#x2B;kXShsAAAA8TmkDKE9pK0t4e6GPg6Jynnhbv6m5JJ0MhAX3fGeWzlIv0aj8tJZQ2gAAAKAGShtAeUrbpYS3dyo1pCxxxUpvZ7ZZvBTmHLf5C925Qt5rhdNaQmkDAACAGihtAOUpbbfJqW6D8NapJErVM3jrkGThtP13Uaq9hQ/XbXN1dqZUWksobQDtWn40&#x2B;JEOANAupQ2gPKXtKcLbm&#x2B;UPxvoYiu6cgnJnKbUdF&#x2B;3VcgcyF1pLHs9FaS2htAE0YedDYVp3c&#x2B;sBfs4DADRBaQMoT2mrREPhbdDeShvjUGBexMRtpW3&#x2B;ch8Hut28V/vUtdHHulb8R43SBlCbj1Et39Z5rJ/8AAAVUtoAylPa6iS8vdxWPaohFIWnvtwZordsjWEFF6Lryf1pLaG0ATyoYFTLpL0BAFRLaQMoT2lrgvBG/U4uPjdaHSdHwD1zQuZT2gBusP/DP/k5/H//9/&#x2B;5eHf&#x2B;iGknAQAqobQBlKe0teht4e1//vn/mP/23//zP05ukLniWatIchsJb/lqS2sJpQ2grENRLdPN7W0w9A0A4AlKG0B5SlsHOgtvSVfLob3lW1arna8Mt&#x2B;S3rQXedh7MUH1aSyhtAGE7P/Bv&#x2B;NFq6BsAQGeUNoDylLb&#x2B;dBDeArFtorrtWE1o&#x2B;4nrhrL1McIxaiutJZQ2gByPRLXM867pFEt7AwBomtIGUN7J0vbjX/1u649&#x2B;/3d/Gd4sBb0zvI0Xg8Ynam&#x2B;jnEFjh4aXzZ9y0viKulqi6bSWUNoAEs&#x2B;OVJsL3&#x2B;H0VHsbTDsJAHCC0gZQ3pnStpPZloS3SrQV3obs9vbv//kfO9eJxLbEakv7h9/&#x2B;/fLrq/Uredj8iWrZGT2ltYTSBrxZPVEt06H2Nj8Hq7C9DbUeZACApyhtAOWFS9uhzLYkvFWi1/CWQ35bOjSabfRxGJz2tqPjtJZQ2oCXaC6qZTo6w&#x2B;SqevJb098LAICTlDaA8p4qbXOqWz36CG9DxvWg1TFw2tvk0OJtj6/01pD3pLWE0gb0p9eoli&#x2B;Zpjv/zqcKh7695FsGADAobQBXiJW2gpltSXirRwfhLbz0yEh7W2UEW77XprWE0ga0a/8nuR9uc&#x2B;enGainvQ2&#x2B;uQBAp5Q2gPIqLG1zqltVhDfhbWJhti3S2iqlDWiCqFZW&#x2B;Lzr2fY2GPoGAHRNaQMoL1DabstsS8JbVYS3QXtDWsujtAG1MffjswLnYA/OOTkY&#x2B;gYAdERpAyivrdI2p7rVpoPwNmhvZJDWApQ24EGiWv3Oj34z7SQAQCalDaC8dktbQnirTXPhbTDbJBuktfOUNuAeolofzpyA1Tn0zV8/AKAeShtAeUdLW52ZbUl4q83Lw5vk1hZprTilDSjutVFtWip1rvtlU/trb0Pvf1EBgGopbQDl9Vra5lS3CvUR3gbtrRfS2tWUNuAMUW3LP/z27/cfo8AlkhOwR9rbYOgbAPAopQ2gvDeUtoTwVqFuwtskUOC0tztJazdT2oBMr41qWz7GtsSY1pJnzYOc9rbF0DcA4CWUNoDyXlja5lS3OnUT3izzVg9p7VlKG5DY/7HsJ8a&#x2B;o/lt3zvb27//53/sn6fNT8O0NwCgJ0obQHkvL20J4a1Orw1vStsZ0lpVlDZ4s5dHtZ0qdlHi&#x2B;jif5HLE2xW7Uaci670Npp0EAFqmtAGUp7RtUd2q9YbwtmxsW7djn9yxnuSktaGyvxjvobTBS7w8qo1ODjibSlg4gCUTRb5n3siwzPy2f95VW3sbXvN/HABwlNIGUJ7Slkl4q1aL4W34tMzbkHHRZ7zcM3/Y28KbtNYQpQ36Y0G1HAWnedTJ7jSeX50/szLtJABQIaUNoDylLUZ4q1ZP4S2JbR8XFJk/ssxuVUZaa5fSBk17eVSb17Izuavs4mrDc&#x2B;1t9Y0IgZlqG/r2hv&#x2B;FAYCE0gZQntJ2nupWs57C2/BpoNtylNv86y2S1rqhtEErRLVDjy&#x2B;elz7uwD2rrAWiYDJT5aC9ZautvQ3v&#x2B;J8dAN5MaQMor0hp&#x2B;/6XP59&#x2B;/YNf/LrAbrVMeKtZN&#x2B;EtZ3DbVnhLHlAVaa1XShtU6OVRbS4zLC1j0vKLJ/NSzp48tfpaeEye5HbUU&#x2B;1tMPQNAN5BaQMor3hpm0hug&#x2B;pWvVeFt1EyBeXjsU1aewmlDZ4lqmUqPsHjUHrCyZNbq2r2y0GEO8LQNwCgFKUNoLzrStsgti0Ib5XrJrwN2e3tkdKWU9dqO8icpLTBbV4e1cqmqf0t57u/J&#x2B;3v7c3HZPlyW08U3g7R3gCAGKUNoLxLS9sgtm1T3erXU3h7lrSG0gbF7f9ofef/ceHwc&#x2B;ZVVqeULPuKOc4POLs0vy2Xl7thT17ItJMAQA6lDaA8pa0Swlv9Gg1vwxPtTVojobTBGaLa0seytfOAi0LO/Qun7agnvE0q3KU3qLC9DW/9qQUA9VDaAMorW9rGrjYPb0pbjPBWP&#x2B;FtTlpjn9IGAcmPVv8TrSqyeFg9CeeK2S8Lrq9W5EAlSVKBu1&#x2B;F&#x2B;c3PNwC4k9IGUN4VpW0Q24pS3ZrwtvAmrXGI0gYBhrKdtD&#x2B;s7fEhaIfmupw/&#x2B;JGV5647Skd3I&#x2B;fx2ttRFba3wU85ALiM0gZQntLWHOGtCf2FN2mNM5Q2CEhO0vY/Wfwvtu/xrjZXcJDZqPi4t/kGD62vVuo4dzZUsUXaGwB0TGkDKO&#x2B;i0rb8ovZ2BdWtFS2Gt5x9rmqHqZnSBgH7J2nCWzfKTp/4Tz/75&#x2B;smnNzZ8mqrKx44FbgHPdjeBtNOAkBRShtAefeUtnlmWz4yYNygYpcQ3lpRZ3iT1riO0gYBh07ShLdujKms/tXLYnt4RXJr4nD1ytA3AGiR0gZQ3lOlbTgx1eTqy5FQ3RryVHiT1riN0gYBR0/S5oS3nhyavzFzI2Vnd1zd2tH6deeEk6txTmwrQnsDgPopbQDlPV7aAsPdlLYA4a0h14U3aY2nKG0QcKa0JYS3niRTMtY2nGtnf3aWf1u&#x2B;lyJ7lXlwNLZLmXYSAGqjtAGUd0Npm0uqW36E21kBjgDhrSFnwpu0RiWUNggoWNoSwls3AiPVHoxPz044ST3qbG&#x2B;Dn34AvMafPL0DABSwVdcSyWO&#x2B;/&#x2B;XPt8bAETAvpqpb5ZLLrFtXBzKD3Oo2qdMXX305/uK7r795dk&#x2B;Azux/svzoRz&#x2B;e/9al55oVTGvLZ1031m1ry6u7uvpF&#x2B;a1pf/pXf7H84m35befutOSn3&#x2B;AHIACdUtoAmrG/MNvqwz4WuCm27XyFgGScovBWuczwtv8sAJgIby9xqG/tfD1WuY6&#x2B;eviFKvGv/&#x2B;u3yVf&#x2B;&#x2B;h9/9sB&#x2B;tGOZ3&#x2B;4c&#x2B;rY8Vd5qb4MfgwC0T2kDeItDA9eSB59sb&#x2B;qd4W5t2bo8Kq21wsA1oDbCW2cOJa7VByePLDvIrOmcNll2tZzHaG/76mxvg6FvALRPaQOo3dFBaYmtxdiOhrfpKbFmdua5nTHcrVEyGwClCG&#x2B;92klcgQknx6f0kc0&#x2B;yulqse1ob/tqa2&#x2B;DaScBaJPSBtCezE72scCNG5lXtNHqxqcvamZlGe4Gd0pGuU2j37YeAHAD4e1Vikw42UF&#x2B;K5XWAi&#x2B;kve17tr0Npp0EoE1KG0CTcmLbznC3nefubHn5R/NBcvs7s6/UdlpnuBtcbT6x5DKzAdRAeOvS&#x2B;Qknm3ZbV8uR7Izw9tGyvQ1PD30z7SQAtVHaABqzbFFnktvWS3ycZ/LjF8OTTL48ts0JbwCA8Na3/qLaUFlX&#x2B;8igtxjTTgLAnNIGUKmt9dVynricCvLQqmyZL5RYDnfTzMoyzyRcYZou0hA3oAnCG7Vpq6vl0N5iTDsJwJspbQANWE1Wq6PNkkfmzwOZOPTEnTkqc2Lb0QrIYLgbzMwnhDyzHSu0AS0S3rhZf10th/YWU2F7Gwx9A&#x2B;AaShtAw3JWa9t68PTb2kaeGQwXYLgb75SMQvviqy8DtaxUqAOogfBGWe/sajm0t5jHl3wbDH0D4BpKG0Db8oe7zSXTS2aOhFvd&#x2B;Pjc1YbHIwx3o0LzJFYqaK1O9hiLbfMN6m1AT4Q3DtHVztDewioc&#x2B;jb9tDT0DYBMShtAn0rlrpPbMUDtccIb90tGiZ1c/yx5uhIGECa8kZDWLqW9hVXY3gbTTgKwS2kD6NYycR1d2m01kn0Mb4fKnNFvNzPPJG1ZVrpx1NpyysdAz5tvJ9n&#x2B;8T0FaI/w9ja62uO0t7DH29twZNrJ//r2u9V5MgHomNIG8C6HxqhVMiLtY/wjxnA3brZVsLZGrZ0cDHd0l254OYCaCW&#x2B;d0dWaoL2FVbjk2/Rjc/yFn5MAr6K0AbzOoViVM4KteP2abzPZgfG3etsVDHfjUpmZbVgbVbY/C2WskC1HxQEwJ7y1RVfrRvKtFN4OuXnoW/KDEYA3U9oAGIY/Huu2M&#x2B;7tuskeYwvCGe52EcPdGI056miLWn380U0tS9hy0sgvvvqy1EA04Q1gn/BWFV3tPQx6O6lse/uY1sYflQocwAspbQD8wbxUHZ1kcrmdnLFuyyeujmDLfHrZ4W4Gz80Z7kbMxww2f8Dqqmmrj0yWajvJpJEAAcLbnXQ15rS3kw61t8y0BgBKGwDrlvM3JgPItn6b/CIzVn0Me8lL5Gx2PkovZx&#x2B;2tqC3zRnuxkeBdjWOJBv7WTKqLGdrgfC2&#x2B;hQD2gBihLeCdDWO0t5OGtvb2NukNQBilDYAPthaMi0232Omjy1tZ37LaVBd8mDB7ArCG8s2tmXnYdNGMjeVDIbLecpHMhtAKcJbmMxGEeNfJL1tn7QGQEFKG0ADzo/NKmLn1a9LbvOXHtveMqRlTju5fO6Z42mJuFXmmXyVj8PIptXUhoyO9XGltPnXiyyrJq0B3EN4yzelEcmNGHVth7QGwHWUNoDaXR2xzkgK03JXiyeorQ3GBtiFk9sy7IltS1N1&#x2B;5c//9thGP7mp//26O5wyk7ZKt6rkkFyq4Fta/c&#x2B;UtcAHje/ir285C28jZa9RHtjlbS2Y1qAbb&#x2B;uSWsAnKe0AVDMcvG2nQfvD0q7yFYSG79&#x2B;Zh&#x2B;WWzZlZeI33/5k&#x2B;rXq1oHAYmxLW&#x2B;ur7X9x/qwiuwHAU/aHuw3C20wSVIS315LWdkhrADxFaQOgpHBY2loNbvrixy2vbmE51eTWc8&#x2B;nvvlOTlvT21bNq9sgvNXhipXPcuQMWTuzTQAaIrzlE95eQlfbJ60BUAmlDaBqNU8dmS/WmbaS2&#x2B;nduVwTO1kVw92esjMZ422xar6K2&#x2B;oQt9WdXD5SXQPoj/CWT3jrhrS2T1oDoE5KG0Cf8mdxfNzO7s2Hmp3JVx&#x2B;HrIU3njkYzkJu&#x2B;Qx3q9NUtspGuK3UN77EVmNLdkljA3gJ4S2fZd4aIq3tk9YAaILSBlCv8DyKTdh6F&#x2B;GJHGPzNGZOL7m/hfnTDWgrS3gr4rrhX6U2lTlvZPJyGhvwiB//6nfJV37/d3/5yJ68nPB2iEFv9ZDWPhrrmrQGQEOUNoD2JC3nzNyM7Ua7reFuh0LX6ts/397mm5rvZLtHux7mmQxYnY9x2ah2hpHlbPMK810S1YBKLDNb8kXV7SnC2yHC2210tRw5aW1Q1wComNIGUKn80jMmnEPlrPJxV/N3sTrEbf9thkfFBVR&#x2B;JPs29CRRAQAAIABJREFUVbemk9uUrC4qSZkrsR169YKZbXVhNgPXgGqtZrb9xwhvTxHeDjHbZEHSWg5pDYDOKG0AtcvpRmcGTh3tWPdLjsCh3ZtnyOt2iWeNya3p3hZwNNEdGrK2tYUrhrLNNyuqATXLyWz7z1LdHiS8HWXQWz5pLYe0BkDflDaA3nQ5S&#x2B;HWNI85ueuKJLa6zZydnH7d3/focb/59ifVxrayJSnJXatTQW69btlaViqMCWxA/WKZbX8jwtuDhLejhLc5aS2HtAbAqyhtADW6dLzUx9gztboiC8JdahnbKtzJVY3uduVqjm2lrHayndgGQLUMd6uH8HbUq8KbrpZJWgPgzZQ2gNptVbckht0wn2Gdo&#x2B;UODXcrsv9bx/nk8QnPkMlcH7Ht49JlT4kNiatk5wHCigxoO/QSwtuzhLejOlvmTVrLJK0BwERpA2hJ8ZaW1J2e1h675&#x2B;2UepVkI3VGzVa0Htt2Utb8j5J116oa1lbPngA0SnirivAW0NagN2ktk7QGAFuUNoBX2wlFHVS3&#x2B;bC//XA1Pw5H3/jVSc88k6&#x2B;SOWLs0LprF3UvOQ14iRsGtB3aB9XtccJbQFXhTVfLJ60BQCalDaBGq8ukXfpaiYsmSHxEtTu8n&#x2B;i2DrVJJnO0PqxtyBuylpnlqhruBsBJhrvVRngLuHm2SWktn7QGADFKG0C9po5y//CyeQTqbFbJ4eDSblfvyf4Enp0deY4ah6yFGxsA3TPcrTbCW0zZQW/SWj5pDQCKUNoAWvJU9Oovtp2RTDVZamBZke3M&#x2B;&#x2B;j5rTWtg2Fto7LD0SQ6gI4Z7lYh4S3maHiT1vJJawBwBaUNgD/Ib2kFVw7LWUTtNsluZB6Q/YcVLJSHeqdJJluXJLGt9dgyO9w4MG6&#x2B;hf0nzteBW90r01EC1M9wtwoJbzFC2hnSGgDcQGkDYBjOBaHztazO5d9iu3TR&#x2B;L9xZ2Ibrypn3qmbYW3DH4e3WP3KHM22sxHj4QDaZbhbnYQ3riCtAcD9lDaABtzcSGIv96pBVJnFq&#x2B;YpN80zWaetsWvzP1pdue3Q1raGrAGQSAJVN4S3OglvxEhrAPA4pQ2gMWMXKZtwigehOseolbWMbZW/5embkux239&#x2B;sFoe1TfUrZwzZxwFthyaNzKTPAXTGPJN1Et7YMqa14VNdk9YA4DZKG0CTCqaRq3NRx2Pdtt7O6oi3mt/7PLa9dqrJCo1Ba7W3HZrIsVQYE9gA3sBwt2oJb28mrQFA5ZQ2gLaVLSJHt7YzwG6MN8vhU6svdPR1zXyYY2sE2&#x2B;qDk5FtHffRmoUHn2lgAFzEcLdqCW99y0xrg7oGAHVQ2gD68XgRyVy9bHJ&#x2B;1spqk9u8chXZt/Acj0e/KQVfmvOSsWs7q7gBcKd3DgE33K1mwlvrpDUAaJrSBtCnzEs/mQOeDr1ubCOxZja9XJ01qLZdWp0ptPgqfbWpeam2nZC2/KPlYwaj2QAe9fIh4MJbzYS3&#x2B;klrANATpQ2AD8IlJrn8lLmdvi9anXlHVyexOmtlZ7746stAG0ueoq4BVMjHqHkmaya81UBaA4COKW0ArDs/62CRDfYd3oZPA8uKfxfmuh/NVqcxtmUOWRt0NYB2iG0Tw90qJ7zdQ1oDgPdQ2gBeZx5vKp8/sNSOLbdT24WwaX8uTWtHjTtT27FqUdLP9luatAbQLp&#x2B;bqwx3q5zwVoq0BgCvpbQBvNd0MWh&#x2B;SWg/8zx78Wj16tXHpdpW31HNF8KSHTuz9N3591jtUQKAGlR1i0wTDHern/CWT1oDAEZKGwB/ZF5W7rl4tAxLwy3D7GqObZNk9OFw8MgkD3Y18EHLaSEHw9cAuuDj9QzD3eonvCXGuiatAQBzShtAvWpYomw51WTsuUv516TOXMDq5srXFV0wfywjRehqrBqX7nt6L4BTxLYiDHdrwgvDm7QGAHyktAG80aHrQUUCTzgUlc1LyRtvYljb5KK9DZdUGE1j9eSigOVIR6B1yed1WycbVRHemtBleJPWAICjlDaASl19Z/SZiz6x5z5&#x2B;r/e0KN3jexJ2fs/nbz/ZmkuBb1OkkM1DkbFZAJPkzp7BHS2nmWeyCY2GN2kNADhJaQPgLFeOrrPTBT8e9uS5vk0UtDUSS2wDuIIB6AnD3VpRbXiT1gCAspQ2gAa0dVUlWdqtkgFk82NYz17lOLO3q39ztjbY1l8zbjOPaioawJadUePTF8eP2uRPP37&#x2B;NnTS8hTD3VrxYHiT1gCASyltADVqfSjStM/jRaWdK0Rl313&#x2B;/IfLhx297HWn5YW5k7vXVmvkKcuBa6tD1savWG8swEGDnoQ/WJfrug2VnYe0xXC3hlwa3qQ1AOBOShtA7Vq/4DLf/2rrznLHKly0rOz&#x2B;JEMPC26ZdgVWbjPK7TzHEPr2cazbsDbcrfXTv3oY7taQk&#x2B;FNWgMAHqS0ATQjPOiqwtFaVSW3jzvTa5Hq7O1wUpLZrMR2Xk65dDChb&#x2B;NHbeZQ8q05J8vv1lsZ7taWo&#x2B;EtczsAAFdQ2gDaEB50VclorQpr30fLA1X/rJ7np4Ws830x/P9sc1GY2ZnGcHpFUx3my&#x2B;yRMhu83MdP7UrO4nolvLXlY3jbeTAAwNWUNoAaHeolgYhV4WWaItNL7ryp4m&#x2B;5wmM4qnOvOOlM5Uqeu193kgFtUlBY/jG8tKEC98s8i9u5m&#x2B;ejgjcw1X8X0W3MM9mWsaVNvU1aAwCepbQB1G4nQa3GnqoK0NEhVrft&#x2B;dZRWq6SkrlLLlRRp2WiWw632s94hrJ9JEzCm5W6SSg5kdjZ7NZAt14nu36E4W4AABzyw6d3AIBjwldPjt46/f0vf15kaZDlDue8hR/84tfjf&#x2B;d3YMvy3R19uXmQ298y3OOLr76c/huOR7JlKDo5lu7lle67r7/ZaW8vPzjwErFTgsDtO/OnbJ2fEPbjX/1u&#x2B;u/pfQEAoEZKG0B7SsW2HKVi2/y/M1sIPHH69fLCU&#x2B;DdrQ4iXD7MtS1utp&#x2B;1cgaxZY7HynzYCzPS/MhMjW3rOLzw&#x2B;MCrJKcfZ84K8ieKXL2nqsiNU&#x2B;NGSt2D1bp5dRPeAAAYmT0SoDdbl2DGmYWOTudYp6emRTr0utPMkycXUxmfbiYoJvNIkz9kaj/8DGuzSua8SgeOLpO2PFBbz5XZoGNbk3vnf14nUz4eeun5uUH&#x2B;HT9mur6C1d0AABiUNoCefLxoUtUSbo&#x2B;4vzJuLaYSfjovl0Sa1Tz23dffZNa4j&#x2B;bP7Wk1sqmuxaLXTpXMfMr8pcO7ATzu6GlVqRuedhpb5oNjK9Gyz&#x2B;puAACvZfZIgHeZRrZNl1fmMwK1eDHl4z4Xz1r5Ezd9fKF2DzvVGnNOLIaV7T37q5RdamcuzVKrx803sr/B6U&#x2B;XT5kvqgd0ZuuUYHVe6&#x2B;Vj9ifN3jp52JnYIPOLFGSeSQCA91DaADq3uq7YzkJl4csuj1&#x2B;vObmK2&#x2B;jMuxi3Fhs12HrvpJQpvdwZYHKmoMwc0Db9aQ3j3nIO4Mn9nL5Nq9&#x2B;v1Y3ravAeSS3bP0NYrrK2NX2084RGqW4AAB1T2gAaE1vP44o9mZvvVYXF6Oi1rfMvt1wSL/BdqOcAcrWttLZaZZKxYvvlJjDJ4eq&#x2B;fXzigyPYTjq65/lr4y2/LrPBCy0HqOVM973668yX2/ltzqvvc3JShOFuAACdUdoA2lMktu1sZGuKoa141sQ1l&#x2B;Q61/6kTPNnld2H6df7B211rGETx5lM4VFr9wwa29r4/NXbTWvDH9e1wDciM7ZlbrbpIwnEfOxhmX90dMTb0RMb5x73UN0AAFr3J0/vAABZkgFSmZIxVTtbOLr9cb23o/tT3LTP&#x2B;Tuz&#x2B;sjY4T2k1PYDbzn8LJ7y3dfflBr89MVXX&#x2B;ZUnPkrjk9Z7kNtNWjcvdW92jmAyeOTd310B&#x2B;a5brnNLav7UNvhBa62Otrs49nCydOJ5OllT06cYxSRxLbf/91fPrUnAADkU9oAKnXF1Yrisa3ETp1S8Cgt337gvu/xKbEMGT7&#x2B;hyah4hH5KeXS3FJw5Nb9MheKO7S1nE3lPDJ/7FrsicB7rE49vXWGUMPn&#x2B;3KiS72trHl4U90AAKqltAE0Y6o4yVf2n7KsRznXZWLXbuZXWGq4&#x2B;nNUwWtDsVVVwiMXz68Jx6scHQf2oMBQs5xtHn3k1m4cHb4G8NGZD/HV2aeLnBXMzzT2t1nJtAddMtwNAKBaShtAY8IXL2678PHmiQrL9sX88LY6GdQLjz&#x2B;r8sNSbVno6vJ3aPuHHpw/Wi7zwcDLzU8Jzkx5feh2qJNTWS7/1JlJWcIbJqAGgHoobQAv8vGKSdnlyrq5qXn/XewctOS62PT1wEHe2YedSaVuWH&#x2B;Oxx29vDI9vqrrMh/Hro1D7qra50TgG1HhIEKgWvMzgdXP95zVeefnZvdPQlDwzNBQ/iXzTL7EydOh5blHzSdXANAQpQ2geQ/OeTjkxbmT659VKFCwku711EEw3K0bOfMWtnIxJbzO2dHtF49bJ49nnd8OoAn5d/AkZyDLX&#x2B;Q4dLdWYKJyZyZlGe7Wq5OnMW7xAYDrKG0AnctfmO38NY6Pd1iffK2q7l/&#x2B;eGv5cg/njyl1wIdzd6MLb30bQ07NQ8GOXvEJvJf5S6ymx3Gbyz/a2bdqjyfwTuFx86XGvuefSGwNuO9mIoQ6Ge72NqszVMtsAHAppQ2gf4EOVPa1thwa4LVciqyqKzJbb/y6&#x2B;RtXZ39K2tvOSyfZb9DbGhG4SlJJFlouJRK74nMotmW&#x2B;RM7DKjmMQG0eH62emJ8enL8XZ&#x2B;dPl&#x2B;93K/gdveuryHA3Y&#x2B;a2GO7Wk&#x2B;TkZHnz0HTWJLMBwNWUNoBXSK5xfLwKU6oPbW0kuUBT1WC1sEN7Xvxtbm0wc6DhUF&#x2B;8JEdyhaWhGpRc8Tm052dG6S2vQOU8JfZaAM/6OP7&#x2B;5n0YxebfPvqU8xt5iR//6nf/8ud/O/76b376b8/uzEss7z0qsqnx1zmzi8&#x2B;fCwCUorQBvMXj1xfKzmP5&#x2B;NvJd8O1rUeunfG4&#x2B;TWapmvQ1Ts/r2tHR7k1fWCBq7X1&#x2B;TuNGDt6EjU9Pvx&#x2B;M&#x2B;e33Nm3soe6j3u8ivvNtz&#x2B;Z/1Z4u0KRvnWo1dU8izgA9OSHT&#x2B;8AAA/bn/xnVZHrLOHt/&#x2B;AXv27umsi4z&#x2B;NuP7v/&#x2B;6/e1hXDl&#x2B;vjosl3X39z6I3E3nV44FofBxlg7sxJyMcMdvRE4s6Toq2ddPKz5Tff/mT&#x2B;39O783ZffPVlfqXbOr9yYgMA1zGmDYCVhb52lLoecWg73VwECV9O2vnunDw4T00n9WbtrrVWyqEjcPRe7EPXoXb&#x2B;yKxKwHXqWd3t4w7kDzIbv3LFSUX4pLHshAovN49thrtdbX4ScvQksLOTRgBohTFtAPzBpbcVh6/jLH3/y593U4bmY90KbvPog11duofAtrR/TI7ejp1zu/d4l3fmWDqxDdjRzdnIqvNLoyVf3zlcO68VOEXZf0rf37XbGO52neXJzPJs5OiUAADADYxpA2Bdcp0i56bg/dU1cmLb0csf4WU2ql2f4&#x2B;QIs1LXxbhIkeFWD8pfvSx/BZEblg&#x2B;p82ACXSo1WK2GUVYFz9xiw92m&#x2B;4ECw9TCjyfgVcPdDq2Rlr/B/W1OJ0vuAQKAahnTBkCunCs&#x2B;d17L6HWZjfkot/uvsnVzGNuSP8qqLZnXg3IeNj3m6CIl9R9VV82gRTm3H4VH4V83DeN5OWcmyXj94m&#x2B;k1EQIl&#x2B;7ka3U83O3QSmn52xx/sQxpsROY&#x2B;k97AKBXxrQBcMB0SSLz5uJS9xEvt7O62ekG8HqWPzlveu&#x2B;1lU7OaP06yMkbuo&#x2B;ugjY&#x2B;OGdmyNj&#x2B;3M/N6fAeyUdz7Mwk/0zgBvPdKHKml7&#x2B;FSo4A&#x2B;cbY1v1Atx07H/Q7fzSeJBRfNdbpBwBcR2kDICJwpaNUBEpa2vJVVu9QbvrSzP4lLdMi1a&#x2B;hAnSFKcst79Sej1R721F64VsGAuYf8VX1tsnRm5zm5y0XncCsnhot50VfPrHOI9yB33z7k/pj2/nxZPvb3JGcFF16etBfYwsft3sOOADvobQBUEAg9tzch86vd1JPtDuzAzsXnuQ6Dtm/KpF5zSLnZu2tx9ywulupq1GiGnTmzCfmxxOSQ&#x2B;cbNZ&#x2B;c5OSui5w8pSkyDJFEE7Ftx/4pQfKnmevUhv&#x2B;UMxxbAC5inTYAyhjX5Jj&#x2B;m3/9hte99CWGxR3ltUWp80dguonb5aRuFF9NZH7nb8FuNG3q4xxKwx8vvXbFcilbr3vefFdd4oE3KPJ5ujVX9vJPazszGW0NI9s6OB8PWs7bLH4o5ge8zuPcioaWbcv/pF49G9l6&#x2B;up5xfKLV5wntH7Hz/mzvnELzsEAuI4xbQBcovgaHh9f7uXXPpKLU5kL6Q0tTEvFGbWNpprvz6GLHVW9i5jpvRdfdgWowf55SPETleXWzg/fv8Kzu5TMVBnemeRkqcLj3IrWR7Yl8j/Nt05j8ucAyN0nQkMMAeA8pQ2gbdO/9itvJMkFpkv3c/VKVsGZmpqw/0Z2rvd1cwQoLrlOsdXwPra9IoGtnlIVbpmu&#x2B;0D3Cta1/UVqW7R8R/lnIIeOwxU3Y62uCuwMKlNnsW2SrLWWaecsovh5wvJEruz2K7E6xDB5787BALiC0gbQqiK36N7pqZ089LqZK3M0ccDnjPmjrK2rM71etck3HoGdQOjiDpCv&#x2B;4/vzBOqZGjalXu0/qI7ljvW3Fki5xVZvHb18fO5u5MvHhoPt7qdx53cq9hpVVVHAICeKG0AXVlWt5o7XCs3aN82Gu9Sy7VS6j/ynHfF1YSjOW1/ssSGrncsL&#x2B;jsFMdD70uBg7YsxzOVstzaxxOP/j7QG3pH&#x2B;wvptXvSeLUmhrV9nO&#x2B;6VLu67hwgZ2KARk8/preQfGuSt&#x2B;YOMADu9MOndwCACyWrStR52eIHv/j1mSsRl76p1UVQ6jyMAcsj75JQf8KXGOaLxie/3n/iziWb6Y&#x2B;&#x2B;&#x2B;/qb6b/Y7k0bCT89ZjwURw/C6s3pq48EGMU&#x2B;kZ2iFNyB5VeuK6wv9Jtvf/L0LhSWc3owt3NukH/SlWww56Tikfh09OB83NrHx0wr45Z6UQD4yJg2gP7VPKwtUeS60g23Qp&#x2B;8W7mqm51r2AeukHMnb&#x2B;A26nGz4duES13yuPPSyepROnro5nM3ucMaunT1SP2dLSdnPr0uG5Z5gpc51WTO6XHxU8qqzgA5aX/EW2yDW43torXcag5RZ4b6Lb81Tr0AuIHSBtC2ozf8NlTd9l2X0w5dKevmePJaWxlp5/FbD&#x2B;hy8bbp/W7FtuW1sKbfL1CnwDlPkbmvaytDNY8qO3RqmrkwcN&#x2B;amENybvkRf/ITP0lrOWHpTHxqYtLI&#x2B;U6uLke3fBfL74IzMQAeYfZIgPZMtyo3tI7FeQ9eg8h56XFWyZ7mlqR7R9dOi8380/TFjsw7ypdXhbaOVbUXtoCGBM6IujxLGc&#x2B;EHzw/XLbM80WTGiQjovLPZM5/yq9uoeB8AOfn7r5UePpNAKiBMW0ATZoPpdoZVtVZilsO4Kv53dV2Gzis3hqc85STr9iorVS2M3nm8lZ3l4Ggezd8yl8xgWHfJyerp4hTDMuZW/JZRcYjcrUiQ8RWB8ef2q3u5J9N7d/ktDP0zTEHoAilDYCGLa&#x2B;kXH09InNuyTcsl0JDkkFX0yrx&#x2B;8PaYp2s6bq2Krn&#x2B;Mv/tcjTb6lOOvgTQruIf91ef5&#x2B;TcGNTiOUxyipizJNvFe/TBdOdc8h3v&#x2B;zSyuQkkVxVZsM2ZwLJ7hY/n8lTN4QXgBkobQJ&#x2B;2Brr19w/1Vt7R/DvSyj7Th9V7eM8vMn/Ds54VLpHJFaIW3ztQyrOf&#x2B;B9H/y9vDJqeOFQ85CvT1VM&#x2B;nNzOTlfbYcqEp1z3af7a84Ti92ZZKxeAZyltAJ0Y/7W/M5NkgH/Ml7W8W9mBpRU5l4G2LnC0ewkpsOf7N2K7AARvlpOvpngznjOUHdB2z7Tbqy9R2wnP0RFvj1ue4be1/82ZTmlyPri7WV3shtkUPx6rIi893VLmvAuAOyltAK3aiWrzazT37lQt6nnjlS8mx3skVxw&#x2B;XnooMh6rqstJsetHO89aLYs7B/bjGDjgDZarheUreGp39NX7O6ss&#x2B;3bCx8eJYve6/5TPnz37zu6V81rdf2sAuJnSBtCe&#x2B;f3O41dy/nl/9F/yRx/c2fWXUlbvSV992Py3DiZl3TadTsfXLJZTbrqIA5wR&#x2B;6xfXbXrnlQTOFdpLiOd2eHi77SPOTw/6mOptsl4xjV9&#x2B;jdxGhCbVHxr7P7Nb/noyVgT3xEAGvXDp3cAgDIy55BJFuQo8q/37i8BnHQ0s&#x2B;U8BT6aX3o4mtk6nmznoissh6bN/O7rb1zoAUopteRY&#x2B;HVzdqChE5sf/OLXdd7w1NAx7M/qp3byxenDva2P&#x2B;KdO&#x2B;c6fC33x1ZfLnV&#x2B;dgaDUKwLAPmPaANqTv7j91RtJnlLnhYlV067edtni6MGZH0/rupEv/4rJ1uWGXjNbYGBfYCrI&#x2B;cud3wGAQ86cJwSGcyWx7cyrV7vq2P7OXDpoT1p7Vs6ndmflZvXtJAdhKzreNtD/42t19k0BoCFKG0AD5tcvis8AeXUhO3/x5VJnlkvZ32yywa3jvPO6y6dUex2KVsyvPqyuQJa/2EZzxrdWZP255ChlHjSZDThq/lm/nLyx1KnLx5hU5FV2ZJ4y1aCqGR2rPUod6&#x2B;zUaNV8BsjV9WiXg/lu2jMAqJvSBtCM1eUxYiPYig9oW91CW//&#x2B;v&#x2B;dCUsFXqfk6FLXJvAjScQpK3trOOiIflxhZdjXXmICCthLadR/6q2cUxac3OHTLUeUnOUWmRshcypfHveFTfmvRtUf2ZDzgqzeETV/p&#x2B;M4wANqltAE0YOff4YF/6l&#x2B;xYPvHtToqv2KylD9ZUMFV1o7eKN3cUeVO&#x2B;YOrDq0xdrWdCytnthZ7/HKGIld2gNt8/JRPzg/vOSU4eq6yH5MOjeyvXPHJJ/YPXVsHp1E1f9CfH6N/dL7x6fHze5LmvyhV5m6biBIAylLaAJq0/Nf1zvxCD6pnT04K33ScPDHnslGS8VxJ4ZBSa2Cc38iq/QtDN9w9ffStza8uFclsrg1BN2qY0vnxk4SqZlPsz3RO&#x2B;Pg3&#x2B;g26/4A&#x2B;dBqzvPPpkeVml0kPAKqltAG0Ib/0TA&#x2B;LxaGT0&#x2B;CEnztUX5WSfcs/vGWnBjLREAU9OHBt&#x2B;dJFOtZOyVsuRxd4lZNHzHUi6Maln8UnP&#x2B;szn54zJ8GdltGu8jPDRPFjOH/7bR0KavOxkCWj1h6xLHnOmgBoi9IG0Iycf2BvXZ4I/OP//FWe4fituG1dR9hZSeWiS1cNHRxqVvmVi4t2b7nyx9FXl9mA25z8xJ&#x2B;e3twNOs3t8Jaj38HkzHnUbnfkQclwtK012GqoawlnSgA0TWkDeIVlcvt4IePjZY6y/&#x2B;BfnS&#x2B;x/msKZ1rmmRft4yIUzI33Mpdanm11O7HLSVVdhAI4qvJTqVETO7l05pRs/tyct9/oIeIiyXnO1rlKE&#x2B;cwAhsAffjh0zsAwFVW/0H&#x2B;g1/8evxv6wGrti4iJF8vewlg3HgrSWk6sPvHdn&#x2B;BPeje/sWU4pdaAgPU5tekvvjqyyYuUQE3S1Zoa&#x2B;ijPPN0Zf74W/Zr/UWbOLBndnL&#x2B;vSiyQV5lWkQ251zlu6&#x2B;/Gf&#x2B;7fr8OqHCXACDMmDaArhy9tfZQbJs/&#x2B;OOckOHhaMtn1T&#x2B;ybVXgNudG3ykUlEx5NP96zrWYaZGP8BSRW891JQhYdWiW7KrsnKU8fp9TcjyX&#x2B;1PVAS&#x2B;&#x2B;M8tzyKreL0&#x2B;ZnyO5EwgAaqO0AfSm0X&#x2B;KdzkjYuB70d9BgHw3zH0UC2YyG5ApfNPM/cVuOXthQych3d&#x2B;c1Pe7e5vxNCZ8LrE8C9q5JWj1jqUiS7Jt3QuVw3kUAG&#x2B;gtAHwR04uPHZyvYpDX&#x2B;/GzkH7f&#x2B;zdy60sN5Lw8dLFAGOL7tgwO2FWskDANUAWyYAGZIFWA&#x2B;0&#x2B;G1pji1b6FtnNZvMRDL6DzP8PgnDuOVn5rMqKZJDB648dKHItO52zuDW/luYhABr&#x2B;jLOf1hrduxJIlhNXmpmDnx9cQGX2WPAeo6aeTfLHtGnqcjMADgCABci0AQDS2oof&#x2B;i98Wm2ef2pacILGkStHuT1oAALWqG3kCsoxkWMDkBSHKHHE4iIfOfcjvHCxYPK59TtQKz5RfrLT5iF0dmj7HHJp0JbZil9VG4ck02&#x2B;jhrIVETUBAF6OTBsAoKzqqV7ZdpArWNRZdslf50GSacXjjgKoVUxrNTcP&#x2B;Z24q5p&#x2B;aCcCUEVZdzEIe4oLW4sBjOyPvhuWwXPos7xv2EIZ8AhRSnINwS/1E7zlloyLUgIAgAeZNgDARJrWkBkD14w3ryQFTXXH7T9Qq9jW05Bm819CrSQAa&#x2B;QimWQ0YipEae7oM3xet&#x2B;C0JM/S85vmogvBeoAtkn2MhHlqGzJbycXk1zbk&#x2B;UizAQAQ&#x2B;LJ7BwAAB3NVImestvMlh1aefOpt0gaEiymnDOnJk&#x2B;m7bAPAWM3f4LXf/k9p7v5opyfq8Ct&#x2B;d&#x2B;6Gz4WX&#x2B;pGCVX89NETE6b7&#x2B;9EMxOPnj19/bMlgzwh5/Z5p3DACA92BMGwAgS9Nhua21Yk0bh98h&#x2B;r7aksBe&#x2B;vnMghKOcsftnqYi91rSbAA2kr&#x2B;1lUHI4qFv/dvqX0P/IScD1&#x2B;S1iIfQ&#x2B;WuoZWqcIoZITnjWthK53mMy8ukJh&#x2B;QBbQ2rJcEGAIASmTYAQIG&#x2B;7WB4KaHYs/La5oy4zeW4BpHjdhivElQ30i8TjG8rzggir7/5tQAwRM&#x2B;X9YnBSVJwFHJYGGQlV/Yrek54Z4hIR6jraSKcYPnmbTUHLZo6AZrsHVETAAA9yLQBAAZLDiNrW0NAs8IF2T4LXnKYMKt2QFvbX4srT66EdiIANhVTOEJ3omvycHtpigTEFRE48yjSJ9iUNbTb&#x2B;CFQkCPMbZGoCQCAUci0AQBaxE0VuYnrH1U5oWJzUlV7k6Zq0KEuOAQcLW7B0Yxsq11z1dpoMAKw0ZDoIlfY8PSsT27PhexXPDyu5/CrQkchiD33EkBJOZVsMeTIDeUfy99bTZR1U6Sk7/ihgix3AAAgAElEQVQFAMACX3bvAADgVN/9/Jv/X3HhqpX/9cuPQdOSMlfHMC9gtrgdR5k/04xge/5T7kmwJI0sALYYnv4JQqDkn6oEYZW1YKkqB9a58839wDpfhXMF0YsczFSFMQv4O2Nt3zpVXRcAABZgTBsAYLWGForiS/wO0cLCmqpBAKp0Nm10Nvrc1GYE4AINYcbs4OSIwf1CsQT9oDf9tp4f/NU21OUmpMQR7oiUNNFm7aR6AACMRaYNALBH/3RuzVsEMETPBGk0hQCAS3fFySQhOoqTZG5ha6FO1Y5Z23lB7hI817HtQE6vDgojroyv4oCTEWwAAIPItAHAG&#x2B;3tyPw0Q/itS/5fB1byaT7GseeHphNcJtnAoWnZubL1B8A7Bbmx5nFpLkiQ11C7fiO5t1HD9RbUJIgzncGp0&#x2B;9DPFSuduvYyEU4frQzZLCUfg21aSRr8VXP6dJMveZfo/hVAADswjxtAPA6VdOeraeZ9W0I&#x2B;QyMOj9mzzMwkNCectmkIADgBBFLHL1UTT9WXL5npNRGo&#x2B;K6eD0NcwC7H2pPS0/nreK2tl8j5CwOYKq6Mbn4ylqU1ZP0Kk69RlQJALCMMW0AAIuG1Ja0NgcJcA2/o3exyYOOxgBewh/21DyFWBz5jApmLhhk37/zmml9ha03D2TMzUIH&#x2B;A4NmRoGsT1H6r&#x2B;q4dgPPV0AgFuRaQMAmFZbW7JhQvscEnVATkOa7dw&#x2B;yJpCRgDwqIoc/FTNE3UkA5gZRa0/r0z2DKzPGb&#x2B;8as0EmccZUkAyKTfrmNucwdjDz5PVprv85d16glhLPiEAANhE9UgAuI1fpua&#x2B;cjTLakt2CooFHbHPQK03NHnQXRpAJ33ocl/YtsZzhnMnWR&#x2B;DuSXXRJvGy7m/067uQcHmLq6RWAyrmktiXnzSAACnYEwbAFyuZ0Z3zdq2sLAPOXF1INpQ8E6HDgXzW9ni9qB5XdoB3K0hdBkSQhRXMrZYpYUClVWptWBMYfxz557UzglnJNLG&#x2B;n4290UX&#x2B;jgwGW5pNuFW&#x2B;/WnH&#x2B;JylAAALEamDQDeSP8MH5cYoglAkKwOtGVPgBmePJPclnHHILBc5SIAGCuXCautnq3clmZVLtKrCvn81VqLFZWz3409hOflwTlvntrN1PlEIBcwvDn3E5wTP4B8BJUn/ZzZqn0EAGAwqkcCwFvkZv7oeXmzee0FtX2Hk3K7N2TlOeTkYJnrLNxgTRtTw&#x2B;49B6UpZERJIgDzzJiDbdTyLvKZGgIt4FeY9ItD9tecbNi65iXB2T765F9jYBLovtCiKlD0D9ydh55QEwAACxjTBgAvlayWk1sm/n1/A8T6zrnF3W4reTSkUBINKLjGlmajUU0z8XpuagUDYJaQ72mIEPqDiiBkCiYAPnp81cadzw1eVFZEsDZS8D5CDJAMM&#x2B;JxWjkXxxLy4RfPT&#x2B;eZCVZ&#x2B;8XkGAByBTBsA3KlqTo7n0T0uFHmQhqao2vyiLGj&#x2B;iIs&#x2B;ac4qbSg4yHEzlsXNMa4BKD4WtzDdqwFYMylUeO3MsvGBDz/D&#x2B;r5rxIEWyOGNnz3KBQk2A6S4VONUVVsRCksm10x4BgAwiEwbANwmbi/Q1J8pdrO1/&#x2B;QvzHQS9MXu5DeLDG&#x2B;TItkGy&#x2B;J0VNwaYrx1yf&#x2B;NzV0FAJ9ycrUhW1Em2&#x2B;JY5fQZxabu88BrR5S43duCB/2gseBPzWepmGZT7gAAAOuRaQOA2wjP88pHff8xPvk8Lzzk720CCFqI9hYIats6DSiwKdd&#x2B;cUSf4tqdzPWVphEHwC5yeDC8U5G8CdlN2aCqo/7UR3HF5dfkWVEriBOshQfPvvXvlaaXUufwsubyj35Cztr5BwC8Fpk2AHgv4ek9np9DWfxQv/Ak1zTuAGYJrSp7GzuK7TVyR&#x2B;niQdGgA8CO2cUee1beHwramRBu7D5oMmf&#x2B;X58z&#x2B;drCnivJlRXjyMdsMNCW94ojnC1dqeKp7&#x2B;RBhGavAgDgnb7s3gEAQK&#x2B;/fvmxrSOz/8LnMV5euGrN/ia2tw7Eh1Y7Vq9hgaqjttCWBOjl2qHW74nAzcH2/NPtnr&#x2B;fQRYtVlwAAHbxgzdlj6iekKw2VnFBYPN2LcSQgeecrwzbDJ6Ed3qmd7UW6vT7&#x2B;tMP8rRzi4&#x2B;acAsAcC4ybQBwieA5vLYVYGzf4dpaNwsaEfxDEw6zpwEleQ5JoeFWrslpS9uT3zAEAPh4IUdD7CGHYQ1dkeIVXpkuass&#x2B;TtoZvMQTAg2JgpL1IT&#x2B;lEX6jtqvZyvOnK3OcAID7UD0SAI6XLCkTT1dWfLAPFmio/LNgmpAeVYeTXLj2HO5y0xQpgC9oEkrWFPJLRDa0Q7k2neY1AMAufrKtNiYJgocZFQvdJvyaCmM3sV7PISQDNvnME&#x2B;NhlL0RTlyN0/LUdwAAaJBpA4ALJR/RG&#x2B;ZUjx/mnzWPfcg3kp1K6jzSla0hQaMVDTG4j6ZJaHbTDE0/AE6hyboFfxoSkskBZzwTcLC3p6vNnBXXZjlOvsmbv9/jWWwnTdiWnOg3WdwbAIATUT0SAG4QPNULz&#x2B;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&#x2B;p4nW05Nn8TcQft5M8AMJb7ZrfctWivttOSPJ&#x2B;H5qh4Y0DWn2YrjkvzY6GezRFTAQBei0wbACDLf&#x2B;xXNlv4DRzFAWGTZn0bvtq2dhz/VVW7VFxznPlzv6elBgu0tb/ErwqKRioLE9Vua&#x2B;pcIwCQFE8b5n6Igyuz390LdmxGLW6z57NKMtS849CgUeyWpFTMe8UJtvgl&#x2B;hTdLnLtSgAA1iDTBgBQqR2q5RqPapdv3cGKfZth4KA9X/8RGa/PiePMyFo9LSNyW5JmyhC58mSwOQBYT5659sov68XHNSqetHAtLOwDFhsYZTWXHJB/qYy1AAB4ITJtAIA6bcOz5DaLsRmyNe0jfhnJNU0hmuPKVVKatlN4L6H2Y7BY1cuVm879KblOV3mStiEAawRD/D9iqHNQecnmMo9j96F59L&#x2B;e8eGGeI&#x2B;4WPfekfqud9TGfQAAwCYybQAAQ&#x2B;y3MQWGDMKrHfkX74Pm5cedW1iWa2HR9H2O/1nVZqSfsE3eLgBMVTWmXNkz6SBT50trWDmZM9gRxzAbQ5RcF6WgEPfCPRqGkpIAgMW&#x2B;7N4BAMBVqho&#x2B;noVr20ruayUZUiKydkMbK23iMl9/&#x2B;uFpy6hKmLmFNa&#x2B;KO3THfwrQsAJgF82Etff57ufftszrVrXd91wOmKUs0vjHr78//y3ZqX/bbrADhwZUfpzJfL0AgDXItAEAuvz1y48NzRa1s74FW6x9yUFqG6qe8&#x2B;93gdefn7vPJKrUtkEUmy38dpnaIWtycUhh06e3CgG4Rm3XFvclfnp3In//k8cy&#x2B;wCVcZQLn9riWLxEZ4bGBS39mR4/sBkS5CRXck34lCyxsGVPAACvQqYNADBA3FQxqmuzv9riCg9qn9LMWvecQ32bUfNf8XLK1gd9U5Ewh4cwbZsrC9nQGkJ2DcBZ/GKGB0UvtYJDM3ukcRC7cWdgQdt4/fjl/m&#x2B;CtQWhy/pUUJC9OzGOSiYySaoBAHZhnjYAQBe5MtKCpopzJ96IT13wG3&#x2B;kWtuUJD0vx0tUFW9MCiZOq22p0Swfz&#x2B;V2YnsQADyCb&#x2B;TmudmOCIEM7l4xIjrixMKsqqlkk7PVykHOwEzS3miqcyq44nnQz&#x2B;wLAMAQZNoAAL2SGSP5JcOzPs2tVHv5p65qxJ7yBCpXTosSBEKpxl2NF6TZAMA5MQSy2QEoOJMnnlisdGIfIAs7OSR6zK2kueMXAAD9yLQBAAYoZoz8XE7tRGKaQottL7egbffazqTe07qkb2OiNQq1XKLu608/aEbF0WIC4CyagVM9X50GM1VVjIQNVTm/IwJL9Gsb7v/EM/E4LfebniSQC5Z6bAylmrNryXSmvux520YBAGhDpg0AMEbDXGINg7T03Ao7izJ9DDep5E6g0GykOc&#x2B;5Cpb&#x2B;X&#x2B;NzQrLtdE97RNAKE7cKDWnrSW4aAG7VH5P0b53v6CTXtUheJv4n5/M94sinoT7kqEoAVTPmHkHY1Vw6M3ht8pwQWwIA1iPTBgBYodiKUTtIq8pBSaCqkWTBC58fqs6hsHDyT8m2wtO71b9ZQzPE7Labg9qGAKCBJrXzKXX34Zu3hzAtrt5BsSXmyY1aSy7W6ZQcW7LnVlJD/jK3HuWcbQAATPVl9w4AAPAvo8oo9bdAbWzD6my4eV7e1mbUs90ha8BsX3/6oa0h43nh2A7CcasH7SAATlQbgSSXmZ226Rnsvt53P//m/luwub9&#x2B;&#x2B;bHnPDwvt3km0SwXk8SxkD98be4&#x2B;mScHin/8&#x2B;rv&#x2B;rBZfpUzmVRWcBACgB2PaAACLBD2I9U0nDb2G4xFyzV2Pq15lqoNzw5gzGoku5jcxJLsbK5uH9F2VNfOR0CYF4A7N46KClzcUM2xjKmIpGr6ryZOcPCfy6P9khW23ie7dxAa5UoRy96DmeKYYLMUDtk6MnZr3uf&#x2B;F5NgAAMswpg0AsI4bblXb&#x2B;qDsLCzMA9e8zuLm7GenFncMh0HN5Ywauh4/f6JdA8DbBEFF7TfvsjFn/n6eEsn0yAV7bZW6&#x2B;y8oDjIqpxVUBaiNkZ6BWc/ObE&#x2B;zzShy4EuOYCOqBAAcgUwbAGCplVWAgr7GM4Z2&#x2B;U1URzRX9aTccodGAs&#x2B;4XPPEvAk//DVvbxICgNnk78FRKbchzqohKZDP6tS&#x2B;VkYuJY7jR0Rt3ZLeE1O55GJP2fMPKToAwFpUjwQAnMel0JorLPUXlgzWXFyhkTJNubpGbY1BRg4Kj2JxoeZCOnHbULzd4nT072keAoDkl2NDVefYpNee/m0elw3Xv7AnJiQQeo9kAUnlC4u/J0ZKUsarwZl0/&#x2B;QMAwAWY0wbAMAuTeNFbYPI8B1o2A0jBs4mcuLhXyNXxifozNszg0jb6Ddh3nsAuIz/PSh8J/pDqTqrOq8PUeyP0FJeBd/wVBkR0dGao6ZRNRVfHjvJXbsC&#x2B;rP95lMKAFiJMW0AANNyo9Zcy4jfYqVpAxrVTqTcnL9Rf58NNsQEuxQfXdzvO7kYbkJdIwBQapiD1k&#x2B;2LY5h3A/KdQaRjPulwXjGcUcXHGYynnF/6txiz8thR3/OLLmGuADABYHTjAqN8XC05FY0J/mCMwwAOAWZNgCAdclKjJ9MKshfYI24uUruzO5&#x2B;MN4cY3z3jjavkUVojOh0X8MQAOwVfM/mop2cYqgjRBo9QUjc1ckyP0j7rNrnqs5YOEiugKQ/Ei4Xg7kX2omgXPXv/pXM07Z7dk4yAOBVqB4JADhPsXno6SQ&#x2B;L1fkMmo9DTdHtMIEO0n6rZkrK5Qr89hvfbOCm6&#x2B;eFg0AGE7/nRtHFPNijOIIeMuCxBvQT9MVyWCYVBt8jiqP2Yb&#x2B;XgCAIzCmDQBwg1yLyYJRblVr3t7N&#x2B;dmB2sntkstvP5aDaKaaCFoN4pdsaVZI9s6mgQMA2tR&#x2B;Cw&#x2B;fQuygsfWzxZ2litHOc9IIfm4lpHP0pQs/JqsX9gxfE4LYeFq7BWUV3Bb7pyIGAGAsMm0AgCP5LR2apqIg5dbTUJKcqqS4dTvtMg0ta2eVirpAQztFfytDrhWGtgwAGKgnv7UxnDAVyQzUMLtez8txBDnayZWI9F9lJ17qTH3tGsSm2QE7JxkAgAeZNgDAqdpaN&#x2B;Jp1eZJZuM007l9vKacvY04bm&#x2B;T52rLxHinK45dy7Up5GYHWYC2DAAwwo8K5C/f4ePR35NVCs7SrVlGNMgFY4dGSrlxewYPx&#x2B;AuAQAQINMGAHivgW1GuSFuF1Rn0jQwnX6MywjNBHHbzfPP4b2JgwFqua7ZAIBD5b61g99XhShxB6C7808ENhC4CM1U&#x2B;kdfgaDYzSt5aLm4dMZJCLZl6jwDAJDzZfcOAABwGCONL9vne9u49Zvkhri5349qXHjWTFINAO6T6&#x2B;vTs86/fvnx&#x2B;S9YVU/xbX&#x2B;dZ/nu59&#x2B;SVQq27AxmkJM6N41ji2lmods1W/Dz3/pNAwDQgDFtALDfn9&#x2B;&#x2B;/8&#x2B;//d/uvZjighFdAqHP&#x2B;OyjbpgrrkdcRmnBRjFcLs1GEwYAvJP7chciiiGJsZ7hdHacuM8Y5YJgKTlSLSgaSZcsAACaMaYNADDXiT2X22xpNoqbriZt6OnNnezTDctyDUMXNBgBAGTNY8jkl8zIvQEYript5oqKT9udwtYJTQEAp2NMGwBgjHgCjxdKNhs1ZODamp9otLrG2LaGoIcyDRmmPJeGiwKgQS66OG4GtWBvj4skj9thYKC2&#x2B;eqIfAAA9yHTBgBo53JIuQxT82o//2y28H/eJUiVaY6r9thzecqGAz&#x2B;0IhOmojkDAODCg848XLHOpBCH&#x2B;FnAXMRCJIP1jERK8nRxMtezSpn68pcJfm6rIal8lZFTDQDAcFSPBAAT/vz2/e5dqKZvpqla0kIv7LgpKv6hSvLlPUfq9pCmKAAAEJDDA1PloC0EfsOZOsNAzqhZ2b7&#x2B;9AMTvAEAQKYNANAr10QSty/oG1OC1z4v3NsWE2cBm5tRkkcX/1y1EsB55rqgyzAAvJlmlHxyEtZiKJLsF6UPZjQBzJXpN8C3LDXlx4SkxAAAmIfqkQBgxZ/fvv/Pv/3f7r3oopkXRK4IZDN7lDwuf1eryjENbDyyebpQJVkmyC/7Q4MIAKDN1DiBOWWBNsZDO/3uxXUm6eYFAHgzMm0AgHa5sVlucrVgNo6ebR3RNFM7A0ptBc54/STb3iPXeEGjxrme9imuIICjaYIZTWcsYepfALXW5POIYQAAcKgeCQBoMXDw1hFNKpoSTMECA3NgQbYyV6CJrNtNnvI&#x2B;xns9AwBu5ReWnDTrGHELMJY&#x2B;7/UsSQUFAAAGYkwbABhyaAFJoZ9ykAeqyr0l21/k4pMDub11W6zabpwAqx2&#x2B;pt9izzmRq2Jitqr6PFP3BG38Op/xn54fhGvHZQUQE6KgxbsR74M&#x2B;lovXNmKn/rW2UefHyNkGxmrInD0hTTF6IXQBACCHMW0AYMuf377fvQsV9Dmhv375UWhkSf7p3NFaycMZ1R989hDAI4YY3sFvBHHNFsn2Cxo1LOvvBk5HcgCxjV/HcqwyaXxbLcIV2GG5DoEcYQZyh0AgCgCABpk2AECXuJ5hw8vl3/Ssv8ekVqS4iWp7c1WA1qvZ5OaYP3793ZX0cT/DIE2bmvLy2WyeAwBBEM8I6bdc3yk78YadPQEs8PNzBKIAACiRaQMAc44Y1iY3lOhTR5oJz6p2bKypvbb9Jqqph5kbUKgv5un&#x2B;G71rr5PMsTGO7Q7BlaVxCkDSfV&#x2B;mQb5Ns/yQ7fafyfuuBVArjlWIXgAAaEOmDQAsOiLZlqTp2ty5ZvvadjV3xjqbgTrnUwleTpvUcDRn3OFJszE0DUCVK79VLdSWlLn&#x2B;Q2s6PAErNQSWrogCnYQAAOjxH7t3AACQ9iTb/vNv/7d7R7q4loupbUlPW8m89Tdo3p/vfv5t4LnSr&#x2B;rZYU1ezZ1t/Sx9SKIt4whff/ohd6X&#x2B;&#x2B;PV3IbXm/vS8PPgngDfz45Y4hnkiAf136/N17L6a&#x2B;VIWKIuWA8oKBIe66VgAALCDMW0AYNqf375//tu9IwnxZGMrSwY5lzWRNA9BK1Z3TBb5HHI5LrsEC9Bl&#x2B;CzyvHq&#x2B;3GX1Xx6vjTcDgEBtmk3&#x2B;zXbL5mY7d&#x2B;UwJfmlf8GwdTcN8O4dAQDgTmTaAOAMllNuD6EBwv9TVTvFm&#x2B;cGSw4yU3pepXxtQ77N7z4PPcryXKz2yga5twl7BOAwyZyZvg/N8JBp3rd8835qBtMrw9HmTeN6N30pMwcbAAArkWkDgMMYz7dpNCfeejZ0qGDeu55O7qP2BA1IsJ2u9vJpEmnP4LabWvQANBOGpjV8offHAFu&#x2B;9DW73XY25g3rx2WOGHR&#x2B;SvBAnAMAeBvmaQOAI7lk26ETuT3ziCSbS8ZOVHac4uEHDUNbJnWDWXdPK7KFfAL9qdqEtiR/JTQ5AfhUDr0KfpNMEfnxg8EckjK6G55s60lYJtdm8NxiBvfFHXzRbw&#x2B;rNFHE9p0EAOCdGNMGAGfbXlXSjbVSNj24xYImD/&#x2B;fAycP81tYTklKVfWzXtPi82ylrVgT1sj1Giav00nZI1uzgLAeGsWAN2se6&#x2B;8PfP/oQoKN39fx7ul3e9IOOIQx&#x2B;OS/yvd&#x2B;RzMsDACAU5BpA4BLbE&#x2B;5CVxLityksrdQkrxy99&#x2B;aLVapTXYmafrLJzfdvEUMRBPMXsWhhMXhblxBAB91aBF0TtpYWbqWv7d754HbfipgWXJ6MyqBD&#x2B;E6HpFBBADch0wbANzGZspNbk/xB7r1tB8taDcxm297BCk35dmzdhToREvQKM1tQMUX0mYHvEf/kLVP6Qu9raCi&#x2B;&#x2B;fiMIA50vBy7ts/iBaOyDz1ZMiOOEAAAJqRaQOAaxnMtzn&#x2B;&#x2B;LZia0tV6sgNPhuVZKqaScWO4ghCJz4K2r/MSvYC9n92yRsmBhtOkzwrriRIsNGhG3iJoKJ11asc/9u5OJebcv1GIplcYUnNL5sXMHLsMGjlV/OzrSAeMNgRp/&#x2B;cUOQcAHC9/9i9AwCAuVyy7T//9n979yQWdNYuFjCsygBNqh0U76c&#x2B;q9cm3mLDGj7zW5Rmnwc0Z3oMttdcI5fyDHAJACSDHP1X87NkMiRo&#x2B;36v3fRnckechrLVbQfeFlb1B2M4S7Eu9NRtFbe7OK6oyocp41VybACA&#x2B;zCmDQDewmZVSZ&#x2B;&#x2B;SlLuVUn6LtvJxa7JHiUPhAFtZgVj19wPVROAUZ9wqs4Skf415TIBF8t9//oZLGVBxc761Zd9xceHI5&#x2B;TeM7d9dpGN2IN&#x2B;bt40qCu2t0wLneMuTgWAICbMKYNADb7&#x2B;tMPix85ThnlVvWqnjaLZzCWsIbnr34Fy1ubSC5rgztRQ7/m4p8wXPNlihejTzcAp2Gg25Oi07/kpi96N87P/2ftGoSzF6w/&#x2B;dqqXW1&#x2B;OZb549ffhe/l5qe25Ai55mFzZkM&#x2B;fUhD8AMAuBKZNgDYb1cvvyflZjDf1qCnnSXHtb&#x2B;4nua7mkUmbfTWfOGhaHSY6jm9U&#x2B;&#x2B;xbSs3214GYCA/hVZMjFWFNHFRSs0EtG1VBGyKs2VycfLhm9YsJvwT1gzsByPHHheHDULCknAXAHAxMm0AYMiCtuCY5SFuzfobVuLyPslCi5c1l&#x2B;TmYhHaku47CcbRQrGSprntiDYvABYkB8cLqZraXkRuMeFbe&#x2B;pXtjwIbDh3GpOprM7dWBbb5HKE2Mv/ch87S5kF/k6OCmOCnqPy6EAAAK5Epg0AzFlfT/JxQcot2VpRLAspL/NOFDWaR9m6kfzT22a5GH4zrFohCTYAsym/amcM3Hfkb/yXB0j9CcuqE0j0ZZM&#x2B;aUTkoMfZAADch0wbAFi0K9n2uCPl5vcc/9T3B9eseZRTujO/vLmtX9z&#x2B;En/SNR98t8zdibfn6LbcDIsNaleecAArNU9M&#x2B;/wwZOB&#x2B;1RZtigfWC52o5iUslaPopmZMMYQ&#x2B;6qiqRELY4LwkiAUAvBOZNgAwYeCUAAPdMZHbWc0ZK7szj81BQtb56W5rhji3FWP4zbC/Q/px5xDAxfpzNn6OKo49eqKRxQOz4lKc&#x2B;pnwPq2lJoubiGePyy1WtV1Mpe/io4ko9oYNbfUhg&#x2B;PqPAQKSAIA3ubL7h0AAPzLH7/&#x2B;brAx989v3z//7d6RsmAc26c0C31nkin5&#x2B;79&#x2B;&#x2B;bHY&#x2B;CJP/7bYdz//9vyX/FPx5dv3/wjFhgZaInxDzoZ&#x2B;Jf6S8aue27LBOzMAfMQv8dzyyZ9jkypVzlhtfBLiQxOmm63a1nMIxUjvk8rhCcPs2nYGa&#x2B;j7LbmY4cSwIVl6YewKjfv60w/Pf7t3BABwKsa0AYBRewtIJh1RVVLZy/hTP3NG1VY0K2xObk1CUaM15AGsbb2Jk7eLC1oKOu&#x2B;BwWlJ9q0WzpK1OzAACOSMTqwtCjooFaQP1XoOqj9kevbzoBP7Bi5&#x2B;UIZSZwUMyYNaFjSOHTYHAIApjGkDAFQzPsqt2FoRd0au6hLe0yO72J3ZAv9UWEsHns41KFTNAlJcm2ajJ3bUbd7hla8CAGuMf00v69DjorueSphjF04u09ADDLPFEUg8se4pWaKq8Oag4wIAwBoybQBgzkGPN5bzbQ9NWZ6g3FBno8yjqrnETSuyINXXwHiDnX3nTpa2S3/lJfda11ImJO24LgAgqA05LgsbNOUig4WDX/ZHlbDmssghjlT9OKpzncEKi7&#x2B;cyv4EewCAo1E9EgCsa5vReiXjVSWbWzf0dYfiqTga1qlfSfzC2S04tBANVzWLWMMH/9bhWW1pS331p1vPG4DXCqKLSbWvkVN1xvyFOdXr5cIAm89fZgkdm7Z0PtOHdlxoAEAnxrQBgGnBs4HxVmDjVSUfVZPPj60q6bd25dapbwLzl6Ti0DXccK7ap33/5mA/Pd8mOMb&#x2B;0prG76gAMFZttLB4DP0RGgaoBacxeUr1v8RUQQB2XynFeZGP5kT1Fy2oVXW8JxZaBwCYwpg2ADhM2wCXxe4b5dbfGdx/4cAOy3ZaYeh5nRN/YAc&#x2B;w/sdhOPVBq1Foza6huYsVd0Pc0vSgR3A9eLpaXN/cgs0D&#x2B;u/Y&#x2B;9CgrYAACAASURBVDBW7gwkw7lPUzx2x4m60n0xwMbnx8XbfYI6N0Xxyk0DAECmDQAOkHxaOGLYypNys5lvaxPMWq9visoZ1c6ypb3GTp7vUPF8GHj0V9f0m1oA4LWKgUoyeGj7fk9uq7k49nbx4QS/8UOvID5UcmuI1xws9jnzHOIg/SHTrvqQH3XU5y&#x2B;gmUkOAIAqZNoA4BjC4BVNR8WNnRmND3FrMCo3lvu93&#x2B;BCw8plhnewTU4rsr6BY8EW3SYaboC5FW4/dQAwm6ZXUFt/nWIGyG33WX9//6TFas9Jwyi3zjGFSoyfu0l/X6Jk/JOMpmq3siWIKobWmvISDIADAPRjnjYAMKct0JdfZeTh4YiJ3GppZuxo6OMsvLatrWTqbCs03zQY2Bjhz&#x2B;52wZwie&#x2B;9mRu6WADCQ/zVdnClWKDU50BOW9EQmxqeRa5jR7VOZn7N8&#x2B;NDomUVsarhyWSzkTt1lxwUAsIYxbQBwnqBupP/PU&#x2B;pg3DrKraFAk4bQE9n1eibXdYTcE37cPXlX&#x2B;Z0GC1Jfyc7X8kuUSzKTB4CX0MQJuRxbW2lEpc7hVhtHa2m2mxzlJg9Z0wxA9P8f7EZy5rzkktirM7BRxocugrog1NHUMNCcFuFRGgCAHmTaAMCEthD/eZYQnhA2VoxUuinlVlvv0bWzrOySPLCdhZ7UtXJzK/rdk41/YAXKnW87RuEOKVQEai4p2fAqADiaplzhwDxNPA9Z7cp3BSE9J2HeELd4efJq59o4Fbemb9P6MKn2MVnfQ8t/lCblBgDoR6YNAIwa2Bh9xGPDk3K7IN/2GdG6EXceN9hiwnC6ZppZFdfsyWJBr2pNx&#x2B;Tcqci9tqfXQoPisSQnU9nYiAYASqd8uZ&#x2B;yn4GGYYL0cHoDzUy0nZGD/PJciLI&#x2B;5zf7hRuPDgBwK&#x2B;ZpA4DNhkT2wcxM/j&#x2B;D2pLGW/CvnMjN0TeRbMxgVc160jYHyTspR2UFH9IjnvyLTTa1nQCE2ebkieiWnbra2T6EGr/G78kA3kMzl1tSboK3eDF/9H&#x2B;y5mFuzaNYS1Y952FZsQFrh4&#x2B;HPPXagqkBchHX1I3mzHhcPSKcBgBcgDFtALBfnBWLB0CMfUKwPwXU0VUlh7SYxK0hBoe1oUGQVxM&#x2B;g2Y/nm1y7UfyYbqSPsF6kuU3/Vd17atoYAPQZZcYwOl6JpStXf7JMBWnK0sGP8rN&#x2B;YtpymNulJzObeDKLR/7O8XZtXk9bzR1EYNlrMUnQqlw4SV0ZgIALEamDQAMEZ5qqqZudi3RwQ/xqpKVzUw5KOWmacjwG4wMtnoY3KU7BLntZGZoQZ/lWgPvD/4ZSA7qUmYck7e&#x2B;7c1DmjKYn39PK&#x2B;oTrgBwJblHUX9AkluD/X5LcTxJquwyyonQFieKDIYiY0uFC8jJAQCGINMGAKbJSTXXPqspNvLJt/If0c57xERumrabnrYSoaqksuVI2bpkvx3qUMoakstoPvuj7g9&#x2B;kumIukDF3Kdmo/rZUADgGi6KmJ0iaotVcuPkLEQ&#x2B;cY6tc1VrLgQEQ8KJF1p2WgjGAACjkGkDAOuWDdewX1Lyc9QQN5/cwFHbg7szV2ehIelVjD/AJxNpYwskDqyMtLHZJThRtXvyrFCYsA0AjjM8f5ObrW126BJs12Cw1Dzaz&#x2B;CxHKTnEUz5LR/0gxT6UA6RHFt/rp7TdURPUwDAWci0AcABkp0f43bbYPkFlUk2Fp88LuWmaY1qS7kJa65tXqHL80rbH&#x2B;/9BFjDdHG1H39r4/kEC3JgpNkA3CGIHNw/43DiCUiWhRlCSJMLjZ6oaWMgpNm0ECvmdp7QrkGyw81HHbEMLEkyRDzr7bkG9g0lGAMAjEWmDQCulXv8EH6fHG9h/KnsoJRbsgUk2dxTlXIT0myfhRWcoLTrAyW0EDWk2fzVNh&#x2B;R8XvLI3djLPZzj8fA5Rp0jjgPAJATRDJjx/G3eYKfZ0/cFqsCoS1Dwar2kJFq89QmYKY&#x2B;NBWn8VZudGVVgLHbWlPcZUZtcwDA25BpA4BTxc8D/kA3/6/BM0nxKULoYmm5RfigidxcM0qxlaS/Qaq4ieTcbzTfDGfks1PV/DFpn42cCg191/Xa22zV&#x2B;gHgLHHGKI4r5qXckmPsGgKbjXUXgxyhIDg6ulX1k7/Bg2/8YOFklNVWR0TT1ann5ZMMTFatzHs9p4uoDADQiUwbABys2Mlx1CaCYRyWn0OOGOLW0HAzqUHKrY1pPOax9nlxzUDFUVZjeyVbOw85y4bznnJCgJf789v3liMKs/QpnzWj3E7h58z0r0pGcWTd&#x2B;slJstwve77fk2k8Aoaxlk2CDgB4GzJtAHCVzsIXyZcnf2P/meSIlFsDZYMUbSvo5M8Emas5qbnbvKQUj/6uaP/mCQBD1I4nixfrCWaquhDp63u3rX&#x2B;B5Lki2VYrl4CJYx4Gry829kxyXQAAM5BpA4DbCM3ffluwppLJHQ8hb065NbcBPe1HQf2ltlVhMc3A0yOS5cYVb6GcYQDoDB5mJ4o6h4I116UcqLi3DBlsUzXddVACZIgTOyoVR/41hEYk2AAAByHTBgAXmlRV0n&#x2B;MPLGl/oiJ3BqMauKx1jsbDeTEefKvmg9y8&#x2B;f9xMJHuRnXOg/hxCYzANhudmRyQfCjHJB3&#x2B;mEuoJ/5bF7twXgfDoqgAp1lUfRz5Q5cGwAAPb7s3gEAwArx04VfGu5V/vz2/fPf7h1ZoaH/cq7vM12h7St&#x2B;nP/49Xd/JNbYj/9xTRhtZ&#x2B;A5h7UHe2LGEcAbXPnlnoxk1h/pyi2SRRurIRvUGVMVt9gWfmzxdO1a8IxZ3MpBJw0AcAcybQDwXpop2YK/3pSZe1XKbYgr2&#x2B;NO5z6V&#x2B;s/m8N7EuSWPSC8Vb3rPDw2H4F57020TAM6yK3R5trsr2UbibZknDOv5opdfrsnANW96mcU7ecQ5AQBcieqRAPAWuZon7jevfSy5dSK3hyuLpGnu8Wso6V&#x2B;FXZqrQSrXLOeZhIahu3NLybul5hS99h4LnO7Pb99fECHEk4q5bNBLEjMupOk/ZH105G9r9rxuL7mOtwqqfN&#x2B;RY/uM2083D7FcDv2U0wIAuBKZNgB4o&#x2B;Qjit&#x2B;qfu5kbD1uncitKlsWLBxM/pFsnJrdcgSNXLtD/8JVZs8vsnKcXHJbwQHenVMEcI2BSaZ4zdYCgNquRfrVMvkZBP2RySmPXfqMYP8R5ZJq86bKAwCgGZk2AHip2nkFRs1DYN8dQ9yCDFkD93J5VfMa71CUbGhwfX6Va2jbtDLjZbnto6dLwfOSGRU7AWCUSf1gkmPjNgYAzYfZ0A&#x2B;p4UiT/ZOIl24SPyLVfumfFSTEXY78&#x2B;HPehgJnnTQAwEuQaQOAt0um0OJGZPcc9Z4HmztSbrGgRGSxpSlYgBYiUzo/j7kkk7sD1NaNnHd/6O&#x2B;8HB&#x2B;RkC0rtpfJ&#x2B;/Oe&#x2B;yTwEkcXkGwrddi5qsWqamXHr&#x2B;1cINbf4QnWJAODnq/7E0OF6ztcAgDQg0wbAOAfik3qwTCOE58P2xyachNaeTqzZT3tWRiubUhWcZm2DNMdaEgC8AbN2aBg4rHPPwODZX1x3J677X6imCTYE&#x2B;WRaipmK4&#x2B;RbkmIHR04yZ0y3e9nbPro8wYAeA8ybQCAAv9R6uUN0MdN5BY0ovnpsbjJqSp5llyM4W67LJhScfYEbEpDJvzQrySuzxk3LdH6A8CguKZiMa&#x2B;mKZAo/Glj5xtNyjDODirRqQiCuJq0EBVcEzC4Mic98afmtdecMQDAS5BpAwCk8WyTc9YQt7hRTG6QYrDadlUTrTWvv9P6&#x2B;0PPtGoB/SxrK/trAzDu6AKSn3/PvQV5ODm7JvzVTo3EZNei3JLPD5o9z/Uryv0yGUTRCekCQsywpaS2Ef3T/Q5cJwAA25FpAwCUMYwj6ayUW5Xmrt8YJcgnFdNL/kyKM8aeWvjId&#x2B;6Dcnjuy0fuAribnzYb&#x2B;BVvIeXm9kGT2XJ727PnuSqabWvL8Xd17JrRQI61XKBiIWoqaq4HzlMhAABJZNoAACo8RAmOS7nF7UpCd/Xnh&#x2B;0taG9WNZarKlF03Oc6Pro1zT3HnSgAMxw6rE2TTPInPAt&#x2B;n1z4szvxE0zV5n6peW1uMrZJoY7bRENWL9jVz&#x2B;7T/hJxb6d4maO7ISajqZ79p5cSAAAfMm0AAAx0UMrNb&#x2B;7RtNqQcltP2erhl1XUrNO9qnP3NhLOTG1Tkbzw0WcJwAxnJduqcjzCAgvSURa0HWOw8Ozzw5y4a2jKRx8aJDRnxXIj&#x2B;Yyn2c5NiAIAjkOmDQDQblKdugs8KTfjjXFtLTXxqy5udNti6sfKVPtC7Yx0xQFt7pf9&#x2B;TNTJwqAKccl2/x/DkzSJFM&#x2B;K/NA8zYUpNx21cbMbZRk2yT3PdcU&#x2B;1fVHrI81M9g7HTZBQUAGPdl9w4AAM5m8JnKjj&#x2B;/ff/8t3tH5qK5Z7g7Ok3LBrZ9xOenZ&#x2B;V//Pr7lSccwECnf7Pzxa303c&#x2B;/uUGBkzbx1y8/Pv91vrxnJdDYGBt8/emH57/aV8U/&#x2B;7m3/ulvqxY2El&#x2B;RewMAzMOYNgAApjuoqmSbpwWKJp7tLDRhTCLXcdJ0yqZtBcBAxke2FYdhKSslatZzXI7n2efa5Flz/UxhQ/pVBRcit/8Md&#x2B;uUDCfOCq5y0U7nTGyf/Ag5C2MB/R1wuxfs8PadBABcj0wbAADr3J1yo3FnIL/ZQm4auGPqtWa17SbvPEsAZjBeKTpOkiW/pmdPwOYKMM5YebPm/ama49Z/Sf8ZiC9o8pK5ZFvDruLzpjihJ/Mkv7Z4Dsee5GBn&#x2B;nOKAAC0IdMGAMAGxpvnYMQR3W97Un25wo/B75UztBVXCwDDWe5D4&#x2B;dmlCOrqrIy/giqXZOZ7aU/5OKS8XC0UQUDGOh2pSCwScZg8Vgu95uBaba9IVZx61X1DwAA6EGmDQCAbSw3z2E91wlX3xBw7oA2d6Rj9zy5tnPPEoCDGOxDo6k3GL/EX0yTH2revZtUJRqrTlpDkuy5iO/Mfb5EsgeScpbfsdmmlZGVHM4FiTSSagCA9ci0AQCwHyk3PM5qFxiyt37bkF8w029GKQ5xExp6zjqlAE53wRd6XH6wZ1WffK7osrFW8bGsTHSRV3uPgTOxJYd5JasLxAsv7r0UZNGCrmnPP&#x2B;VRawSEAIDZyLQBAGDIBS10mESoiLh9qFbbDvRXHwqKIPm7UZWNA4DhLHyhN2dfhFc1rDOZUYunHDsi6xZPgTb2XAnkDY3aCg5SWwghWFguAyBscT3NGD4AALb7snsHAABAwp/fvneNdHinP379/fnv&#x2B;aepWTF86&#x2B;e9CM6M8iUDd6BzghMAr/J8oe/6Tn&#x2B;qCD7/CcsE/49NGi8V1Lc0sqoifWZLPvN6wRHVrpPhbmepGpjVFuGYTVP1hFgMaAMA7MWYNgAA7LLQIx7LFFs9ks0EG9tKGjbtDz7zU3TDW0DMNiEBeC3L3&#x2B;lBsi2ZmGnI1rhVTR2y5nbs2YrBrFLV1Hcx5UviY7d5NpATTzMmBDND4hxT&#x2B;afc4QclHHLD8oJjcUGmqWMEANyNTBsAAAew3DyHeYqtA3bySXEZn&#x2B;Rvkn/qbAR5GlPsnAoAkD3f6Za/0P0MjTBnW5w8E9JpwQpHyWWSXNbNWmXFYH/IhOGxPiFkKgWl3xlhbjm3wLDdAgCgBpk2AABOQsrtneK8lPF2BNePeM1&#x2B;Gj8bABAz/oVeTFA1Z7D0uaVnyQUb2khIZD7iP1nLHaJfLs80L44ylWbT0J8Hel8BAHYh0wYAwJHs94jHKEF7gbXmg7bGGmuVMAFgF&#x2B;Mpt4emDmFbBsjgsLP19NPj9eQdOc8WxEUOgwXiGolTJUOvefFYcfDZkNl/n2SbfybXTyoMAHihL7t3AAAAtPvz2/fPf7t3BFO4ZgKzBjZbGD9SAJjN&#x2B;He6n6fR52w0S2oGn/31y49tFSxnj2xbmb4iVXa0rz/9IJc9/MyPhfz1rw8yg4ONJ&#x2B;t18/g2rDx3OPZjaQDANRjTBgDADY7oEY/3qOo7TAsIAJuC9t9lzA5bb8v0FAskdro1/3RE9UsIlJOHxfeZqaOvinezlfUqk5Ue/SWVpyK5z0eUWwcA3IRMGwAAVyHlhmU6W4JOaftQtpQBuNiWFtvLvtCb823Jsof&#x2B;evw1b8m6LdsoFSDXa/js51JK7udcfcjOctzCTur3f8Fdbkshx13dJgAAr0KmDQA2o7cdJjHbIx7XyzWgBBNmLN0nj34HmNIDgG/X7eualJtLj9Vm3Rjd5QTnMPkndErmwEZ98OPJd5sTbMrXGnzMzO35jLiLWA4AsAyZNgAwYXvTM251TfMcrGnri739XtfZ4DKwrQ3AoTbeBy77Tne5olyK6Luffwv&#x2B;VDWoK355D8vjySzv20HkCKFY5/CTD2&#x2B;SiSX5NlLbHyiYgK342sXkIWUN50ez2uSGNIsBANDmy&#x2B;4dAAD8yzNRNj3vMMOf375//tu9I7jQlS0XFI0E4AQ3ge2h2ulf6H4CTBiklXvt4sFbbosMGoOjfGT749ffq3Jgz/JP5im5iV2zrA1X3M&#x2B;G22wxn1e7QgAAqjCmDQAsYtgE5rmsRzx2aWjr2d42nSP0SedWDOCRm1ppo3O/0JOj2eKBWaMmdetZoGdQXafimD8fWcAZaj/1uSc45RraQo6LA5WqMx//8uIzAwCwiUwbAJiwZWpovNy5LXQwzvXF9ts47MxF73ZAuOsGf&#x2B;L&#x2B;DMCyU77Qi&#x2B;Uc/TzWvFnc&#x2B;rNxi&#x2B;XOydjymHBGDbdqXo&#x2B;8/u1x1HBxFQE/aKwNye47PwCAU5BpAwArNI2/wAxPC53x5jkYl&#x2B;vEvXIUiGY0cEP7C/dkAI5r9rVZfsB&#x2B;yq2YwXqyXHFK6dOUUavdPfeSXLJtbwbOVP7vtZLFpXtKHfq/CRJLFm4yK&#x2B;91tRuiryoAwBQybQBgjoVnKryQ/eY5HEHuejzp/tZQXyjYk2TbFhNnAjjU0X1okmm2j3oI19hhXm6j&#x2B;gFkbvmBu5GT3CsScmvMCGlyUQePh7l40o/fOEsAgL3ItAEAgH9Dyg2T7GoBKTbBPL8Pkm3k2ACczv4X&#x2B;pMoEuZFi5dXLjlQ24i6ZYJkG2m2sYrBQH&#x2B;0kBuY5SeTOjfRTFNne9TuNa&#x2B;HBBsAwAgybQBgQrIuh83CRHgP&#x2B;y10WE9uWDHVrXhgqozyRAAc/4awZthuP8tf6HJmSPirPgHmlilmofwRbMk16LkM4oJZ38iuzSAMokouIIirzgbxUhxmmL2ZfFLVC4aU5tavx/LJAQC8GZk2ALAi2UJNsg0WHF2ECivtzUgFN8&#x2B;eVZlKGQI4hf2wzXLK7eHnzzQJJLdMf2HJJyXmDxGLk2S1aTM7I&#x2B;HIxuklQ4jg090cZpxeH3JBmCenIU85UQCAFyLTBgDmPM8Sfn9JzRNF8CpgOPvNc7Bgy10o2GhVM5D&#x2B;BgsAvqPvDMb70DSkhTprPE4twLhgWFtuu&#x2B;s3erF4RNqjuZvRKQ9u7jFz9k3v9DQkAODlvuzeAQCAyteffnj&#x2B;270jwOfPb98//&#x2B;3eEeAfcnfIIU0z3HgByP749fe4oJy7L1m&#x2B;h9z3hf4MSnNprZ781pOmEpJVVXkskl7XaCvzGC9mP3sk3Lv8m94k9s8PAAABxrQBgAnJiv/MDATjGOX2QqYaPnL1nZ4fcnOf9G/C1EkAsJgw6iI3f1uxPsH2ygT3faEPrPEY/9UvL1m7LXkr1Hi0o1grsnbCttODh4GFtY&#x2B;epg4AgBwybQBgS/K5Im6vkZcHFjNehAr3Wd8L4WkG4pYLoE1cd87m/eTilFtxVFkuy&#x2B;XP3KZZT/K1e1NoJPCq2PxsVqlN3stVAZI1M9siMepDAgAuRvVIADhJ/BDit9fwiIK97itCBTxcn&#x2B;vdOwJgj&#x2B;ZJmIRZJI3XLbj1O31GzinIvRlJa1Gvcg2DH2T9LskVboPb13NDezoe1R41ERQA4A0Y0wYApsXFNOIHm6eXtKbr4vbaRHiJ&#x2B;3rEY6&#x2B;Ge1fnjY77JIBAXNystq1ZDuHMumzY&#x2B;l&#x2B;//KjMhLnhaHHKKhjlNmSvandPz0jm7z7vHJ416n5191kCALwTY9oAwATNQ0uyX2FyVcabbPAeT3f4//nvv&#x2B;/eEZzKv6Elb24M5wVgXE8BNztuGuI2JEkWpK8MDiD77uffnv9278jx9B9M4wGJG8HWnCPsuUfF5SgBALgMY9oAwIrkvB3K55lkL&#x2B;l4bcAuT7Ltf//ff&#x2B;3aNE5UvAEOv79xwwTgc/eEeEDbp2ZYW3KGtuefcekC4zeii4et68eTuanXRiXY9KuaMegNAs302MY/s5/8gFr/Nw2VA3KVV849UQAA9CDTBgDmaOqkVfWP5qkGRrik15aUG87SObaDWx&#x2B;AgYrVuXuKQMqlws3eys5NuY3KVAW5sQU5MFfNkmTbbMLH2SWZzH42Aw2lU&#x2B;T1nHLgAAAsRvVIANhMKH1WnKHNvVwzPZu8Lbzc4opV//Pff3/&#x2B;W7lRHCq4cfVPjBSsvHG3AMBTdWvKVW97bnea8M&#x2B;UU6pKarJTf/3yoz9lWu0mltWQNFis8ia5j6fwz1MUd/uOarcAAGxBpg0ATJATZvHv2zonMoUbBFveG7NTbiTzrtHQpFW84x3aTAbADuVtpDMAS9aZtOaIidyU85b5&#x2B;bZP5Ri4zhwYg9VsWhwwFCdUq1rV88PYDpfHdQgAAGABqkcCgC2uIEnyiaX2MaanlhFeaGMlnI0TuWEUfVmhYmG0eRWKyK4BGCuItYIxuPE9RxmbCdMgGb&#x2B;PnVhVsjhNmkuAaRJpyWUo&#x2B;Xio9R&#x2B;32gGy7ud5uxrcynJ7yIMnAODlyLQBgEV&#x2B;84qmMqSmXTtY5ogpQLCGnafisRO5MaDNprjheOwtiIYeAIsJ6bT4duRueprWauGGNjBKnOSslFsu2Rakx/pTbsECwfrlhFwxI4hRdn1q9AGMcG/pX7nytcLTJQAAL0T1SACwy6/yEf/gP8zEDzZVD1o8F72cwVRrf1VJ0mzLNHe&#x2B;nsd/Sxt8ewPA5593p&#x2B;Q9Sj8y&#x2B;IgQzn5VyUfVmLOnEGXPMLWenBnD42ZwxfyXRQ5CichROTN3OP33CuVMdcRdAIDXYkwbABxMWX1oVCvMxtKCeK2xo9wwnME02yPulMDtC8BKyaqSbqCbP&#x2B;hNOS4kOU4ubkM3e687YohbQwarapSbvJ5c2cnmfYNZ8vj&#x2B;qsc3f&#x2B;Hkw9rA6Kt4ezF7/wEAYAEybQBwDH9YW/DIFP9GkxXLNfp8Uo9JR3SaxsX0KTdGsy0j3BbkZt8gDVaVxdcP9aC5B8Bewl1oYFg1uyTvcEek3BqMLSxZtRjOInz8n8exqjTbpyYzV9sF0y2vuat03nmI3wAAp6N6JAAcSf8EkiziX1yVUMwEFzviyVauKkmazYJkfdrOBhT5dpQs98RNDIA1&#x2B;r4Cmpfn1nbKre&#x2B;pKnlEYckq&#x2B;sKSDFODk5vZcchqH20B2MpymgAAHI0xbQBwqv5nHk0XRfs9o/FOZNSOtr4VmPsYACOSVSUfyd&#x2B;3FZE7y5Nsu2yI2&#x2B;efibR549L8NZO0O4VQ/bX281sV21TN1kbUBABAAzJtAHAtZZJM83R3aMMNckigYqzkLSLX5tsztVswi4lyJQ3vdj4jAOYZcntJjm87N9n2eUFVyU5//fKjUKDS/ys2aq61GJTxH/tBbsjJGaGpxQIAgBFUjwSASyQrezQ/pPlr81dCNbYL5JIiuT8BSVUlzuQlhYncGtbvr7Ct5BEfBADbJUvJ6TtFHX0fu7WqZKxhuBvpNJuCwvvFD2DQcyguf538uWf3hFUZSV/5lcCZyAAAcCLGtAHAKwSPc667ZfMDjL7DJl6lfzYIrDf846zvyu2aURp6fw9cWIP3NoB5kv1d5CAtHnp7X6v0raPchvju59&#x2B;CRB3D2uwr9lKKFxgVcgg97ezgARMAcDQybQBwP3nwx/ND1YNf0GGTx6HjKMuK6q9s7v1DCT77hrTMdk7&#x2B;kXyTBGWU&#x2B;nawV9z8vX2XANxHjsruS6Tp3TqR26dyWFuw8Ox54KDU9tmU6yLOCzPMBjDCkLs33/0AAAeheiQAXMsvwZHUkDAbW6MS6/VMkVW7GG&#x2B;Mu/W31GhqK7WVfxyLJm8Ai8nV5JIJue23ygXeU1VSI5lgy/3y&#x2B;W/&#x2B;Tr1dfx&#x2B;1tshH2TPJQkwVUJbZtLbbAAAkMaYNAF7NH5nR03D8rIchbtcYmEVg9M&#x2B;hZk9Bbz9TFd/Q6FUNYKXaCO09U65eUFUyrv3o&#x2B;EUghcU&#x2B;utFsJNiG0KSy4ux4VezUEDBrXmIzCA9qpdjcSQAAapFpA4AXcY8xfntxc4tMrkGH56XXun7CmIsNybgrzc7hdcrNk&#x2B;R6VfPGBrCYH3Hl7kVB9GXt1jrJBSm3IjnZFvMTdaTZOtV&#x2B;49cu3x9UCC83exPg4REAcCuqRwLAZl9/&#x2B;sH9N2SFygcV5VRJApqbL8bj7nv4pYSmfqh5UwFAj2IF79zPb3BiYUmXD4v5GbKGbBkJtk5jH81yhtdF9LtUzg66/AfYqnP1tlsTAOBVGNMGAIZoOvQNrBPi96Nsex7zi0biYsq6oHGH&#x2B;mSPe6qMmiLcBBZ8uve&#x2B;DeS34nvqsAE4kf992l&#x2B;o4BpPsu2UIW7JZNuTJ4uzZc/CyixabsI2Ib0H5ZxhyuWLU6bpd0xjZUCVm79WM7tk8Juec8hIOACANWTaAGCntuoZA58r2tYTtOn4PShzLyG5YorwFpr31Pq8B5LvHBg0o1iiqSueeysmD9nUngPAQz9l1NscXVVSLhdJZcj1kp&#x2B;m5EPckt35ly0fc81h5p5wO7t4Vu0DAADrUT0SAExIlgMy&#x2B;BSRfECqKhhi87heSLgKxWvkFrDQyoAZTmyi1d9euAsBuMyJN&#x2B;01TqwqqfTdz789/&#x2B;3ekWs9NRiVaTb3ksk7tVkwTK1Y0la/NgAALsCYNgDYKTmQwh9gMarrX8P&#x2B;CJLViqr2ULk8I&#x2B;GGi2tMycVbgklf4gwrFURxOu4wAC7ArUx21ii3eFibkFFjlNtwxaKFwZIvfGBpPlhKcwMALkamDQA2U&#x2B;bS7JTaCx4vm5&#x2B;U7BzRApoV/gAAIABJREFUyzVfwaAITDHtGswow9VfY03rj9nO3cGO5aYJAQC8xCkTufmzsikHrpFyW0xTP7/ompyTEGIFT7ujDpkQDgBgDZk2ANgpGDC0cU&#x2B;SNMm/2mRbcvnFQ/deTr5k8l&#x2B;Fd6zmnTCkSQJK8cV622nXvyE1qwqah952MgGciDtVzilD3NqKQwavIvFmUNzn7NxPa21dk8VbBABgGTJtAGCa37abrN237EkjlyGr2oFn4aBOplCfEJPkupS6C/T8s/ZhOFkBFVtsydzbv&#x2B;g970yDnSEAAJ1OSbn18IfHoUGuk01x3LxytVcqzt9WO77NfpAJAACZNgAwofZho3mCtB5uJ&#x2B;O5vgYiSbOMn1ELfg7yuFxl&#x2B;5KVPGcLKoiu2ajS1JNg7WABAJ2uT7m1DY97s9pAQhPc5oK04&#x2B;KKhixjHDTenWsEALwQmTYAuMHK8W3BuLR4N6r2JPmIRRpmsVwXXXch5Odh/7prhrUx7m0suRboZ3Ji3sJFlFtqmltz/GkF4xUCAK50ykRumGdxBqghrrAWigx/FLV2gAAAaHzZvQMAgF764WVff/ph4KOj/wjU/zj0JGmSfxq72xAUMxbuv9zL23I5XGJf1anQJLwvbq3IvXPmjbS7&#x2B;GQCAJw/v33//Ld7R2DFqLDKD6SFoPp6uXD3tScEAHABxrQBwE7&#x2B;AKDaFza86jFwXMuMVuzcgCeGQC2gLzwoLDmvsugbzCjUOXaFdmgObcjhc&#x2B;cBgNe6vqokZMkYQJ6wzf1SiB8ODS0ankDlHlHxygEAOBeZNgA4mD&#x2B;fVvDEsrKe5Gwr553CQ3PO9bO4BW0Nwcq5uI5wKjQFDONakUP3zoRc08yVBwsAsIOU26vIz1DK/n&#x2B;3dhPUJBrbVgUAwNHItAHAZje1ERcfljofOP2X35RKNKWhNo6mf6tw6W/6CCj5x6tsqYl/E7xQORe9bgcHvGq4ONcYnEZ9brjIyCEDAAxiIrfrFdNsHy8SOzSIjXe7OfjJzd6dnOl2Xn1vAAC2I9MGAPv5TxpDntYsDxgafoAwIjnEzX&#x2B;iLj5a39rz15ebVk04cOofJulbalxDGOl5AMAoDHFDst6AX3Fkz24prHmSSnYss3xaAADoRKYNAGzpHN8T5CrekJGqHR6E2YpVJWurTV5D/3nMVYXNyZ3z&#x2B;PfyiTVy2uUPdVUXciNHBAC4FSk3BIzHHs2Ph7lgcmBRAQAAjvZl9w4AAEKjnkY0lU/2&#x2B;uPX35UHK4yCEv6JvVzf3twCwjAj/fTpp9DkF4W/Ph&#x2B;WqvqHtWk2I/hQAwBO9Oe375//du8IxntCViEmsRliybtdFVgKm5AXsHlmAACYgUwbABhV&#x2B;/DTMFSl&#x2B;NA4nL8b/ZNp5w6qYccwlfxmLr4J296olt8JtWmz4LXPD8kDLA4oHLszww1vr3GTqcQvN3LIAIDLkG&#x2B;7SRyCxhPlrokoeiJhfS33qjULRQhMhZcAAKxB9UgAOEBVScncBNfCSlYW6&#x2B;ucj0rolZmbAUveqFuSR8HZNEX/xqbH7FzW2naN4FwNaQ2xb9INKndLBABgHqpKHq1YaWDZnnwqY7mqaKq/kiQAAHAY0wYAZ7i4V&#x2B;DwapnBKJaPYtTUhyfGVfRdXIcUkDR&#x2B;Wad2&#x2B;A3e9ss6XPePlO0/LcnX3noLBQBYRlXJ4xiPHodoiNaEOIoQCwCAD2PaAOA4nROb5ch1UWaLR6Q17D/PeGfR1DkMEkXykqe/AaqGrn4qPyP2T07nAD6mCQEAGMcot3PZjCKKHariehKaChOC/kc2AAAuRqYNAO5R21IvvGR43qK4b/4CuWfF&#x2B;EHR/&#x2B;Xzg/AA6Q7qgqzMTZTP/EIxHPcDl/VjtRFk3ui63HW3cNQAAMRIuZ3CciwRBHtxOJTb&#x2B;f7CAz0vBwDgYmTaAOBsmuyanIHI5TmeV/npq07FlbRtJTgDwcEGR&#x2B;cn23o2iiGE91h/3R63ZlMZuORxVe2e5szYOd5HsTFo7PoBADjCk3Ij32aNtTgqNmp&#x2B;tfhBkkckAACakWkDgOP1PwgFz1S5rFvnVmZwSRr9gLnkGrBLbkRawwDN2JCVLGD289XAP5CpJz93ca85kwCAl2CImxGnhBDCQ43&#x2B;EKYe7ClnEgCAsb7s3gEAwHju8UYzFZbw8u3&#x2B;&#x2B;PV3zc4ED5ZHJFeQTOj6/3yuvvI9kFvnZY44wK8//bAmBxZXSbJz7wIAoNaf375//tu9IzhDbZwcmxFYEowBAF6LMW0AcInmaa6qXrK3oohczVIewKQss&#x2B;kW7thNqFRNJ3bK6LSc4lx0cjfk&#x2B;IVxiVQjcsfYs5PF4rcAANyEUW5vJpfuH/i0cnRoDQCAQYxpAwAcQ05UNKzweUaNn1R58lwjd/5zC2v67Vq&#x2B;dv4ovVEDsC5ONVm&#x2B;lAAALMAQt1fxqwLkKgQM3Fby9xcHlgAAzEamDQAuN&#x2B;956XkCnP0c6G8r/n1/0chij1HNvjVsFw&#x2B;XbBv4RvXfLcbbC&#x2B;Tdy/3V&#x2B;EHFGnaYjxUAAA&#x2B;qSr7Brsgn6Pcmj6gDAAACqkcCwG3iR6O22dqqWHsqay42mHthrrgf&#x2B;YDthEu2fmdGcR&#x2B;o4OjsfMTmydUUfcOxAwAgoKrk28jVxftVlZcAAAAyMm0AcAnNM1JusqizJsEKjlSe7ss9oMozXfm/cSt8XutXccm9EHvZfwPnUtGaN5Wd99vUnN&#x2B;Wizi7AQsAgBlIuZ0r&#x2B;dgSh1iTgiK38iMiTwAAzkL1SAB4HeHxqeGhrr9&#x2B;Yz957qvhe2U8qfNmY6tQjqJ/wxjceSc4igWfgtlXkw8yAOB0VJU8SzH2WBMKkmYDAGAGxrQBwEv1z0/mll8wGKXhqS85HK3htUlrjhqxeBDYQWM0/R7E8h5aa&#x2B;aoKqnaTNPPehSb7xAAABowxO0IxWrnbQX/zyqQAADAxci0AQA&#x2B;n0xyQpmxKCal3Nqad88CoZYLNeiW8Wt7yos9P1hLqCT3x3/zGHkj&#x2B;eUugzYgg2l1AADwIeVmTK7sdu6ZYmrFSAAAMBuZNgDAP9S2oQfLJ5/i/AVyU1XNk5v5oGElRSTblsm9UZPn38JFkT9ZFvbQkT&#x2B;kwUSG9q2/5wAAYAEpt43ksWujwpKzqiMAAPAGZNoAAP8SP5X5Q4jkZzZlqml9RmrI5txu&#x2B;2mGXMqBrNtsByV7ZKbeJ83VVm1SHgWfVgDAxZ6UG/m2BkEg0RMt5GqHJDfUtjm3PFENAAC7kGkDAGjFA9T04idMg8NNkm3uVemHYOHi0Rk8CafwByzaP4FyC8t2wnu7mFc&#x2B;0TUHAgCABkPc9HJBgvyY8CjWVyjGfnH6LXiJ8ZASAIA3I9MGAOjiP&#x2B;/Fj6DPX4PRYMFimtFyn6HPkMWcQUMeMbceYbdr03KIHXTSDtrVpCHZqdNPAgAARyPlJqgNdTTLC9M85xbWLHbNNNgAANzky&#x2B;4dAABY19k9U5NF&#x2B;/rTD8VH0LHDUITcWPOG5FkZ2l4OKOmLJQZv8mAiQ30rz0GNO&#x2B;6o6QYOAMDn8/nz2/fPf7t35FSasL85xigGdU8YRgwDAIApjGkDAJQFQ9D8PylHpGlYnjBJOAO5hRuGzVk&#x2B;A7CsqrSp&#x2B;2c8AlWzracntX4g5va3dDK7RmIbAIDPP0a5/f1//99/7dqB//nvv&#x2B;/atECO/IdEEcnVBiHK9iAKAADokWkDANQpTlGg/JMpydxYVYnL5DqT1TI1mwbGqnqDjZoCZFLzUGe1VfLZAIAjrKwu7tJdG1NudujPeTytWqfkeohbAAA4Apk2AECjUeNC/FSTawTfMv2A27RmcjXBkJaRUfVn8FrufZh70/pv9VFvsHlvVGWGLPfpYxwbAABFpNyKhj&#x2B;k5EIUgn8AAM5Cpg0A0E5Z4UTo75l8SW4SqTWEKdyq1tM2iiiXTmAgDvRy772entd7s&#x2B;Cd8zjy2QEAPYrXmbIrAlyTcrNZOrJKVUyVi6biZBsfPQAAjkOmDQDQ5frnQM1QmOG1JRl8gyH8d28xqy3/Uvj9dqTZAGCU2ul4cb03j3LLZZ1ra7/78VixOxQAADjUl907AAC4X3MDfc9UTG0v1O&#x2B;GsIna3f760w/CU/fwGSBwN/l9IrzZkooDVdfzPxSfoZ8LPmIAXq6q&#x2B;wXe5n/&#x2B;&#x2B;&#x2B;9jh6BZHtAmB&#x2B;efQZ8LsmsAANyETBsAYAV9&#x2B;/6o2nTDk23uP/3ybRtqeBUQ04yVPPFd6t9MRn3MaxOQAHAf4TY4/K6Lcz35NstJsn7FlDOVHgEAQIxMGwBgov4nT4PPrvp51ITkXNu4Ilq48PlnWiiZHIoT1e4dWBzrFvzgBOWSDH4kPx07xmcKADT8rwl6J6xh8wvX6Uy5nZirS77t9Z3wgn8av74AAKAW87QBAObSzHPWIzeDQrDM2KdZP42RzHYkZztv3grgNHya4p7XtfXBbL4VR41/BQDEZsdvuEbDRG6npNmSfZXi8EP5SSFcAQDgboxpAwBMV1t6Ua/46BsvM1xuyJr&#x2B;qZsHb2jIg9g&#x2B;uswTb7YYGTsACDz3w&#x2B;CuGPRbIg&#x2B;HgHKI2xFpNj8&#x2B;JzwAAAAaZNoAAEsVH1b1T7NyE8/Kp2L3NF670fgZnnYr9MtNJZLsmk370aR&#x2B;AABwgaqojBgGH7Gq5CkTvFWFBLztAQDAg&#x2B;qRAIDVprZoPx2un4dezYZmFJbkkRud5MJEmnnXYvp5RN7wBiavBgAz6AMwBO47dUck1Xrk4qWbLiIAANBjTBsAYI/iIBJ9c7&#x2B;wKs1KhucVgv0RDvMNKQ1UCcYExO&#x2B;Q4O1U&#x2B;85P/n5efVclRkIAgB3yd0GygGRczZsbuzVckWZVjyRT9wQAAFjGmDYAwCXksTjrewrzsI1aVU1gtW&#x2B;wYu4tGCq37A0cNNRO3S6fSgCo1XPnZCJMpUnfgMmv/vsGz00VFxWIcTIBAMCHMW0AACOSE48P735rsD/vlv0xeB6guSJV0xwWJzIM1rblXTFwi8VV0RAGAAskb7YEHkNUnUZOeL9cJQD/Z6ILAADwYEwbAGxGx1Jf53mIX54c6Ob3sN41K5W/XWGwUfMJEXqRxyWekothJXkaNuVbVD8T26hVtRn&#x2B;iaMxEQAGKoYfmhgmt2a3hubdQw&#x2B;&#x2B;MTU0CbaFuwMAAM5Apg0ATCDbERieAIuzF59/tiXdd9rjJM19x3guuQxR1ZVKXtygAdT/58BUXAPhEz0j4c17HkA/MkNtinf1nr5Et9KfEM3ZC86/Xy6iYd/A2xUAABRRPRIADKG0ju/Jgc1&#x2B;st14zpOH1n&#x2B;8wpwc2Ct&#x2B;sxXnTpPXptyu/FGKE3XK1VaR02xt26XZCwCs8SuBc5ful&#x2B;woVrsGBmN14qQBAAANMm0AYA5JkUCusSZZF/Gss1c8NOrs3UH5zuxvUPPX86kZxFaV2B64hwPREAYAk8S3/YGDpJ&#x2B;vyONCuOEapmsd2y/n5ec/tqbPH5S4SwAA7KN6JACYEJTZoahOTDghwelSNlUEhfWC1648/7UlgGpX&#x2B;7ycN5VNfgnT4oXWX8T1Q9Nyi3VWyJTxlgaAUeLiw&#x2B;7nj&#x2B;4LqPaenJtJl3u7Xn90xwNIjJOwgBwr5pYEAMAyxrQBgBX0muzhd3JsTkUEbQ1Gnuv0D6I9a8YyuU96sb6iv&#x2B;SWlLCy77yyQuYQ/uaYTgkAphoyoFkT7r42PhEOXBOXupyovgvaa091EoPYlmkeasnVAQBYRqYNAGxhxvIqFz9uDZmwLe4bfvEZO0KurqO&#x2B;HSF5ZzDSMNRQ&#x2B;WrU5rhhAsBYxVptPdN8xkUF4q3r13aT4JyP6rzy2vMJ&#x2B;yxEsAAADEH1SADA2YqNNUrJleytohMcWtw9WTn9iWZb80bOoZb&#x2B;/O8a0JbsKb9sZ&#x2B;TRqLx7AUzyhsKGo2Kqsd5w5gPK4Wvy7zVX0&#x2B;YVx3sIgy97cvkAAGzBmDYAMIGn3B6u2MuQkT1Ghgc9Bh7XRz1winfjRrmLMnW2syr&#x2B;uNtcv/sZHyLNCu18cgHcSshw8O3ZI/7iiIdzXXyS5e&#x2B;v4ixWudOiqSH5LEPhRAxX/MDWTrMNAIBxZNoAwIqLmw8sqD23F7Q19BwCb8UZiqnNZPFY/69jM6/CnsjLKOuJDayFmzxeOjsD2MLdBuN5Ii8g3Evn3WZzpZWTbg2Yi8m2Yr4tuR76qWCLqsl9c5VFxu8WAAAzkWkDAFt40hgi2WTQdhpzV&#x2B;SIvtVVWRnaWbYTmhuWbf0ss1OPAPBCdu6owhfTEWFYreTXWZw5U6bc4jUwNx6My7297dyUAAAQME8bAJgWdJfmMUNvSBnJ5O/jckb2r0tVss3le/x/1q4KMr/vea4Go1tg3W5laEawcY8C8EK3JieCAGD4vV2YX7N25rD7vn1y05G6i&#x2B;JnI&#x2B;QJ23JJC&#x2B;FVN51JGBS/99bP&#x2B;AsAwCSMaQMAE&#x2B;IefANHZb3cgse2ITX3Rm0ubnzRbFo/ZxtvwjUsD9Wq3St9otfm8QKA0mVfkUa&#x2B;iSzsgwXJaqXyyXERYC57l/un8EtgID7aAICbkGkDAIvkZ&#x2B;aVe3KHSU1Fu&#x2B;bx1h9IkGAbtZO8CdvkzlttYai9LO8bACygzG2s3KXL5EZi8QWUUwx0G&#x2B;YU5D2M2fx3LJ9uAMAFyLQBgCG5Z4zkwzNNOQ2GNNM8a/D/H1hwaeQDEd5Io7YYDJhrXu3bBDOxuVNqZ76x5AVt2yvNG2P78QJAJ/2gcDhVfYaq1uzPpHvNJdDUvXB/avti5W2MNSzEugAATEKmDQAsSlZ0yY2gEpoSLmtoGEWealtTdFE56HDjyR/1EKtv3IGSzc/j&#x2B;r2iqQXA9QjDpipWRPxc1x9I&#x2B;dWp7LtDxUgMx00PAPBm/7F7BwAAKjyx2CFcC&#x2B;FPcnuHMHF9s2dt/dOMa14YTBnStqG3sXOiBt5e3GQw3LIAvJBwA5zxRb/dkBt&#x2B;chaxqh1w65mxCSN6RqoVA1dXp4HvbvTg/QMAeDkybQBgi3vKFRoFci04pzcibBHMEBAU9xviuTSaJrYZF1EefteQRSs2xFzZmDjc9vOTS8H271jw9hDqrALASwSzZF12SzzicN4cJ8dlGwK5&#x2B;g3xXL&#x2B;vPYcoIs0GAADVIwHgSK7xmvnbZgvOsPLE5or2WLguVa0kcSHT4WnI97xdjUzGFpzw2RMKzls5ABzqJd96K1Wd0vcEHgEXgWgKLQCy3PukLdANuiN8iCEBAAci0wYAm2meRpLLuN&#x2B;0zWHOU3SS/qFOkzIpdiK&#x2B;SXA23nDIJ8r1W&#x2B;9vzhDuUQBwqM77mBAquI4mfF1&#x2B;JsQMyTM/u/PQWYrJtuJzREMdiDef8Gv4N64Z3e8GrhAAgMWoHgkA5sTV&#x2B;Z6KN/5cC1XlX&#x2B;TFqAYTqD0VbdNa7J3YrGGLysNMvns7Nw3BkM/vqJpayiqpAHAQbmiTCHHFwNb25Fb8X1JV8qPonOcvGXerqjqHbz7hF4jfKn6R/M&#x2B;4G2axRykAAAYxpg0A7IrzYfpWbB5LJkmW65SXL75kb//NscP4iuivOlDtmfTbQfxLOfB2sb02JgBM0nN/S1YPfsnAd&#x2B;V5G5tdW7CVmxQDPKFOYMPmuApnaRt92xMNEkkCAA7FmDYAsMgfGhKXrddPFcaj7DxVY3eMX4uemdvaFqZH81T6cYRcBQCoUqy51zNL68UTFCWPKIiOcvWN&#x2B;zetD10uvgQafv2MHEK49xC6BiYfUdsEn1DeXQCAczGmDQCMEvqW&#x2B;iNR5CnckiynfI7T/2w5ak9m63/bHHSwR0sW9vm8vvUQAMZKjk77EGUdInnJimm/l9APcRPOkjwQ6s2ndy991l/otvX8PPB5MznqFwCA4zCmDQCsmzcciqfcNmOviMHhbrmn3J79dM/kzIwy1bL3EtcOAJR3woY5dD/R8JGqHTuIwSjI9&#x2B;ZOKi5O65yN2Gf8cl&#x2B;vePKFih3BZ4HrCABAjDFtAHAAv6Nfch7yfbv2Urk5ruI5V4QuvUfM9T183ywf7Dyze&#x2B;nGbzD6BQPASvpq0snfF&#x2B;v1tezTIRaUOC4OOixOQ3X3JfD5p8LlXXrGG&#x2B;krWmMqZZotFj9&#x2B;Dvk48E4AANyHTBsAnK3hUYcHm1GSic8ZXLpuS0MPbxibclUiP6kkrlC&#x2B;KXhfCYlhsncAIGi4T2pmL3vcnenJnYf1G122deNy9SGJBC4zKWdWXC3vIgDAlageCQBHkquvKOvy&#x2B;dU/XlKkaJJgWNvYsYZxOan1FyjYojtA3iqW3d0sCwBmBUHa2Ip5t9YzvOxw7lbsxwP7lNeuOOQ07rDVv28AAByKMW0AcKqG/oNKPCMZt/0CdTaH0ZrWQB7UGOd6ayei790/AIAnN/Sn9htcGDq/cbD79Ypfi36xgcuuQjAsvjjyTxNCBKeIib726n/HuuvORQQAwEemDQA263lEiesU9XQypbV9lPhMzm5uy5nXAET5oGVynYWTAw0/mffGkHcgAKBN8zemZvg4N/NPU4z0ab0ubTO9HaR2ImHlYtecnxMNPPnxw2byoYCq4wCAF6J6JADs11&#x2B;Fb1Qzelzg6NYiRbNNOl0GL9DYolgI5Jrz9JdbP/iVzzgAzJP7uoxLTQYLaL5kqecsWzbO&#x2B;5oL0f9gkgtg&#x2B;lcOm/yLziUGALwTmTYAuM2QzMfTUhCMpOGpaYvgtPvzwCV7cG&#x2B;fxS34U7y3ZOYWSPY41g93AwAMF9yZiazmmXduiWGUhOcRzuECwknuLPxYXDMAAK9F9UgAuFDDc45yloWm3cHnE82k9fygrO5YVQTS7GUyu2Om&#x2B;Nc6GOWgL&#x2B;KUTLPlFu7aXQBAvSH3XmEquPsmD3OEknS5osqCeJn&#x2B;S3Plae9EsNGv81lg3iXYe3FvnS4RAHAoxrQBwJ3656nuL1uHQP90IPoH7I2XKTcI70PzU558ZkZdzWKNMgDAGlVFgPXfnnGJ6Vtv9c1dxOQX1p6x/nj7DnFZyOCcUGy8We15E&#x2B;p29khewe1pto1bBwAgxpg2ALiZPBm18vmE6axnGH5KuUyXSQ5Hq2pYzLUwMkc9AJjibsjxD8nFcia1sB&#x2B;k6qttSO4hud1XnXNfMgLxzxLhx2xTO1TFfenGrr/faz96AAAjGNMGACbsmiFcWVrneTAWplsw&#x2B;Kxl34zuvfIsbrsuk8FusJa1dZAXxg5yqgHAOOFG7d/be&#x2B;7neyOBZXaNnXr5mC0//tQsPH&#x2B;PLiQndJNpMHddRr0/GcQGAICATBsAGGI2ZaWZSMzmnhsXz6dVXFKzcM7GVrbgSN/8bpG7G8/ugAwAeIOg&#x2B;4X/LXz994KQVNDEXW84RTPQrWqq5geBOy6BUIyUCq4AADuoHgkAtqx5Tpjx0MVk1D2KFXUGnti91&#x2B;jNhYPiD8iQuTeE37/2VM/DjQ7AGj03cGWp4YtvZbXlN/m6HCKI8Tir/do&#x2B;pA1n/qy7AWk2AIBNjGkDABP0NT1G1d9vfjIpdvWlL/BUQx4mn2vE8LJlVmbQuazz&#x2B;NeRGx2A2YLgsPaeo4ktL76Vrem9pNziq3AeZkgWgQz&#x2B;2fbGzk3r27CqUZJzFTtCvXQAAPYi0wYAVgQzbE2d0TpYs/yU0pCTu7jhZqOeh0mhXNLei/XCvqjBIQ8//3z0ZnjVWxSAHdzSF4hPMnEsLEgG7e7nYCY2/Uosi2s/JOefAwDAJqpHAsABZj8jaWrsFIv&#x2B;5RZIlieiApuenUfKeVfNzjEuc31hnyMo38&#x2B;ceQDXc1/xr73jvTAUgVn6&#x2B;ZvbypMkc8nFUvazVc1aHf&#x2B;JjzAAYDsybQBgiDzwyP/9yseJoEBHMd&#x2B;We608&#x2B;fxrW3Y0Bl7r4qq4FlMNuZRuJa5NhMaFZTjbAPbS3IU6JwG9PhLQzCV29xmAZblyjvFDVtW7NJlay638IM/OX3/XAgAcgeqRAGCafv62gVuMf9k2O5G1QoVH88/bqLeE8O7iStlBw8FiQuVePhQAjNBMX8QtS1A8gcB28RuydiibPOGZ8PseygmDcxPOVR0jdzkAgCmMaQMA65LPG2s67mmqSubII9ja9wkTniqZV/wgtCnME99X&#x2B;UQAME74Uui8g3EDBGZrK9laXD4ohRLbG0xqDrl2gvC&#x2B;PQIAYAzGtAGAaXFPxvVD3Jq36F77PM4Vn/qgN/sJ2b9kGKXqqiU/eqTZxuJ8ArhAUAux87ubcV2OJhkQlxzgmwVTxSPv/dFgyc5zfpXIRXtZKRjQpr8F5cb8AQCwBZk2ADDheVbv7NI46emiZ7WayiFHzw2w3byUGA1t2/kXl8/IDHFXgAcNzQBeS777Xf&#x2B;VVAyril8Q1O1ETrGWo34NH2O94homFwg&#x2B;SqYOBwCANlSPBAAraie1jp9nDD6cuKIowtRHbrG1u3aV5id2GoN20be2kIpe7DnbnHMAh4q/NYJ/agZMy18918dsz&#x2B;FrvgiSp&#x2B;L684MGwSwAnWvTz7s2KZ7xn92EWZ/l8pjBYDv9aemZ4AAAgHkY0wYAph00tCLuzHjKnuORy/3knn6v79iOFzqiBwMAFMnfzrV1EeX1XBwJJEOgIDjnawICIQvV/8EJ3oemugrFE9/6H5xiQcviI3BybQAA7EWmDQA2SxYu&#x2B;0Rpj1yeI1jAf4xZ/9TRUH4tuZPXN9xM1XbemtuJeMrVc40gtMqtJ9fa7SkUBgBHEO5muYFZVeXgLg4DLj40VJFLdCx2WXAy6ikSAICNqB4JACa4MjVC&#x2B;2/t44SdkoxVe&#x2B;6XIjGy/&#x2B;fqfwTVT6LOxdIQKqlSJbKBXJXIX6z4GwAAlPi&#x2B;RoOBkZ6mBuxiyXisYa&#x2B;2HwgAAM0Y0wYA1vmZJ&#x2B;HZI9f7z8jE7MrOickGcQv7fy7O3hG4TA3IlgFAFU0w5i9TG4OZGvEzGyOe4ZOHzid/M8T2D5pcFaD25XHtB54EAQAHIdMGAEaNfYBfUOKPp6BDBe&#x2B;0zuv4qla2Tpyfefw7XrIeEScfwDu5u19VJckGb7jZ5mL1u48asWU9BccG7Qbl7j/3HSkA4Epk2gDArlHJtu0dAxuOonbyuTc06IzS/L4SWpTclfJ/z0XJ4Zz0a2hpeharmnZIXhUAnCsoX9wfcFqurDBPcnJlnEu4lD3Jaf0bQzPqVLmqxYIdG7WfZo8XAIAYmTYAMK3h6SLcGThiAAAgAElEQVRugI7zH2seWmbU1bm7I&#x2B;cyVQ/8moWT77SqNbwB52EGf3wGZxgA2iRjNm6qSpyoOzQ8thQfu67X87iXq0Dw4TMFADgTmTYAOFXxwUZ4RLGfbHPDoYSX07A&#x2B;nHw&#x2B;KZEEm5Q3GU0jTnIZ3uQA3mBgB6nkZG90lsJBap8y&#x2B;quvCx/AvZ&#x2B;XSTmweLWMDQUAnI5MGwAcL3gUlCeNmNHRUn4c8v9au/VRxTN5YFssmAYmbmXjimCUIXeJGQNwAeA4/pd17Td1kF0L/rqrvgKwQHH6Qw2DHdrmhUbJvDv3BADA6b7s3gEAQJ0/fv09OXNA8VnI5qRZzVO4&#x2B;S9XHjtiwplpbjWw9h7DfdZ8onknA3inZKgZ6J&#x2B;bitgMp0vOT1wl&#x2B;RnRfADbPA&#x2B;MGz96RFYAgLsxpg0ADlY7DsNfOO5NvCAV53daLOZ45AWYEmwUzVuo&#x2B;ZncXancpbGZAMYuM94PyRtdcjHGXAJAjyA8IyrDNeQBZwNzV3Y&#x2B;MsGws0n5OTvHCwBAPzJtAHC2K4uePU0z75xXfKP4WXfZu4vGOBQlk3Bj7xK8CQFAJpeIjMWzTyWncAMMUr4/O4MQCx8BeQ7Fqf2fAAC4CdUjAeB4wSRto1Y7u7rIk0vT7HCusoq8QLChhj3Eh&#x2B;dhGODfixpuSnsLJQE4GjcQvdy5in9JaIFrBG/vE9/byRqYjPIHAKABY9oA4Ab6fJXxBqOg2KBceDD58viX9JgW1GY69R3Y2/ZH7lR7rpuOZSVNpUf9qpL1Ibk0AIoodOzT3IGFZYwHooBAU/1ev6oRe5RQlSSbWkPex/0TAPAGZNoA4C16SjLObmMSZvAagmTbKCurldKy&#x2B;UK1ad0qjKsA0INvJSd5r47LQpJUw&#x2B;nkd3LcP0zznrdzD9FkDfWf4twd0s7xAgAwG9UjAeBCuXqJfj0Q/WOP326yoNFkah9Pef&#x2B;fBWgYki1&#x2B;YOZyvEruA8gcIQCMIE4I5O6onCWcqzZOOD2ukJ8cAQCAEpk2ALhfsutx87PT&#x2B;mTb2MfXXDrN/w0PlhrCBHhtJ5DTjqTaO4AwaQqzNgIYgi8sn7u15m6w3HjxBkLJ68V7oiHU0w6mavtUHgKxFgDgtageCQCwaMETGiUlhwsqR/Ws5/PvWWGuFJSFyBYMiQPwQkdMdmtB8V7dUJUOsECIJUZN3qZUNRNb1QqTvyluxX3qCbcAAC/HmDYAeIX&#x2B;ovl&#x2B;/8RrGkeuORA7ep6xgzcYj&#x2B;tHG/XhqnobLPhEc9MA3oyxGhpyZYK2SubALrXf&#x2B;89dwuB7WzPbXEx5IDYPGQCAxRjTBgBv0fn8E48rEkq0zaAc0VIrnuqcB8UZGgoAciEOtT4XFd8cJr15SLMB&#x2B;BAnKCQ7eMWj3vmuh1ma545l4UePhkxh/CriHwAANMi0AQC04qRU/NepOzBq/dSAmio&#x2B;vfoLF7TEGWywQI/h9Y6SSLMBwEEY34ZzWX7fVsUtLnov9q18FrB84AAA7EKmDQDwb5JjvJTJj7NSI7ms4VlHYZZ8DpUnmda3aySbaQaunzcJgKn4PuonDxLiDANbFCN2/cIAALwc87QBAEJxO4j/WBU/ce166Io3/fTEbFvVoJ2CJHgjJUvTcC3u4M&#x2B;6d9losMsOB4DefTe0xeQp3ACzTn/rap7XihO2HXfUAAAsxpg2AMA/CGO8PtHINuVrz0UXzi38ZBtlJA8lJOYB4AJxXPTgq0qDs4RTJJ9ujnsDK3c4vputqfgNAMBNyLQBALSSD5zBOKRdSZFRqb7cFG4ke0bRX6n70rfvkRueOPCaDvw8agZT8lYEXk5z&#x2B;ypW2P7QZg2gVW0o0pxjq3r5cG0zPQMAYAGZNgDAvwiDUdz018K4t714GDtFbqJ19&#x2B;5KTsbO9T1F7m5g8ApSbBaAXq4vjq/4bcXXWUxzYoEt7Hxa3/ABecMxAgDuxjxtAACtF/Yx9OckEIpnYjj6/tsxcLRo/0qGD2UT/ur&#x2B;G7VFABd4bkT&#x2B;vYjpi4bgNAI&#x2B;PwiZEYokP24zPoM9O08MBgA4C2PaAABpfvEQeYa25O/vxtQFA&#x2B;XO4dveVAZdfAmKabbgn9QyBRAL8m3&#x2B;XeKFnZOAO1j4wMrlAQYW4rbzRBPcMwm6AAAnItMGACgrPvBYzrc1P63FuUaqGs6Wu1ic5PVsfpyHi99yLzlwAP1yt4tktn7JHgFoZ&#x2B;FzmpsS&#x2B;zNn92YfsuYmGezD808L1wIAgFpUjwQAqAQdt93PwXA3m89FU/eKEnNjCReLU72McJKXXYUFlcTi9TMMBUBS532Pby4A&#x2B;KTupYReAIBrMKYNAKAVdzmMR3pZ7ri9ptum2cM/COdwvVyP6WRa3f3z0CulafJ2XappHwfgVH3RC8P9z71/AhhIvqXk7iE9wcneO09xt4MFuE8CAM7CmDYAwABXNkYXu1gmy5sw6ApXyjUWj93KgnFsvtyn1e86sGxnABiUvCkFt45nGbmtPHj5h9sL8G7&#x2B;bSQZjQg9n5rtSlxpDjD3wjl7BADAFIxpAwC0Y8BH7imR7uqwTzPzx6veyUEtXOXC7zk/wGtNmoz2VTdYAE7nzWT7w5dydG&#x2B;uSiT3PQDArci0AQC6BMm2oDXK&#x2B;KOUfvcaemIy68Bwk9o6USR8xo/TsOd8fgF88ne/J2Em3FtOv20CGCh3Kzgl9T7qViYXiuSGCQA4EZk2AECvIx4LqySnoNO86sOMLPNxJmcQ5mPLLXaQXOfrYvO3WyA4P4eeBwD9kveNqkZhfw3cT4C7CZ9xIQjpuS1svKXIk/76R0oiDQBwJTJtAAB8PmIdyNr18PQIU5RjTIvv2yHDMhY3AAXNOrWJ808&#x2B;dx4sBuBV3EStM0pKfri3AOeLS1L7dwz3GVfeRlwMY/MpI&#x2B;588MxemSyKIERW3PoAAEf7snsHAACwaPjE4/oHY5uP0DiU8u2UW8xvJck1jpiVK/JWfGEyzRZ30KY9CIA8z6X7ofbm&#x2B;bxEeNVxN2TgVWZ8PG1&#x2B;5KvuRcUl3WDf558EWgCAszCmDQAw3q3PRQ3HFfdUFdrubT5C41yz31FbPunKbNnUY7/1FgeggTAEtr84JOUlgeMoiwTMWPNBcoP5bjpGAMDbMKYNAIC0YMzKkKauOOtW7LHOAydq9cz5oRmqJVdWjNc2sJm44ePQsAO5LtXDDwfATXIzO/avmWAA2KK/Yvbwu4G/8oFrG0JZpVwZShk8QAAAZIxpAwBAsuAxjx7rGEUoAjlk/Q3znC2QnAWkczdo1AbQYOCtzw348KtQEi0Aayg/d0G0kByn9fyyeVrH&#x2B;IU27wNtvZr8lwtlPwAAOAKZNgAANpCrSgIG6UfFzd4TX/w5indA&#x2B;eHKNZD17B6Ad2puVXcvT/6eZBtgRFWJyM6Prf1PvT/6X3Pr66m&#x2B;AACAWVSPBIDNqAh0nJ7nwKqnbh44McrYm4ydmeqLx1V7gw2OaPsBAjiXqzdL1VngJRrCLTsx1TI8&#x2B;QIAbsWYNgAAqg1MtgW1oR7PP2mbgynWWkaE/QlqSFbhQwfACBck&#x2B;Pc0hrUBsxWHywd1Dq0FSP38O8883MoAAJch0wYAwFK5SQhy9SR5CkWDBY0&#x2B;dt6Zbk/8o76v2QvAFqOmDurpAQDApudz7SfFk5/xXOrO5g1h&#x2B;F5RKxIA8BJUjwQAc6gneRz9s2LD3Gy8GdBv1ChMy3KfFMaGAmg2fEbVjbcjwktgiGS9R02w4S8QfB79ec623CWe/Zl6i9h&#x2B;jAAAzEamDQBscU84tIacZewTI4&#x2B;gGKj/vRTPXrb9/em3c8VtQ0ErmHw7tXA4AE4xKjzbddsh3wY06PnUFF876W5g8MNOxAUAuBvVIwHAEGuPQ5inYVKHUQWs8AbDqxKZfctx2wSwwIypmGbcV4OdTBbXBSAIuvKMXXm8znlptp6Xj9qr53jNxpAAAIxFpg0ArFjz3IUFlNeuKhfCFG6IJesXvVnyPMQfMU4XgCrBVEwPg91f4tsdbdxAj6pkm2aGto&#x2B;B24UQPbp73cDNbT9eAACWoXokAJhAmg3AQzl7X67B92jN04Q89YiEMpIA0CBZ6yyZ0Fq1Ry2CpCBBJtBA/pgnbwsG8/E&#x2B;4zcuAACOw5g2ADDH4JMYeiT7wz7dzDsfcemr/v/Zu3&#x2B;c2Y0zb9jUSBjbu5Axjs4SBnCmUNlk2oAxhvPZwuc3egPDhmcBWoFCZQa8BEUy7F14bEA4X8DXHJp/isViVbGKvC48OHhOP90ku5vsLtaPd9XDpBU4FpJ31zrcV9cJ2ana0PUS9u4GcF25z&#x2B;EsA9bNi&#x2B;Z1psPLLYrY1h8yeT8ltLgAeC01bQBtcXLySNMl5PP3N&#x2B;20du/6&#x2B;ganPaeEvXe52V6SmD2z9K7rcxUopMREaBc/sk5d1gDMLUKps5dA7dWMlpuM7VQTy&#x2B;EPAEVJ2gCgqisn29Nj97r2IiM3Z9oPMPbmmEtjtB6Ad/5z11YBT7I3uVGzHzLrNgMQKf4KtvBMbK21Q0qcAjT1BAHgRkaPBGjLYsy0xsf3J02WsaHCYgbrs0fdJfK4XvfqBiaxvyj7AuN3sPWrMY14FrMEk1wCd6nwgeMzDdoROE1b6OXInT&#x2B;jtG3u5ZkCQAVq2gCasHmWUnQMfe51vdrm8LF2mDZtliGu7xMz2s/1IUMLXWod3uC9zb6&#x2B;Jbp7gEJiPmy7GAjX5yQU0uzBtW7stdbiMgY&#x2B;AM&#x2B;gpg2gFTF1TuqQnmdexDPtA1fONisUzJEm4/uSZVGVP0zWEeN8Xz01IcpgPwcqih9gYPo2L7QlkZW&#x2B;ZzfACAowBKvkF8dIeMTIpiRcmRceQaHEKAh5FwgAd1HTBtCcjk7eyCVhnL3AcvZmceNGXdQ63CjhcuaW50EBHiMhharw5ZvxE88ICrAQaFRspuldtEC62MhJ5MzTANAUNW0AfVhcPunq46dSqfMGkVFoTJnXdJ8GC173hoiM2cMjn0trTxl4mOTmVrlpNSfrJWtCQDW9t0AWHxdNPZ3FOW9T2wYAAWraABoSuHxyOuVYX9&#x2B;nV&#x2B;VhIqdw8753JKEv4/Bu007S0Z4Q89zn2WH5LQKIktzVe8tHWfxI1PNEUEE87Gkn7AlPefsAT31eALyBmjaAFp29fM/lfo&#x2B;0mMVq6jjzXvcrcrih8FscvwPU31Ui69X2yt0C/z28HaCcK1&#x2B;&#x2B;FerbAivNtQSfvbxcC4fAlXG2T02Fe2otGW1upHMfAHqhpg2gY&#x2B;uzDpcBPsxmcduDr2MlxuZAsm32QSymUou5Z8xomQD1nRpUYPPDqv352wIP1/Dg2RpvUA1Jx2C/h&#x2B;38DKjZdwQAFiRtADdbRCmbs25snmCMNwrb3qPceebjB6J5qr3KsEa6JBI2wx4INOXKxS53fRRH1geH7VWWJG4TsCXtmMrV0mukubg2z9ia3UgAWDN6JECj5hOzbU7INP4&#x2B;LwRZF4U4OXmY9bB719/i9RX6dptyYkZNTFhOO5f9Jk8dZ5gyoE2bH2t7o&#x2B;AGFlJzCOgrq1g8382nv2iCApHmx87eZ8hmi&#x2B;jiyV344XcNbBuYoXz&#x2B;Xx81APRCTRtAB&#x2B;Yz2y9ONsIdPa4&#x2B;fp4xdp1&#x2B;SqzCblOZFxygcXvfuZGTU64fFVNN3k6t&#x2B;d5zb2cLIYuioU7MwZJ9NrWmDtL4AXgT7gYAt5O0ATRn6s25a5IP3iPyclpKSx6LrPK4OpG9w/Fuv7YaIN7mZS7XBxKokLftbdvZbTaqJE/VwkCFpY&#x2B;vU9drxhOYAcBI0gbQqCvnQvNzRWc1xLhSJOeq9kMZ&#x2B;24qFDXuKfQWLyaqvL2fCyDG2Q&#x2B;riw2z69&#x2B;z4Q/Y&#x2B;aDl10cABiJNR1zMsIoZ20g3xmyBZ6ERCEDXzNMG0LTNebnCk2fwQtf3hGnmmPVcMvGTJZi4JaD3EtW966yzvN32GaBHZ2drWz98OPlFcONcqptP9uIrAG8Tk7gvGuR7zl6FuffYEh8pgeUfrm5&#x2B;Bx8vAPRFTRtA69YlLJtnLJvDylXbSFpw8R3fvIz98JbNOzgxjtTjQdrjNgMUUqHIuNCAb&#x2B;vln/363mt/qnSHTfVHHCn06XQ2Ajw1xK6PDgD6JWkD6Nh8sJGz10TrB2FT3tnayeL2cGvRRaKODSCXmA/D&#x2B;h&#x2B;YCWtcN0e1M2Fu7&#x2B;RrMWBJ4Bwt/oCKDNiSj/S9hcRcoheYJXrxAZK8kQBwC0kbQN&#x2B;uz6WhE&#x2B;SRsl/BunlN/WJwGGfCZ8V0ItSfjK1CDG9XAR6pTmVbubK2tfn8bXlXCgypRatZZm3MfuFUeKviB5sV0gPQKfO0AXTJxBjEiD&#x2B;F3pstxryA1/VyTe7mZcjzbT77sWNXAV6oaNhW7nM1y2YXndETurM3gXF8i3pzdNZMW5fH5nNcPMHI57s3GWSuTQWA0tS0AfTq7PzSgSVM9UmtnbxR2mIf2Ly&#x2B;NfKiV/vPochy0tb6FLIUNLT2pADu0svnYfL8bcNOy8HQ5TxA5A48v1vCDj8dQc0eL4ENm479eeXcYhiMyLX08mkJACM1bQAd2zv9iLl8eJpvad37v/nYvasyeZ7FKfF6iMjFZBL1t7Bf4/G1eNHmXRJ3bNQwrN7lmO6hyK31oQG8VvgDMKHYq6&#x2B;v3cC3iUI3elRhaMe946L9eq/As46P2Zp6RgBwlqQN4JnOnuOF799Rtw7Jpm6vzdnIN/9Lgr2YrRF7GfziDtO1zO3MMAfQo5a/WAOXhpxiVEker/5Q4bccPtfnh7u&#x2B;EABolqQNgF06QZ5qb/KtixfhOnPedJha1bTZZ7ruHtrcYKP9AO&#x2B;U6wqJeQXzNHB3rm0r9MF7cbHhr5XpT7416NrmNWoXG8brQ/v2kQ8SZi6IfwV8CADwAOZpA2hRxkH5L563yE6Il/FS94fZfGVuj9n2bnnDOwIQKeaT8/oyE5aw&#x2B;Lju4qN7Pm/T8M/jVO9tv28lWrOYwjBwcVJCS6/BuQyTr77aK2ZdL0rMBsAzqGkDeKBTpyuHV1w2dbJHCTFX3c53qvhd4nBKiffsXdOLfFdvQsxLvfl&#x2B;BXqZ9YwA79RmGdbtWxXTpAxsoS8X7nW4B5bbM/eOndaOhYyFerd/XgFAdpI2gJvFzxHdAidFT7WeOGHvjb6Yjb15F2rniZ/NVkfviUUBRpGD66bJtcz6ozfHf52tv/Sni06MJ0l3AlHclcNwb4e/dya20mt3jAPwPEaPBGhIzY6S&#x2B;Km5nAi9xzSsU5aURTDTjnm/yTSi0d5wPePt0/hF9a/sBmhWxsgt11Rtw9ZW3TsA3WJYy4QRODUh6MhirMhTDaTNZOsBAyquW56b/wWAJ5G0AdzpbNdDoe4Y2LMYNDJtn1mcVE99i/bA1qy7P8RsAOWc/R5cd8qHP43rfNVubkPCetffQdoJvErgKqiObH7sPOOpAUCYpA2gCafG4QkvJ&#x2B;06ykhOkEgWMzULV8T0qE6VauE7L/7kYmSAyfXPwLNNtZhvycB0qnXCtkVZz&#x2B;Z6k79BXJ1Ds/ptFEW2CSO1MwAmANxF0gbQilNXBF88I6pzLpTx5I0bXd8xYua5sZNclPYCbj5q80YXIwOvVWLi0sgC4vm6rqyu5pfs5hRW880If5uEr8vRWuBh7mpcVWiKazQC8Daf3b0BACwtZlCbeiXyrmUxcXfy8gO1LzzG5mhOgRm81ta78fi7LrOLIt&#x2B;FxfEeWNriUelbBvAOp74N5w4fFfnRHV7&#x2B;Xn3b5jd7ro/9&#x2B;ZanhWrr5Uxilgztu3EHLtT8jjzwAeCp1LQBNCSmxyHv6jbrVOYJ31mCEwLsHnl5PQEqiBmYt9CqN&#x2B;tdwiM0Rt659DfIooW5KGs729TcfB18CcJ1eQd0NQQCAG&#x2B;mpg2gLXuFPuMV08nXTZ8V2XkROXGIrpCHKVFhmXeBD3Y4U2Pkn051zgIQVrSSo9AHcrVW5Xq9Ndfl64xGtHC4bQ5q0t3JWqERXwDgIjVtAO2qfwFv8hnLfFPX1yk7EXo5F7fmEjj8Y17kvYcvHuv9AggLzyVWeRsO68PGT/XAxJx1trlcXrg3K3Bf4QFkF3N51vzYSTtkajYaTdYIQMskbQB3iqkyOXX2stfXcKOmNobs4keJkd9cdOVQWnwsGPAHIMbeR2JrbZtT2xP4qK8wpGTgvwnL2ZuFDhpxY8sqEK5Pv18/ZKo9u9bOcAFgTdIG0IT5tYT3nkXsTd4W&#x2B;djN250XvdNmR5g457orr97iE8YbARAjZsTd&#x2B;p&#x2B;oyRMsBR5bbf62iy/X3hK0OWEh8liLHEwl1yEcb/PsWAsWgAZJ2gA4IX7&#x2B;Nuc/73TYc9dg2WUXFjMAZTm&#x2B;HKQAJUxDMgYGNswlUCUWuIprMV7cA74O1k9cS4Nb3FjBtjl6waLduLl5m9OEN9Jcb2EbACDSZ3dvAMDbTTNnJJ9IVOi&#x2B;uTJRdvxjzW79DIsZvy7O/fBC67nrS6zFgQYQY95Ou1hS3MvneZ2vofnyLzYypyxhb7g8X3nUccuetgjY9rYhkLEtbrk&#x2B;nUEJ8w27fWMAYJOkDaA5p3ocukgvzk415/SJ54nZsWNGJ5v/Hn/4L&#x2B;7sEANIEB9B3T4SeNpVXHulLRXCtqKP1bbkkS5&#x2B;zuzNd7h3two2P2MdvAD0QtIGcL8uzh82O1/SLkOufK0097pyrfpjxLwCgftkeQEdaABpLhZdDbPxDG/8KJ6exWaLLuz2pGpvAwLPQvODXAKjbjTeuErbvMVnRTVt1tIBQDzztAE8RMwU1iXWcn1d&#x2B;kEebz1r&#x2B;uK/9oGFtG6FRmbUAHiezTHWyq3u&#x2B;uf54eatv5oPF1JtptWzoVqkOjPn8SThXeX2&#x2B;PnUluzt&#x2B;ZtDMsZ8PuS1N/Tr&#x2B;nfZGwDNUtMG8AR7E1Tcfg3yKR1tKgm8vwEJQzuuD/bM2wTATPI1EMNOfVXpjuPA1VHzsrZwiHh9OuE0GV&#x2B;Tw9cBFlpL18KtxPVp4KkZsltztujWgQxAO9S0AbQo44WEpa/bnQ/xf2pF8&#x2B;c4deK0ecpHBe9568MX1OssAHieRj7wN6dl2islWd8eOatTXjGT4Y1NynDj&#x2B;bBiBg7dHrMNs5Om&#x2B;SZVqILNaN0SPrzsYO8ODmEAmiJpA3iFBq9E3tskp0yv8rZgKbIQzVEAQFExk4OGu&#x2B;8jR2K8/o22l6Ilz0H1trYHFzW&#x2B;z5yaDDjjoZQmpiWsGQxAp4weCfAihcYpWozyEb/wcbiPs2dTt8zRTTkJ&#x2B;0CnDp/m4UuxGPJrcwnJmwdAdqe&#x2B;46YWTrkP8/X2nFpX2ld2rpbb3jfg4Zfj5qKm2iBfnWy6a8eI2Y3DBaaHu3ez&#x2B;3w4eFs862afBQCvJWkD6MDhiUSgm2Bzgo0S3QrxC1xMJHB2nBCe581v8XgIxHcRytgAmrLXkb0e3m1vCeu2UNF&#x2B;5CyLXU8cVa3Ztrn8&#x2B;JataI1DN&#x2B;4hgWZeYK7HvTsEFlhT8jYYKxKAvhg9EqAnGcfJufdcZb49h6eFTqt4kr1ihcB&#x2B;rk8QoFNnC9ri71xidtv5Mg9nPpvuNqyabdVaboftyU0mBmZT5D5fSGC3PGw3Rm5z5aeWPC3xLVNCAsB1atoAOrM4M4kcxqepE5XpSu2Yyrb5QwaRA52bduDFkRsoDgCgFwkXUnT3aR/f8qzTZiv0Gl4ZYxPihYd/HKJjtvUee&#x2B;8&#x2B;nHYBWfy1oQ5JABqkpg2gS5vnIZHD&#x2B;i&#x2B;uEyx3Ye/hZaGH40bC2wSGgZ3/rn8BoHG5Bmmc/1xf4J60wQ8a&#x2B;TKavhZzlcKEh&#x2B;mDLNLqvQ7vvI7oarYb9z6sYjYgvjLv&#x2B;tOp87kKwNtI2gB6lXaOsTfzR/2TjZg5SCQKvMpmF&#x2B;HZgbwAaETCJ3ZkiX8J62&#x2B;ZzZZhuFRlfUVXNZHXb/km5XbrI2u9T57aSwOFX5Uztr3NiFzC4pf1dWYXX6jF8jf/CwDJjB4J0L2zw&#x2B;aE71xzovj5us6OrbR5DmaQSVoW2QkYmLlwfbzY1QFadraLOeaepT/5Aw3L9RfWohl2&#x2B;7dS5ACekQM1nxrqHOprPyVaT3wQuPPZIr/rMRsAZKSmDeAJ8p75lz4DSZu&#x2B;fo/zJR7jcLwdA90AvFD9Mqzk1Y1fUo0kUouCmPGXRd3MYSd&#x2B;YBwIX8dECtd7be6oCdoZ/CDLNuwdgLm08EIB8DCSNoCHuH5yde/5xpW16&#x2B;mgX4GJ2ZJnOgSgF/HDaNcP2wKjQd44yuUphyVuZ6ejM&#x2B;4cp8wztspTLZYTnj8yY8x23WILjQkBQFGSNoCnCQ9hH&#x2B;67r3bWUeIcTGcHHQn3V2acNx6AXjRbPhUY/6391tfU9C202e2/AuQVeUjG3Ce5LbeewCxtOQuRzyvLuuZOjTAJAM0yTxvAG61np1inVhVmAQn8KfIsbrqnbg7aF3lYidkAWGshbAtvQ&#x2B;TkZzc6O7fx/IGBv7YzYCaNy7irZN/lYg6NOtlhLi1/FgHwSJI2gMfaGzCn/X6QSeB0VJcH/VqPXXO4u9qfAW4RP2Ri&#x2B;66PnLaopFkPpTiV1zTbzlxs9qmXYv0Cbg4mqY3Keh9r9oiIt3hS/T6jxTvieAQgF0kbwFs8vvyr61M&#x2B;XsIuCsDCYQPmVE/9Xoy0mKwoY&#x2B;fy3oY1238duWExr9K8dX04oZ02QI9ictlFwloonm/ngOriSW0ebpvvkfAbgFwkbQC0YvNCab0SPJWzeoDGbdZslVhR5LjBZ6dQKt2DPG3SInBah0&#x2B;9S34uT3oR3ubsaIrr93qv9vF26&#x2B;0JzH5daBK1jHPLZV8mAKT5l7s3AIB6Ojr9uHhG2tEz5Z3sogAdubfH/MpKS2/wNFxktTXeJfl5PfUFeaoPX30x/mz&#x2B;KfDfvVua2gFitmfzaR4&#x2B;9/rWz2X679nNa&#x2B;HpAPAAatoA3kX/PtzF0QfQo/HTe15SVrqKYnMKtCtLqFD28aRBvDdL9NKWMHnMi/NgGd&#x2B;jLHOz5T1Uszy7K4d5U83gZssNAeiamjYA2jVeKJ1xdJHAZaoAAGcValRM8d71x1Zr9hQaZe5eySHlM57&#x2B;y8WciazvkCVmyys8admm9ZNqKk2POTATjkHniQBcIWkDoF0ZT3XWVxY7j6KajIExAPeKGTIuo/XXx1v9msEAACAASURBVMXVhR9&#x2B;sYE0JRO9f&#x2B;uFtz/yJdoLOyNfZC3VG0Xuw3v3WeRArR0OMfHh&#x2B;sY2d8i8MdvlzQHg1SRtAG/X4OnfnHMeAKAFiyZT9gwsvN6E1tr0kMjHlm509TW0QN4SvbSH9/JaPczF93pdbhXzPtY5Izv8EFvcOWYhgfsUekbT65krZmv5XBiAjkjaANh1Y2/I/IQn7zZsLllHBgBw1rpoabPtlKtB1WN3cI/bPFmX6OUdk9PA5l2LSZvqbEmy&#x2B;FElD8OtLiyONccdAHl9dvcGANC6cTb4&#x2B;utdTwZwfc6SvSUP9z1NAKBlmy2EmNEFS7Qrrk8BFTPeXV5PbV8lv2Kbb2K5fYaLCo3X2vV7XTSj2jwBjBFfvBuYc67r9wWAe6lpA&#x2B;CfNDW7RvzwJleWPHFZMQCwZ7OREGif3JVdNduSaaR5eVHRZ7EeeJB25Jr6q5FTreQPir2QOMuTip8E8UqBqQMNgBLUtAHQtJiBWWIK1E6dg4Xr21S/AcAbTG2MK1/95SZvy7i0auHcM1pQe&#x2B;Mu5FpalsVyXfZqthKH7fUpAE8tIeOef7jw6ca8kyYCQCFq2gDY1ctpzHRVY8YNDp9aN3u1OABQwmYZx6a9YosKjYfFeiPXqFWTYD6FW5aBzaffw3P&#x2B;Ucf6xb8YpjZSxzZknTay3DOKX/ipCeTOjgMMAKdI2gAIaee0sI5XPVkAIKxa6Vj2WCVhaesnK&#x2B;kpat7M1gRtR95atKbe2eSnVqGqrM6nzfyIWz&#x2B;ppt4sALpj9EgAHiUwAs&#x2B;wc8nw4q9ZhooCAJ5hahikTQsUbpksXG97nFrdEPFcNIfKiR/B78o4gVx09mXv5W268XmF6wXjV3SqoC1h&#x2B;QBwiqQNgKfJPsWaSbMB4M02v/3DGdVe4lV0lqPNVafVrMwddmfLgUZnU9XAf8MP8VLX8eDX&#x2B;candrZ27cHvAgAPI2kD4I2K9oMAAA92tm5setSw1a4oFLZlX&#x2B;agvi1CnddHtFna9bn32pSwhRWe1PyDJb50WPAMQGskbQC8wnxMyLu3BQB4lCtdvWMv8&#x2B;2dxWcvQrp9g7uTFtBSX5tx1C2yP69FuW3GI2Lvc&#x2B;mpbw0ADZK0AUAU/SMAwGizQO3Kw1uOr&#x2B;ZbO22z&#x2B;rYYe4WM6/usbz/kLXihx5yMXIzE5gVtkVN0A0BpkjYA3uJKVDaepwnbAIDJxdqXdbuiXHayt9hAFHS4JZKeSBlfpYsRL12r8L7n2lfDE1KG/zucGRnSsQBAOyRtALzI/GxtujRbJxEAUEdMD3L9&#x2B;rbk/EY76pTNa7biX8P5XFbzdmw41SCvu17e0pFSxue1t6mRs1/Hz9AGAE35l7s3AAB6Ej4LdeIHAK91dvSzcLPh8A7Zhbd/HvPIcpKNr97iNcz7Xtffc6ipx6MvbYc89Ux9LgFwO0kbAC&#x2B;17ubIQtcGALzWM9oV&#x2B;qyhgviju6Oyxfmm7o0SGQiDEz7xfF4B0AhJGwBkNp49itwAgEmgAzr&#x2B;gTxJ9nhgPUw6rZnel0DUNP9Z/HVeWlpuI7OI38LNlyLm4TI2AJpinjaAmyV3u5BRzGzb3h0AIN665bBu9UXGIdohT7V4W6/HY5tTwdGCmPflyjR&#x2B;LTichzK8f64fvjlpZUcvCACvoqYNoCEKoZ7K2woArxWO3AKP2nzgY5qLgcKdl0t&#x2B;QTZjCXpR&#x2B;kDItWMkHLOL5Cxme3wyANAdSRtAc5xU3G5&#x2B;4rd5ZhhvOkt0uggAr7XZpxyZt23ev1CjIvtobJFxmjbSKG0WYYNGZlFoCuew&#x2B;ZnCYkvWd06Opu4aZTGwN47bU/nzDQCKMnokAGxI7hEbguFcXyPAAAC5LJoH17uSA42KRmqbFs9RK6gOr3PLDt&#x2B;ayPdufXClb1M&#x2B;4SsUD8eWBICuqWkDaJEqqKZkv7g749IAgL5cbFfE17Vcb0mWKHHbW1HGtTzDqRc/&#x2B;3xvZDe9oTEH5sPewb2nc/g076rGA4AEkjaAVoSvSuZe1zvFnCUCAKPFOHWnGnvziqVeWonrMeLm1S3aSBeNyc3ilexl33iVzYztu6&#x2B;/nR8OgRzuVe&#x2B;pTwYAuiNpA2iFkV4ad/3d6a5fDADoVDutjvWETHO3b14XYlKHRoYMZc/mrn5YjHhlQPt7He60rc0qBwAXSdoAGtLFWdObJZ/4BS5Nnf9c2zoAoDOL4rbDO4&#x2B;/3HV51sUecGFbHe2ErGyKPI7Gu63nY4tJ7G43bU/MUT89TRkbAF377O4NAHi79RlUzJ&#x2B;4Ua6wbfMWp5cA8EJnW30xbYbNbvr5X09tYUbjxmvlXrH5AmpJtuPKsTZN5xZ5z8g7X5F3&#x2B;esXx34LwAOoaQNoUfz5FQ/jTQeAd4oZbO1wIq7AWHOB1C2B6pPbTW/BYq/QmCwn8uVNfgv2Dqv1jZv3LHRIRj7lzbvZGwF4DzVtAHeaBspwEvJmCZexD679BICHCjQMFtVggRqmOuVNGWexhcZFNtcLndaFj5R7S1TX/93LCxspqwWAEtS0Adxv3RUSM9IgHdm77HTzYuRIdgkAeKosveqB8cnDdzjrsBQvYZlmsT2lZoUTa9nnXZ6Wc/ubON&#x2B;S9Rnr2UrZ6fTn9ucFANlJ2gBacXi&#x2B;obuhd&#x2B;GzynW3V/aTdgCgd&#x2B;HS9sMhJQt1cOdd7PxZaAjFmzc1JRnV7B10aRfS3bvDX9mA9fNtJy8EgAqMHgnQhLGsLWYUQSMHtmzxvkxv6FS2OH/7wu/1&#x2B;hJRbzoAvFCg/zre4iF1hi5fN4SowEtdVExJ6Nm3YO94rPlWbp56rKOyzU3N8hkFAL1T0wZwp&#x2B;TTJ5f3dmdxdfbFJQAAbxPfbmxwcLb4tuvm3bSCqCOcn9U8rDKu6/DoSz6&#x2B;Fq/J3vRsaQsHgL5I2gBacXaYe7owP7e8/p7aKwDgzU71WccU35RuWlzpeW8wL&#x2B;TBYsLgvfsk76vTAhd5Vd6YLdeiFmI20iEMwHsYPRLgZvMhOM6eCBmKpwuHAzSFB5OMGWoSAHiJ9XjU1xVtUl4cqXIxBOV6GMyr2wdxwm31vf/Gu2tnXgwRefGkwyEJwGupaQNoVOAsJf4ExiCTjYg5Aw/fuPnX22dNBwBuEa56Wc&#x2B;udKhoc2Lc2ukneTnrjdQKgrOuzAnniAOAPWraAO536lLfvcQlcAelby3IeNX55o3eYgDgioR8ro6LVXFQzvWDpdrhtpg0erOCzYEGAMnUtAE0IePlvU6QujONiXR9IQDAmy3mZksLzxpsVCyK4eb/TR6GHW50vcTzooQKUYcYAASoaQNoRfaJr1u7HpmFs1P0rXuUAAD2XGkwVKhv26tUi5zgdpMqfzhlqmwLH3SOLAA4pKYNAG5zeMp62NM0X4IEDgBI7hDfrLApPX9blocvhsUziy1tyljElraTXznGHVMAECZpA3gOVxr26Popt/cdAJhbtA0uNhXu6mGfl/4n5AryNpqSffyS5DsEtiTmo&#x2B;PeQS8BoFmSNoB2JZzDOO3pVMwpqw4jACDSNAvUooER35ZooW5ey4fe1Tw7m2fS62Nnc0vmd9vL1Q4XAgAMkjaAxrlm8FXmb/ferGy6nACABPOmRaA5MW95bg40V&#x2B;HSn4shXwsZIQzVY7bDWwKmCds2/7QZ2wMAc5I2gD44sXmPvV6t5AVOnWJ7ywn/FQB4qlMtzMV0aAU2538FNixmZLzD8h14kiz7tsv7AOAKSRtAN65fSChQ6UuheNVZNAC8U96mRekmZYnZ5rSEKeqWiyMXI0CmbUPkaJMAwB5JG8BzhHsN5Cs9Wp/inj3p3StiS98mAKBb4cEhE5QO2&#x2B;bD1u2NrX3o4sB6EOP2aCpyAw6rQg0UCQAJJG0AXcrSS6KLoQubk7cVWlG5hQMAjUjrSZ/ajY30wh&#x2B;Wph1upJYw3Qns9sk59OZCAICzJG0Avdrs5tBl8FTXe7UW3WrTGEqL&#x2B;1xZBQDwEne1GbI0h3JtDC9xGG7duBkXhy3JXuQKAK/12d0bAMBVCSdU00M&#x2B;fPWFcyoAAHoxb8pOt1xZwmKaq4ubx5MEzrNaiNkm64PicDl1xswAgPeQtAG8zpiuqX7r13g&#x2B;nPwO7r37441OtgFgsv7GfOQX5V2ZQfJ6522hKxu/OX/bI99izmqkjm10GPjFnBc4&#x2B;wOAooweCfAoWebBdhrWhevn&#x2B;fqSAOCs1zaTTrUZxtmkpp/FnzZ/T9ukEi2Z177FjPbmQmth6NGY6QNiNvL2JwIAzyNpA2DD4STzAADPpi2UZrNQ7JYtCVjMXzv8c/bQ4AZzo5q51Dqfjq8BHXfpw71XzAYAJUjaALp3vV9Ab0Lvspwwt3ChLgC07/ENp3CToNmnf70Zs1kt1OzzpYKazeO9gG0t7exvnS4DABlJ2gDe6FQ/gv6FLjhzBoByfMkmmDdOxvbkvFW5brpcj7Uyhm2LzGNz2/Zu5wEqN60DkyhHCkzY5jQBACqQtAE8wd65096QOHv2Ogt0IvRrs8MIAIg3fpm&#x2B;c3TBeR3MvFFR7hUosfCYi8xi1vue9/21mi38ijyVS3sgAHCdpA3gIQJh2&#x2B;G82QAAUMLeRT/h5mihMO9wG4Rtr3VjwDafiS1mM2IK4DI&#x2B;HddcAkCMz&#x2B;7eAACymcYMCaRuTpNeaHrfvfsAcMXLm1IJY9mtbzy1kECzNnkb9up&#x2B;4jds3Ko37wlcMc/VSiy/Tl64DvYqrBQAWqamDeBpEs5zTj1kmpFC/wIA8DZtjixX05WymwS5lhPe4MNIz/vOdYsTqMWVcNNFk1ci7ex76fUJ5ADgJSRtAO&#x2B;y100Q2X1watgf2rH3ptffEgB4gDd/h2Zp/oVbnos/lQvb1inFYd62ebsmMdeFM7bpT&#x2B;v7TOH3LdVsgRsB4FWMHgnwRoHhJYeTZ0oXR/WhmsWb610DgIvmTaZXfbFWaP4lNErjF3v9npsDSGoVs5a8D7c20/Z69y50kAJAp9S0AcCL1LziFQCeIaYr&#x2B;Q0Da8/bD4Enm7GZMS2q3Gu7t4q0NT5&#x2B;H&#x2B;CUvUkBw49KG0ayDhftAcAeNW0AXOUCXgDgedZFS6wFGoHdNRGzlB&#x2B;JIh5vfIvDe/7enxKGJ11/EFXbtQ6PCJ&#x2B;QADBR0wbArrPnTuOll864AICniplL6cFtocjK&#x2B;Hmh2MVXo2ZZW14P3g3e7Er4lDYLYNrdspuvdwz/7OEAMKemDYCl&#x2B;YWT6yso986p5rd3dwnzm5liAQAOLeblGv8bGE3xsOqla897XjeWDfFsCaWx67LIjHvj4eySMZ9d62e0&#x2B;DB0&#x2B;ADwQpI2AK7aO0lzitURbxYArAUuP9q8JcazQ7hJd9lV3unlNqsb16t4yc7wbIE38dQ7u4jzSwgvfH3d5GJ79qadG&#x2B;vbDLcLwMtJ2gDYsHemdOr0SdgGADDviF&#x2B;Xvj24sfTgp3Zo7&#x2B;0e3v2y9OXw8Mw&#x2B;pMdhwVmuhZ/96yYDYwDAnHnaANgWf3bn/AoAeKq9FlHyiHDr2zWlTpkmBu70det0s19l2rsOJ2UM3HJl3rXGY7bI&#x2B;RoB4FUkbQDsCpxEBU6uAnOWAAB0Z93sSetl1i66brNKrJxcccLmuJH2BzYVDbHWZ2qLQrqzI16uFwsA7yRpA&#x2B;DA5hlXYICU8J/0KQAA3Zk3h3IFb&#x2B;9UuVjnuivlO&#x2B;MD5//yMFmqu8aFTD9ZNixtMyLvuVfwZycH4M0kbQBEWfcRnBpNJeavcjgAoGXhvO2UNzd7ugvbrpg/2en3dWVey0/hbeLrJrsLlvam4h5mk65FPt/NKeXsxgC8maQNgHOunFLGnIbpawAA&#x2B;nKl6dJdZ30Lbqz&#x2B;2Vxp&#x2B;DKyzVnlvO/cbhG85ToFs28D8E6SNgBOc/oEAHC2RXQqpHmz&#x2B;Ndkb/6zoq/qFPKdnZxY2PYkWQaNzLIlYfPDYXO8x/HncAce77DY5nuHuwSApnx29wYA0KWYsUciF7V52gYA0L6YHmoSnH1Vx3mC1wU6XbQw90Z96GLj3yAwC3Waau/sZrS2vnExFGSgRjMcrdljAXgzNW0AJNqbuPtUz8j8EkvnZgBAd9KqOtSCrJV4QUrnoDHvY&#x2B;R7Hc4/qGN6zbs4PMPlm5H7z&#x2B;aMawDAWZI2APK4OH5O5KMAABq0NzLk2SuQKgx&#x2B;2LJAKHWYAdz4omXM2xZeuye0oPE6tvC&#x2B;sZmfhbdhMTDJZj1cwnYCwEsYPRKAqgyyBAA80rw7O6G1s3jIm8v910ORr0dQOBzCrn6Dc2&#x2B;Tzr6Vd20/AVeOx3sP5PWcgnOHNXyv/RQCgLPUtAGQzdkzMWOVAADseXnWsjdQefzDx1/Gl3FeL7gONUvXEU7bEP&#x2B;QvcnbIN6VszMA4BRJGwA5LU7nCuVnbx5VCQBon0uImnLXoOVnB1c/e08KuV5WWPMTIDxVWyBjXt9zfosPMQA4xeiRAGSW66zssOLtzaMqAQCNS65Jmg8&#x2B;ObZ2Dkd4e4/p1YhpB4aH8Wy5JTlutkHXKwtMUTZE7zDN7lTxHvAUAKA&#x2B;NW0A1LY&#x2B;eWt5insAgCv2LhgKNG/0dMeIGeRgMfjkeizK0o3M5NEvh6Pgh9Y0Usd2cSE&#x2B;fAAgjaQNgBbdNcgPAEB2WeKWocqMYu3bfCVPvcL1s4QrE85xr8g6thvf3L0j4uxj7aIAcIWkDaAJ//rv/zb93L0tTdi7&#x2B;rv&#x2B;lgAA5JIrDXp5oyhLbLn53wolbodbJfBoRP0KyICElH3Kd8O7kxgYALIwTxvA/Rbp2vjfv//xTzdtTitMTQEA3Ohwytg0uVo4LU8zVkHguU&#x2B;vzN5sW4vlVG5wRl5PFngKlFDoeL9unQePwZh9AwCaoqYN4GZ7RWzvKW4LnMquL7F0SgkA1Je3BRIuIjm7Lq2jteuvSf1XddofFpFPU6nPGzRVAZa8H84L4DaLJu1aAJCXpA2gId/8&#x2B;sfz/z54MMmY87ppjBT9RwDA7Uo0SMKFWYcPmfek79VvvaopdfHyrKlUaHxshVdvL&#x2B;1YvLMSkXtNr3/lN&#x2B;JKzDb90mytHgA8jKQNoBVjzPbNr3/8krzN7CMAQPvi&#x2B;6bTWi9T1lK0iP89eVtMQdLZZVaYvG1zH9irSaK&#x2B;ahVgm9canl27RA0A6pO0AdxpitAW6dpm3lZvs2oxaAkA0Lh5RdFh4FEnEUluPr0ksFm8PuuXK6EJ&#x2B;pKX7rWm9/fec5PN3SzLJjntAoDSJG0A7XpJcdshp4UAQH17Adu86CT7/G2RNyZ7SXHbYiaq9Vs5/nJYALe4pcKrV2EfoEGHu9bZHW&#x2B;&#x2B;z9h/AKACSRvA/RaJ2uJPbyhuAwBo3DSJV&#x2B;m1lHjI4j5vCNv2zJ/7XgnR5nCO4UdltCg/EpO80HxmuOR8d74nAwClSdoAOvCS4rb5qaBzQgDgXvNxI4f9fCV77jKvx4psEcXc8&#x2B;WNq7PT4K2HEzw1juh1YpLepSVk85Q3Mtp/c3AOAO347O4NACDKGLZ9&#x2B;V//M90yhm1//&#x2B;OfbtumMjYH6rllSwCAlxvDlcDkSX21UubPZZEjvsHZ3CLyzX3hK/lI1d7E&#x2B;X4VXmlfHy8A8HJq2gCa8&#x2B;V//c/4s/7TqwaT1GcBALRgXcnU72CML29fLZ7&#x2B;9VdjfOs72gHYdEvMtv5v4E8vP3IBoH2SNoC2zAO2zbBteM1gkoNTSgDgbgkhSvK8Snvytohe3r46OzLn&#x2B;uHjL2ff5ex7Bd053AE290mDiAJAF4weCdC0L//rfxa52mhzMMnnjSQ5bF1FDgBQwTTYYKAREjkg4WS8c0K/eeAhMcs0wmHA5ht9dl63SN6I98hb&#x2B;bp&#x2B;uB0JAJqipg2gdXuVbcObitsAANqR1mk&#x2B;f1T2CqfDpampOiUcr&#x2B;7dMr7I00/B7aMHm3P&#x2B;napR25wP0q4FAA2StAH0bXPmtkfmbXsnpfoyAIBCslSNBBoqyQ2Y5A3Tatp05Y0ODMDgpX6zzXc/ck&#x2B;bR3Sq2QCgC0aPBGjUN7/&#x2B;8VTNtjeG5PzOw8sGk1wzGg8AkN18fMjN&#x2B;pJI2UOXjM2e5DEtn2T95srJKCRt13r5EQoAjVPTBtCuvXRtbzzJlxS3Dc4zAYCKxsL6zVmXegljAgPWhatn3iZmZL/DV2m&#x2B;EC/pexyOtDHG9jG7RGCEUgCgTWraAHoyr3IbtqI4xW0AAHUkhyhTIX6WGCZhUQYJCJsXMkZaFD7C3MXj3U4FAO1T0wbQlik82ytcm1PcNjjzBADqSmt7rEvi8mZaMYtaF1qpuNoz1aVt1jIGTEVLytp6N9WozX&#x2B;uLO3U/adSWic7ANAFSRtAuxZBWkz2Nvnm1z9&#x2B;T97m/BMAqGnR9khuirSTwRjwcFMgZgu/XIbi7F18pHp2acIzAHgkSRtA38Lx22beVniL7uGUFQCo6UrFyY2NlvCq13&#x2B;VGA1x7UwN0ScJ7PMXDwf7CQA8laQNoC2nCtcivae4DQCAGIvAYDNRmw8yKW&#x2B;b522bA0vO/0S/Frt6iev5HE0A8DySNoAOLKKyzVsOl/CS4jYAgBacGlkuy0RQa2cTgnC0Vq7QpyObucv86Y/T78nbOrWO2Ra/XFnmuJB1yD0YnwMA&#x2B;idpA&#x2B;hefBmc4jYAgELWfeUxydmpQCvLVmXJDE796Z0EJ73LXrO4&#x2B;YFgPwGAZ5C0ATRqnoplHFJys7hN3gYAkEsvXefzTv/1Ns&#x2B;reXp5RvVNr0wgaPTq9eLwiMj4VibP8ggAtEnSBtCu8BCRZweQDD9W2AYAcKN5t/vY419hdrR5R/9m9Zsk4NB6gMHN4QHpSOnd3mEFAM/z2d0bAMA9xrBtXi03hm1//&#x2B;OfbtsmAIBH2JyQqWXj7GLj7&#x2B;vEaIzcFrORTb&#x2B;LDcIzt/EMi&#x2B;nW4i2OHccLADySpA2gD4cDSI53OFvotpm3CdsAAK5LyNsWnfLDhf79sxs2hW2HU8ep2dqzfvvoReBAu/6eStcA4PGMHgnQqLS52dIeZeY2AIBCpjEYY&#x2B;b0Csge4Sy2qsQqXigw4x3diR/B1bEDAC8naQNoV3LYNv6cetQ3v/6xvA0AoGWFevPD4VAgKNqs/hE5jNnqOsgEAOCpJG0A95unYmeHf4xcbKT12oVtAAC5pOUuFdKa8Cqm3OjsA1/Oi/N4Y658OOAqAPB4kjaAO5WeES0tbFPcBgBQyCK1OgxjqpVGTZVYkesK3E3McEjxX0fCB4X3EQAYJG0ADdosa8tY6xa5Deu8reYGAAA82Oa4i7dsyZ7FrHKBzVO5FWPzVWrtTWchPnge/nnUUADgbT67ewMA2PDNr3&#x2B;8Lkdb3BhZr3ZlaMrFGsewrXQdHgDAG7Qftk02N&#x2B;zDV1/EhArTYxd3Hm9/VSzxqif7NvM3t9kDGQAoR00bQBM2c7UpGEtIyCLXErMog0kCAJTTbACTsGHNPhe4Yh2eTbu6WQwBgEHSBnC7cInYOugaBTKzcCyXELZtLlPYBgCQS7M98hdHw9sraMNIgx2Zx2yLSRY7qkwFAIqStAG0Ii0Dq0ZxGwBAOfNe&#x2B;9YCmPm2nR00MuGvcKPFzrkXsx1q7SgGAIoyTxvA/f7&#x2B;xz9FRlab87cVetTeooZ/DgX/9d//zcxtAABZtNw7/93X365DiPWN0Lsru3TLhzAAUI6aNoCGxORh64EcY2Zx2xuCcvyJ3Ly9pSluAwB4g6m4bV7itr7P4S0TKR29EKEBAAGSNoAmTGVh1caQnK8oLWyTtwEAlNN7z35kiiZsowXhw633gxEAKE3SBtCcw9xrSrnWcVe5le5tyeIWYRsAQC4t9&#x2B;9f2baWnxevtblbzicpBADYY542gFbMZ2sbc69wipacse2FajEr3duMxcxtw6xKDwCAvMY6sNsDgMAYkleWcPvz4rWy73vjXIZ5lwkANEhNG0BDFulUtZEkr690czDJTFsEAEDT&#x2B;VNg22I2exHUGU&#x2B;SZwjvyR&#x2B;&#x2B;&#x2B;sKuDgCPIWkDaMs6bCudt&#x2B;Uaf3K9KDO3AQBk1EvYdn07JRA82Dxjs6sDwDNI2gCa8/c//imhuO3KnG15wzZ5GwAACVqOEuHQGKEFwjN1bADwVJI2gEalFbdlzMyuWG&#x2B;GsA0AIJfvvv72eaHU&#x2B;Iyuz/0GbbJLA8CDSdoA2pVW3JYme0SnuA0A4G0WNT3PiwMhXiARd2gAwMNI2gCKyBgpNVLcljZj3Gbelm&#x2B;jAAB4GiEEz7A5H9sjC1IBAEkbQCl5w7bKM7ftSSuqU9wGAMBZRtvjqezbAPAwkjaAgvJGSou87Upx25UELjlsk7cBADzbvFinUOHONEClrIJO2XUB4HkkbQDF5c2Tss/clrCEMeRLG0xycYuwDQDgScbB8SJjts3h9cL3D/wXGvfd19&#x2B;Gd1q7NAB06rO7NwDgFcY8aRGSJRuXM2VUY&#x2B;J1WKb2za9/HMjG0hK7L//rf86Wx433n68u74sDAMB7fPjqi71UbwwtzIlFaTHx2LgfBu4pYwOArqlpA6indHHbYVo2DuE4Zl3zhOx6YdxZm4NJVt4GAADucjEAmz9ckRA3it/B5vcUAAPAw6hpA6iqaHHbkFRkdtGVNS7K7BS3AQC8xzotOwwtFvPASdG4l5gNABipaQO4we3FbcOFOrZ1OdoVm8Vt6tsAAF5lM3s4DCTWdxgnfpPA0azDYSQBgB6paQO4R&#x2B;/FbZuzvk23JEzetljav/77vyluAwBgbpFPLJK2&#x2B;V8lGZQ27WPTfniqKHO&#x2B;nO&#x2B;&#x2B;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&#x2B;QwmCQC0L9Au0iy5S3zssXnPmIcbZJIEmzuMlA4AXkLSBlDV2bBtKFDcNs/b5qHX&#x2B;gLtopLDNleRAwAtMMb1Xdaj8H346ot1pLEXlQk/iHe4twQGMrWnAcB7SNoAaksbSbLOYJJpCuVzga3SqwUANMJlQHfZm/UqUIs23V8EQkaLXc7eBQAvJGkDuEdrxW1DdJFZnbq3aWMCYZu8DQCoyWVADcqeahg0khh7Y5OK2QDgnSRtALfpt7ht3pc0/r64pdoolOsV6dUCAEqYXwa02V5S3HaXKd6YQg6zrFHBIlSTsQHAm0naAG7WaXHb2Je0maiNDw&#x2B;EbYc53KmhLBW3AQD1KW7r0dn4TVxH2JjyKmUDACRtAPfrt7htz/TwvVAte92bq8gBgMqMcd2g64GHyAQAgLMkbQBFfPzdl2cf0mlx2yRQ33bKlYRPrxYA0AiXAd1FmREAAJVJ2gBK&#x2B;fi7L8/mbS0Xt&#x2B;WqQis9hZuryAGAdmiWNGI&#x2B;hVvCw8eJ30z/xqDqEQDYImkDKOthxW3hnOx6inaloC28JXq1AIAs5s2M&#x2B;Nlt57dollRzsbJtfOwiXRO2vZZCSQBgj6QNoLiHFbeFrSOu&#x2B;PgtV8w2rVevFgBQwrp5M7aUAu0lxW23m5e1XUzLAg9X9wYA8EKSNoBKHlbcFjCPuEqPFXlqYwZhGwBw2bo5tLglELbJ2&#x2B;6VUJCUPNpkwqMAAOiUpA2gnrcVt52K2RbL3Hxs5Ko3N2b6XX8WAJDg1KCRgTsY4/peyaP/jSMHXpzvjb4YKxIAiCRpAygikJC9p7itkOthGwDAWRkbP4rb7mW2LWLYSQCAeJI2gIICYdt7itsSxKRiCaueFqsnCwAo7bCtYk7Ze10pbht/2SxrE&#x2B;MBALyQpA2gLMVto7MjSYYXO/61XNQHADAXmHrt8JYwxW03KpGKjfGbsK1HUlIAIJmkDaAGxW3D&#x2B;ZnbIsVkcvNtGH/RhwUAZJfW1DGY5MN8&#x2B;OoLs7gBALyKpA2giHWE9obitjYrzBYbZsI2AOCKeVsi7&#x2B;Rti1uEbbf78NUXipwAADgkaQMoaB2hPa&#x2B;4LW0wybVAxVvMYJKRA07O6b0CANJEXrhztl2kuK0R83Rtqk5LKFNT3AYA8BKSNoCyHl/cNqQOJrkpfoTJzbs1W1cHABBpM2&#x2B;7a2PIYi9yG28XyAEA9E7SBlDDqeK2swt/WHHbEHGdePgOh6s2gCQAcMqVxkPalUCK2&#x2B;41L2ubfk/LwyKr4oRtAAD9krQBVLIZtm0mZAkjSQ5PLG67ch&#x2B;VbQBAU9LCNnnbjb77&#x2B;tvxZ37jxfozcRoAwCNJ2gDq2YzQFLfdSF8VAHBWctsmS3HboAFzh0XedoWwDQDgeSRtALWdCtsUtw3R4zUZExIAqONKwyahXaS4rQXrsC0&#x2B;fgvXxm0WzwEA0BFJG8AN1hFaoBxNcdtQIGwTywEAh&#x2B;atl9sbD5t5210b807zPCwhGLs43xsAAM2StAHcRnFbRuvOr5ZHrQQAGrdow4wyhm255rJV3FZf9vqzi3O/AQBwO0kbwJ0UtwXcfuU4AMBCuH1yKj8br0DKNZjkqSVwu/B4kgAA9EXSBnA/xW171h1JAAA1rVss88bJqYZKoGGTUOKmuO2RhG0AAD2StAE0QXEbAEAvxsxsyrrmoVfN5s1mcZu8rTt5x6IEAKA&#x2B;SRtAQxS3AQA0YnOqtnKuzNxmMMneCdsAALomaQNoi&#x2B;K2AINJAgD1RQ55HXnjqTvEU9z2SCZvAwDogqQNoEWK2wKEbQBAHVNzpXIJ/tguOrtSxW0t&#x2B;O7rb8efuzcEAIB6JG0AjXptcZvBJAGAHqVdDLR&#x2B;1LwtlNAuUtz2QkrfAADuJWkDaNpLitvSBpMEAChtXtZ22ESZV5WlBW/rVaSFbfK2FuStbBvjtECiJmwDALiLpA2gdZth28OK24bUwSTN3AYAlDZvpdzSPkkr&#x2B;jeYZAtKjCSpgg0AoDWSNoAObNarKW6bCNsAgKIWYdst9fdpK1Xc9lTCNgCAdkjaALoRH7Zt3vlQ18VtjRtfqMXP3RsFAJxQf7DrXNcSKW57gM1cbboxe9kcAACnSNoAerKuVwuPJPm24rY27b0&#x2B;OrkAoC/Jg10nrzFj4b7ithaMg0kmBGPTQ/YeXmKYSgAAIknaAPqjuC2gr5nbdHIBQF/SrgdKaJ&#x2B;UaM9sFrdpivRlrGObQrXxv&#x2B;PMbcaTBAC4i6QNoEtni9sSVtF1cVs7eVvMa6KTCwD6smii9DXYtcEk2zGvQluEZ8P&#x2B;TGwSNQCA1kjaADoWX9xWcyTJRorbuqOTCwAqyPiFm3w9UMzdIpeW3C5S3NaI&#x2B;CEf5/cUtgEANEXSBtC30sVtCSNJDorbUunkAoAK8oZtCcVtpxonMXdOy9sUtzUrcihIc7MBADRC0gbwBIrbwrrL2&#x2B;7eBAB4uLwNlYQmSonGieK23gViszF7W9whMLzk/CfzVgIAsCJpA3gIxW1PopMLACooV9w2ZMq9zi4nY3GbpsgtwjVq67Bt8z6HtwAAkJekDeBRFLc9iU4uACjt9uK2YX98yOTmTXLIZzDJFoxjQgZGhkyYsE3YBgBQlKQN4Gk2w7aXFLc9NW&#x2B;7exMA4OFuL27bG0yyctg2GEyyVVO6NmZmMdOzLbI6YRsAQDmSNoAH2qxXe0Nx22AwSQAgSQvFbaPbJ5dV3NaOzcq2U5nZ5sOlbgAAeUnaAB5LcVtAj4GcTi4AKO324rYrNfqLhOxia0dxW2uSC9QW9XAJSwAAIEzSBvBkrypuS&#x2B;jM6o5OLgAorZ3itozS1rtZ3KYp8hhjcZvIDQDgOkkbwPPFh22bdz7USHHb0ExnVmk6uQCgtNuL24Z/BF1nB5Nc339aXXLetrhFO&#x2B;QuMdOzJRC2AQBcJGkDeIV1vVp4JMlnF7c9I37TyQX1TZf/65SEN7iluC2Qk6XJ0hBS3NaOcea2KXLLlb35XgMAuELSBvAiituGf&#x2B;5dWtytOzq5oCa9kPBONxa3lbs2KG3Jm3lbpi3itHneloWvOQCAZJI2gHd5eXHbM6rZFnRyQU2FRu4Cqkm4MOjGmduyF7Rdp7jtMRblcQAAJJO0AbzRa4vbIv9U2s8&#x2B;/&#x2B;n658oCdXJBaYsr/W/vl3TIw0X3NlTCxW1nJ2ZLs1nuH8lgkq2ZfytNv6tRAwCoRtIG8FJvLm4b7o7ZTt0eTycX5LXuoxy7L&#x2B;&#x2B;N2RzpkEvLxW1pYVs4M1vHY5EPDCxwcYtPpxttVqdFhm23Xz4CANA7SRvAqzVb3FYob5t&#x2B;8i48l&#x2B;vFbYNOLsjhw1dfjL2Tiz7K8fbpr/U5wCG7Zovb1jlWZPy2F5uNt2cP2xS3NWienN34nQUA8B6SNoC3O1vclrCKhD6s4aEdyjFBmuI2uNdmunbXxkwc11BOC8Vt87xtKm4LVKHtWQRmi4cfzgmXNqntZt52diEAANAvSRsAw3CmuC15JMlGitu6cD1sG3RywYM4nKGC26eY3RtMcsyx6kzeNq064VGK25qyOSCkUSIBAAqRtAHw/2yGbYrb7pIrbHvnqwfJpvK1ve7I6fY6hW6OYqipteK2ITX0ipS88L3SN4NJNmUxc5uYDQCgHEkbAP9rs15NcVs53//lz&#x2B;PP5l&#x2B;zhG3Dc189yCU8PuReN2WFLktHLtyi2eK2i3JVxU0bs7dV6xX5NLvRmLeJ2QAAipK0AbCkuK2cvVBtL2/LFbYNj3j1ILt5xjYP2777&#x2B;tt752YTkMO9Oi1uW0Rc60naIsO2wN0iMz/FbQAAvIqkDYANitvKCRSx7d2eywNePahgEbPVj9wcp9CIHovbpkndpqBrHb8FgrS8s8Ft5m0Zlw8AAI2QtAGwKz5s27xzjDcXt23mausbM5a1jR7w6kEWm1OyHY6vVTR4E4dDazotbtszPnb8dx2qjbdcL2jbXOzEB93tjCQJAJCdpA2AkHW9WngkScVt15WubBse/erBWWkdjiW6KR2VUEdaW&#x2B;XsQ6oVt52tQpvPspa3gi3AYJKtMXMbAEBekjYAjiluq6xC2Dbo5OJ95rOyLW5f3DJ2QU69kNMvhQraHIxQWbWwrU5xW3hAyGE/jTtVo3allm5vM3z0AQDwDJI2AKIobsvlZ5//dPET85By29PXqwe5bKZrkY/NWweQdgymXZ0ATBLaKskNlbMPCUgubtv8a7WatvkaFbcBAPA8n3z8&#x2B;PHubQB4mk8//dEPP/zt7q0oZd3HFOioSusLTquKW/Q9NWLReRTIzBZ1bIt7Lv76m9/&#x2B;fv7fX/3yF&#x2B;mb&#x2B;A9tvoAt&#x2B;MnPPwzD8Nc/fHf3hnDVmK4tcrJ55Lb3p0JDbCV3Lo8frf/y3//x4O8aKGTdSEtoq7TQUFl8gERmZou6tPFRMVndXkHblaxusUztkNt9&#x2B;OqL7oaUHBtpg3YajRn3TO00gFdR0wbAOYrbComsbxtWMdt4y/rGs7p&#x2B;9WDTfLjImIEfx/sXGiJyIbmUTTUb5PW84raAeTCWHJLlqoRbF7dlWSzJuovZAADaIWkDIIWZ2xJEDhQZjtwCiVqWsK3lFxAKWfctzvO27D2PyQeajA3KedjMbQHj&#x2B;I2n0rLDxUbmfHsbk/BAAABoiqQNgESbYZvitqIOs7RcxW1PfQF5rUCZWuVL&#x2B;JWywe0ytlX6LW5LFh5hMjlvG3/R/AAAoFOSNgDSbfZJKW673fWwbXj3CwiTjDmcUjZoR/jaoISlnX1IheK2onkbAAAwJ2kD4CrFbWm&#x2B;/8ufx58SC88VtrX8AsIpMZnZd19/u/jJtXalbNCgForbbh9Mcjg571rkSJJncz5lbQAAdE3SBkAGituuiIzcsoRnCdp/AWH4x8xq8/nVxl8Cadl058DYktcpZYOW3V7cNrQxmOSp&#x2B;dIiU7TksA0AALojaQMgG8VtYYdZWkKJ269&#x2B;&#x2B;YvxZ/2njMlcIy8g7DmMytZ52yKQK0QpGzQo/tqgtxW3ZRde714KqMkBAEB3JG0A5KS47br4vG0esJUO2wZ5G63KFZVlHCtyUMoGbVs3VxS3BQQq3mKWGV71/E/K2gAA6JSkDYD86oRtt18zHmPRzzX3s89/emXJ62htr7gtL2EbzToVlS3unD1mS3iUUjaoTHHbKZFh2yKWm/56KurT2AAAoC&#x2B;SNgCKOHu1uOK2QkrM7qa4jQYlRGXfff3t9JNrM5SyQV8Ut51yajq3TXeNYwkAAEVJ2gAoqOWRJG/JihbDQl4sa9tUoaxtJGzjFh&#x2B;&#x2B;&#x2B;mL&#x2B;s/jTXVs1qlnKlvaBCWxS3HZK0TEeDSAJAECPJG0AlFWhuC15yLU6WVFgAMmhetj2m9/&#x2B;fvq5viLFbVQWyNI2U7e8Y0IGVC5lE7NBdorbqlHWBgDA80jaAKhBcdtkUdY2DMPPPv9pibxtbZGu5Yrc5G1UcHu9WkDlUjYxG5SjuK2E62NOAgBA4yRtAFTy5uK2cFnbaJ63XQ/eprK26ZdAoparvu36QmDTGLNNYdthpVoglstb5aaUDZ5nM2xT3LanXIqmXQEAQEckbQBUpbht2CprmxSqbzvM0hS30YtAVHaYomWP2RIepZQN2rd5xOUN295Z3AYAAE8laQOgtrNXiz&#x2B;juG3RnxUI23L51S9/EZiwbZPiNhoUOeNatSnZBqVs8A5FR5IMLC2skeK2oqNBGmoSAIDuSNoAuMGpq8WHhxa3VQjbRqfys1xhm7yNCr77&#x2B;tv687c1UsqW9vkGnHJ24Ouzy&#x2B;&#x2B;6uM3sawAAMJG0AXCbtxW3rWdr&#x2B;/4vf47P284WqN1O3kaaw1nWItO17FVu7ZSyidmgJsVtAABAmKQNgDu9rbhtHbYNO3nb4pb15G0Xi88CY0tmKWubCNuI9OGrL8afYSdLWyRn6yCtaH1b8p4sZoMHeG1xWwuDSQIAQPskbQDc71XFbZth2/CPvG36ybvShSlj28vbsodt8jbC1iHZXmx2ePt3X387/uTatiulbNlHjBSzwY1eUtyWPJhkxs0AAIC&#x2B;SNoAaMKritvW3Vgx1mVtadbRWp1xKYVt7EmoRcs&#x2B;MuQepWzA3BuK24bUwSTN3AYAwGtJ2gBoyNmw7ZHFbZN1Zdv//T//3/y/GSvP1mFb3rK2keI2wta1aIsQbp3JHQ4pmazlUra0Tz8gF8VtAADA3Gd3bwAA/JOxQ2rexzT&#x2B;vtdR9fF3XyZ0SH3yn98k9HyNfVgJ5Wh7xkU1Ej796pe/KJGurWV/GenafNTHxS&#x2B;TdZy2GCsy&#x2B;1a1XMomY4MWnGquJLRVwo2fPSUaKvPPwzFsiylc&#x2B;&#x2B;bXP5bMAQDwHmraAGiR4rbRuqxtUXyWNxsruvCFRvJFmhWYuS1htMl4LZeyDWI2aIzitgAjSQIA8B5q2gBolOK20Ri2BSZp&#x2B;81vfx8/0dqpKdnCwdv12d0Ut7EuaBsKB2lhStmAs9bND8VtE2EbAAAvoaYNgKYpbht9/5c/jz/DtYjrsExtWvh8Lb/57e/XD9y8MYHiNubiY7a840YqZQOSbR7Ritt6MX7&#x2B;z3/u3iIAAPojaQOgdZu9V&#x2B;G8LWEtyX1YpbuxYuwlYVk2KbycLHmbjq2XmwKzQMy2&#x2B;FPeudkaL2UTs0EXTjVXql0YVKKhMv/vl//1P10PJrn54miWAABwlqQNgA6culp8uBC2tXDN&#x2B;BAx3NNmWds88Rp/LzrR2t6qk&#x2B;nYYmEzeHtqKdtgxEjon&#x2B;K2sNbCtvDLolkCAEC8Tz5&#x2B;/Hj3NgA8zaef/uiHH/5291Y802YH06me6xjJvdvZpxwLd/HE5Fu/&#x2B;uUvrsyvdipCuz5z26i1mdt&#x2B;8vMPwzD89Q/f3b0hDzRmafOatvH3ecY2v&#x2B;VVpWyHC/RdAwnqHDinDuqabZW837DrT9FTWdqUz60fNf6pdHsg8lugtWYJc2MjbdBOozHjnqmdBvAqatoA6InitgS5ArBDuUroXEX&#x2B;WuuYbf6nfkvZhgIxG9CydXMlPJLk24rb&#x2B;qJZAgDAIUkbAP05OxXKU2duqxahxcs4XqVerYf58NUXgWnYaqpfyrb3EbT&#x2B;4DIrGzxJ6WuDzNxWk2YJAAABkjYAuqS4bXQYtq2jr4th2K9&#x2B;&#x2B;YvpJ3KNyVxF/hjxGdt0z7GCLftwkUrZgJrOFrclrKKFhsqVmdvuytsSXgHNEgAA9kjaAIr49NMf3b0Jr6C4bbi1sm0vb8sYtg06tl5gTNfmRW&#x2B;FYra0B1YoZRvEbPBo8dcGJY8k2XVxW180SwAAWJO0AZQibKvjhcVt67wtUGE23WH&#x2B;3&#x2B;QkbHMtdaI&#x2B;vVoPEEjOig4s2X4pm5gNHu/NxW1Pzdvu3gQAABryycePH&#x2B;/eBoAHmsdsP/zwtxu35D3O1ohk70AP2xv&#x2B;MdleF888RZtnYIt0LTIei3/UOr0rlMBlfyUP/eTnH4Zh&#x2B;Osfvqu83jfYDNh6L2U7tcArGdunn/7I9wucdfuBc6q5UrOtkvfrdf3ZGz9K5JTMFf3GzxWV1W&#x2B;WMDc20gbtNBoz7pnaaQCvImkDKGjK2zSyq6nQgRVeZkCJvpj4fqK0JOxUPpcW5iWo3KslaSttMWhkLpUztqH6rGy3BwbQo0YOnPjPhH7DtiE1b&#x2B;sraRuEbbeStNEmSRvAC0naAMoSttWnuG1PQhK2VyEXs/zFQ372&#x2B;U&#x2B;HYfj&#x2B;L38&#x2B;XGmkah1bkrZNYzw2z8YKBWZpHlzKNmkkMIC&#x2B;tHPglL42qNmGymHY1l3SNpK33ULSRpskbQAvZJ42gLKm5vWnn/7IzG11nJoKZXjozG0xkmdr2xMT3f3s85&#x2B;Okdt1yZNvcd161Mf5LUUnXTt0ZccwKxtQzeYssxlnbmuqoTL/74NnbtMsAQB4LUkbQHE//PC3ed5278a8x2YHVuDOyXlbwqNK9MXEhG3rJGwzbLuSwC1WsbeoXGHbUKBDkAT3RmtzVzK2tJKRyiNGAk&#x2B;y&#x2B;RkSCNvS8raEDcveUFlfFbQXttUpaCtHswQA4J0kbQCVKG6r79TV4pv3j9HUNeOH3VKbYds8Dxt/z57AFeUq8i58&#x2B;OqLooFca6Vsi2UqZQP2KG57GM0SAIAXkrQB1DMfqF3YVsepq8X37h&#x2B;jkWvGh9RrwMe8rdksLYZerbvMp2fbm6GtdNGbUjaga4rb1r/3TrMEAOBVJG0AVRlJ8haK2&#x2B;ZiZlO7InL544Rti5&#x2B;Lq3YVeQljLdphVLaXsZXWeClb&#x2B;P4Ac2evDTq7/KYaKvP/jsVt85it06EjFzRLAADeQ9IGcAMjSdanuG0uJgzLVd92ajlZ5m/Tq1XIZtgWSODWEV32NK5yKdtwFLOt7yxmA05Zf26ER5J8UnFbC1wGBFznkAd4J0kbwD2MJHkLxW2TyMqz0gVwa8K2liUPAhkYWDLNLaVsex8IStmAvF5b3Ba48Ua58rYsGwM0zsEO8FqSNoDbGEnyFgnFbWkrauSa8WG/xyohRet6IjceQykb8HhvK26b/2Rc&#x2B;CnhOE1xGxDmGAd4OUkbwM2MJHmLU8VtV0aSbOea8c2uq3DY1leutugCc6JbSLisbf1XpWwAyd5T3NYFxW3AHoc2AJ98/Pjx7m0A4J9q2uYDS1LaqY7ytN6o8DLDsl/ZvXcSuBmqTTnc4q9np3kb7x/fOfX9X/4cec&#x2B;5afnzh2d5AX/y8w/DMPz1D99dX1SPNsOz8I3Z52MbVc7YhvOlbGlrSfbppz/yfQFndXrglG6utNNQqWb9nVK6obLQ70vXlLGRNry4ncbtNhuo49l9j183ACT77O4NAGAY/tEKH1vknfYBderj775cdEh98p/f7PU3jbcndGCND0noxvrXf/&#x2B;3vB0x49LWJ4T152ObfP&#x2B;XP2eZm20yLi1LLxibNsvakqdwi3HlMuHsw0VuLlMpG1DU2ebK2Y&#x2B;&#x2B;dhoqXfjZ5z&#x2B;93swYv9pe&#x2B;OrBkyhlA2Bi9EiAhhhJ8hanpkIZHj1zW6TDUSUjh538/i9/Hjuqpl&#x2B;yc/ab0Wal2vrG7AVtrc3KtlimWdmAOioMfN1OQ6UFY&#x2B;Nkr32S6yKhR7508AZP/egDIJmkDaAt82o2YVtNZ6dCSZ65LeFRQ8WZ2zbVqXhbdGaNs6EsfipsBlc8eFa2zWXK2ICaNj&#x2B;jzNyWy7wdsvd7CfrroTuOWQDWJG0Azfnhh7/Ni9vu3ZhXOXW1&#x2B;Ob9Y1zpw7o3b5uLrFoL2Oy3mi4e3wvVEvI2Z8IZ7ZW1TT8Z19V4KVv4/gDlnC1uS1hFOw2VyvZCtc3itrwXAPX&#x2B;0sFLPOCDDoBCJG0AjTKS5C0SrhbvvbhtiBtMcl3Wdj1s23PYdaW&#x2B;7UbZB4dc66KUTcwG3OhUcyV5JMl3FrcFRoxU3AYv5wgFIEDSBtAuxW13Udy2aTNsW&#x2B;dt5RK4BWHbIyllA4ikuK2&#x2B;9UjX2Vfx4FcP&#x2B;uXABOCQpA2gdcK2gHK1TYrb4s2jtWox2yjy3XdiPPrw1RdZljOVtb1wVjYxG9AUxW1P5dWDdjgeAYjxycePH&#x2B;/eBgCOzWO2KXtjHrQUGtJns3fpVO98pOQe/LR4LCxwPpmQpY3FcItUbO/9OhudTssJL//Kq/STn38YhuGvf/gueQktGGO2eTY2D94Cmdl0t6LjRlbO2IbzR3GDGdunn/7I1wGc9dQD51QBbvYK4LASDZXrNr93EtoqpYeUbPPVa8fYSBv6b6fRpuQG6njy/sivGwD2qGkD6IORJNcWvSGK2zIKdOusx5CsI1cyx2hR35ar3C1B/VK24WQHtFI2oH3rT6rwSJKK29bWLYq0sRPGsbU3R9hO0MurB89Tv4EKQNckbQA9EbaFlQtdzNw2Vzls&#x2B;/4vfx5jtumXBWHbWTfmagu3zMq2d3ialQ3o3dlrgxJW0U5DJa9AWyI&#x2B;b1una1nytvZfPXgeMRsAZxk9EqA/RpIM9HeUHsPnbEf8AwZo2jvPjOw5mmK55NEj09I1o0cGzAeEXI8qGbhzxm240mlYrZQtbS3VPHUQPCjqJQdOs4NJtjMW4uJrKPmqnam9cdguynKhUjsvYCOMHkl2WTK2f/nv/xjeeqoO8Fpq2gD6886RJMcLitOG8clIcdukTmXbXiBXOlJ9ng9ffTFmZovk7Luvvw1HaOMdeo/ZwkOl9RizAQQobmuQwSShfUrZAEgmaQPo1Txse0/e1gIzt01&#x2B;9ctfhPO2ommcsG3TlKglPzzjxqxdnJUte&#x2B;GFESOBpzJzW02RKVqusO15LyDcLvnISv4kBOBhJG0AHZuPRyFsq&#x2B;xU2LZ5/xi9FLetE7XDEI57TTVqYzI3/RRdaRelbGI24EkUt6UZp4YtcU1PlrBteGJaCTdSygbAdZ/dvQEAXDKGbWPM9pKpR9oxdkjNz6/G3/c6qtb3j/TJf36T1vn1r//&#x2B;b9nn8/j7H/&#x2B;0eS56S672/V/&#x2B;fO9ookRqf1a28P0B&#x2B;vXxd18uPvQCzZW0tkq4/RNQoqESaa89szCGbXkbG7/57e&#x2B;ztJrG7TdzG1whYwMgFzVtAE9gJMkbKW67lzEks8g7DduCUjaAeyUMfJ2wlnYaKtkllLiNxf17iVquyrahkxcQ2iRmAyAjSRvAQxhJ8kabvVfZO7CGHmZuoxfjQJGL4SK/&#x2B;/rbvJGbWdkA2nGquWLmtk2Reds8YKsznnYvLyA0wqxsAGQnaQN4jh9&#x2B;&#x2B;Nu8uO3ejXmbhKvFFbfloqwtzTpmy7t8pWwArVHctqd0W2IdtmUsaxspboNIStkAKEHSBvA0RpK80WuL21rI20hWYuhIpWwAzVLcNgq0XkrMAltnRlthGwQoZQOgHEkbwAO9YSTJs7NlVPPO4rbBYJLdKlHKVvlKYaVsAGcpbjuUHLYFErXFn7KXtY0aeQGhNUrZAChK0gbwTM8bSXKai77ZjG1Ocdta5LuW9ua2v0u0Y5qMLfusbENjpWzDTsyWsBaAR6oTtrVf3DZatyVKVLYF/Oa3v59&#x2B;ri9N3gaTyqVsWpsA7ySSmN8MAAAgAElEQVRpA3gyI0neSHHbWkIeVrmT6z0eUMo2GDES4LJ18yP7SJJDw8VthxX52dsh87K26fd1upYxb7u&#x2B;EOha/bEW0lYHQO8kbQAP94aRJFumuG2hl6rEJ/nw1RelV3FLKZsRIwFyUdw22myf/Ozzn0552/z3XAKJWpa8TXEbr1W/lE1rE&#x2B;DNJG0Az/e8kST7orjtrEU/l7K2ZB&#x2B;&#x2B;&#x2B;qJ0zKaUDeAZXlvctmiu7F0MlDFjG0vZAtO5LShugwRK2QCoTNIG8BZGkryX4jZO2QzJTiVni3s&#x2B;ZlY2pWwA5ShuG6pM/jofNzLm/mZug3j1rwPT2gRgkLQBvIqRJO&#x2B;luC3Z28rarheiKWUL3x&#x2B;APS8sbls3VOLDtnUTJUsqtpZrsfI2nq3ydWAu6gJgImkDeBcjSd5OcVuMN0/ktlfKlhaeKWUDIEGd4raERw3FGiqLWxpsimTM8IRtPI9SNgDuJWkDeCMjSd5r86xMcVvY28rahmEYE7Ir1WklMjalbAAvceraoLS2SlMNlc2wrX7e9qtf/mL82fxr3rBN3sZjtFPKlvyxBkDvPvn48ePd2wDAbaaYbT6wZEfW6UuDFyAHnA0JSmQVh0pMtBZ5Mnzq/V3ceXHPK8/iJz//MAzDX//wXfISDo1x2ndffzvlaoGYLZyfTYvKvpFNZWybi31bxvbppz/q9KMbbuTASXDq87ZyaUj2VkrMl91m&#x2B;2Sege3lZAvr2Gz9wJj7XNT1lLpjI20o3E6jZVcC4&#x2B;yfV9MC/&#x2B;W//2Po9hQbgDRq2gBezUiS90oYSbJycdtQa4ymSHuVbV1XvG3GaYsbTyVnjy9l21zs22I2gGpeVdwW00RZX/ezaIdkrDyLyd4uUtxGv5SyAdAOSRvA271qJMkG85jNE7bwedotM7eVGKPpsDNrs4KtwTexkEV9W2R&#x2B;1s6sbMOFK4VPjRhpVjaA0s42V7qeue3s5LK57BWrZS9i2yRvoy9NzcomYwNgMHokAJMeR5I8O3rkdP8GB5ncPENrbTDJW0aS3IvWpjdx8w69jB4ZMw3bFJ7NR4YsN0rkpH7GNihlO8MgeJDAgXPR2eZK14NJhr8H18NWL6rNDhOyU/c/u/BkfQ0mafTId2o8Y/v4uy/HM2tfNwCvoqYNgP/nVSNJNlgXpbhtz14s&#x2B;rPPfzr&#x2B;5N2eRkwR2maWFpPPXdR&#x2B;Kdvw7pgN4BaK2yYNXraVheI2WtZ4KZuBFgDeTNIGwP96/EiS8z6RNhOahJnb0lb0mJnb3qNCuja62IVRonxBRwZAU86GbU&#x2B;duW0Rti3qzPJOqBYoYvvNb3&#x2B;/&#x2B;Lm&#x2B;OmEbDWp8VjZNU4CXk7QB8E9&#x2B;&#x2B;OFv7yluazZsq9CBdbjYsMrFbc&#x2B;4bPzDV1&#x2B;MP3t3ODsUZImhI1sbMVJHBkCb1s2PEtcGNXJVULiJMv5s/jVv2DaZp26bq8iStyluox1K2QBon6QNgA2PL25r35uL2zY7swLdWF1IrkgbH7h4&#x2B;Hdff5s9ZrurlE1HBkC/FLctrCvP1onXFIOdnWttvP9hzBb510jyNm7XTinbYM5gAPZJ2gDYNp/AWdh2i9cWtw37nVldh21rkfHbI2dlG5SyATxC&#x2B;8VtGRsqh5PLbso1ouN6sdVWLWzjFq2Vsi2W6QowAOYkbQDsetVIks1S3LbQe3Fba5SyAXBdy8VtQ4HBJAN/3atUyzKJ2tkyuGnVV1Y6UtxGZU1NG&#x2B;wKMAAOSdoAOPCwkSR7DGkUt61N06KE50dpU2SNWolp2BaUsgGQS51rgxppqISL22LysM1RJa9u1pnVpRG2UcEtpWx7n0hK2QCIJGkD4NiDR5L82ec/vXsTYtUsbkt74FC3uO0NxvnY5rOy5YrflLIBkF3CtUEJa2mquG2viZJWfFZUxrBN3kY5StkA6JSkDYAobxtJss0EbvPUrkRx28U&#x2B;rJrFbc82Vb/lnaqttVK2zcXqyADo1Klrg660VRIeNRRoqFwJ25IDuc3Y7Fe//MX0k7bYePI2smu8lG3QOgUgSNIGwAkPG0ky7Gef/7TBvO3s1eLDa4rbuhhAcl6RdhiejXf48NUX0z2vF7S1WcqmIwOo6fENmBYobhuFE6&#x2B;8A0gu1rW56uwDVArbyKX9UjatUwDCJG0AnPPgkSQn84CtwbBtSBpJ8g3FbR1N2JYxPIvXSymbjgygtKc2YFqjuG34R53Z5v1LV55VC9vkbVyhlA2AZ5C0AXBa7yNJng1jmg3bFLdt6ihv2zSflW1xe/IylbIBjLpuwPRIcdtonbdN/13cnpaE3RXmTYRtpKl/HZhSNgAK&#x2B;ezuDQCgVz/88Lexl2r8d17r9jxj2NZgfvPxd18uzgnH/&#x2B;6dE463J5yXhhcbNp5CZ59o7e9//NPzunXmcVqucrdeStnSVgRw1qsaMI041Vy50lZppKGy10SplnstVrpI737z29&#x2B;X2JJC7T2eqvGMLXx/AFhT0wZAumeMJBlfsqa4ra/itvndsq862V5&#x2B;VmIYyVtK2YajjgwxG3C73qvze6S4LV72AR7Dudo4M3GuVq7BJInReMymlA2ABJI2AC55Xl/VuqNhXsqWsSciLzO39WtvuMiL7ipl05EB9GLegHlGG6Z9Z8O2R87ctrZOwkqHbZvLz9jEFbaxp/51YAmt09NbBgCSNgCy0FfVAsVte3/KvrpcSgRsg1I2gGjPqM7vy7q5cnhtUMJauituiwzbsidwC3nDNnkbC62Vsi2W6QowAK6QtAGQR199VQ3OuJbLy4vb1j/Z13JdoYBtpJQN4JTnVed3QXFbjPX8ale24ZZZ4oRtjJSyAfB4kjYAsnlkX1WPmdybi9t6UWLEyIvdgiVK2TYXqyMDaJDq/PoUty1sJmG/&#x2B;e3vx4BtEbNdj81Kl8dNFLfReClb&#x2B;P4AEEnSBkBmNfuqvv/Ln7MkYdNQOXtj5nSaty1ueU9x2wtd7MJI7sXQkQE8Rl/V&#x2B;Y&#x2B;huG1uLz&#x2B;bp2IVErJxWuL5z/Vlau&#x2B;90y1DmhtoAYBbSNoAyK9ycVudGOwZYduguO1xOipl05EBNO6R1fntS7g2KGEtHRW3JYiM32Iq4TZztSx5m/be29xSyrb3&#x2B;eAKMABKk7QBUMqTwraxf6HTsK1OB9bhYsMeX9xWYrjIQSkbQAFGkqzv7MDXDy5uiwnDqg38mN2zG3tMlLIB8EKSNgAKankkyZg7L&#x2B;4zhm2d5m3rG0t0YIUXe0j/SzylbADlGEnyForbRr/65S&#x2B;uT8MW45bETmPv8ZSyAfBOkjYAyupoIKaYUXGyzFRxi7NXiw&#x2B;K2xqmlA2gtI4aME&#x2B;iuG1yGLYt7tByodui/ayl91RK2QB4M0kbADW031cVH6H1G7YNSVeLK25rilI2gJqMJHkLxW2jveK2OhVveWWZ6Y3/v707ynHluM4A3LrXsJBd2LCfsgQD2YHftAcFDrIfA9qD3ryDAFlCnhRIuzAU4GryQIFuk81m9&#x2B;nuqlNV34cgMKwhZyzOkNX11386s1RVtsXntDQF4FJffXx81P4ZABjFfItqPpeplrcX/PdBkQ9f2eIAyQd7Lz6PxGZHLmtfHfQu6V/&#x2B;7V&#x2B;nafr7f/1P7R&#x2B;kwhbGFPrFsJFRxufPX2d4I4URZFvAjKPMciXVQmXXZ/1zj&#x2B;1tCPfwkP/8j39/tR6&#x2B;LXfn/zS8AF58klP&#x2B;1d0WaVOOddqwsi1QM2Rst08NnxcAQ9FpA6CctgYxdRCnrVBua4sqG0BFbS1gejJauW3amT9dV267L4NPv0WxZltnVNkA4EanDYAK8pwNX7nan28r9Ndpu1Nue6t6p61KxjbtPCy8/vVcQacNysuzgBnNruXKRedL1tUqt&#x2B;2ttW3ptC0udP/4u9&#x2B;/Gvaw8qjFrz&#x2B;x1qbTVlG2Q2CpVqc6bQAD0mkDoIL5VYez4XUpt2VWscrWykYGQEnKbbUsLldWvniccttzrvacvZ1iPWab3IltME1U2axOAShJpw2Amu67VLVO/K3fmuLVl8Xu33b74rR9OOW2V2p12hJW2Raf2S5GLTptUFH1BcywlNsWbWy2LX5ZYDW77vkZVr7FwX9dOm3lqbJtodMGMCCdNgBqmh8M7&#x2B;Bs&#x2B;JbDvGlP&#x2B;yq35ZG2yiZmA7jpbAHTEOW2ja5otm1cxKZd63Jc/phNlQ2AWiRtAFTW3yTJLWFbzj2IxUvT9aviI2HbkT2sjvO2g1sYF53ft5GRTR/vltA0kyTfumi1EzgbFPtGeRYq//ff/7uet71qsM3ztoumSi7KudDliCrnwFZWm06AAZCN6ZEAZFFlENOR6ZHrmwi7JudkExjD0seApkXFpkce3JUrlrG9fQiXmm/om0oEGZgkuWi&#x2B;7LlozVNs8HX4U6/wJMlAlrZreuTe/GzLuHXTI5vQRJUt9l0uYnokwIB02gDIosogpsXdhI37QcfvY5HW4sWqctulVNnYQswGCZkk&#x2B;ZZy21nWy22LzbYVe79&#x2B;0Q8//fhqSbzlde9mIderbFW2xee0NAUgA502AHIpv4/8vAuwq462vdnWUKftTrltur7TpsrGRnozkJw/0rvF1dF1K58y5bZUC5WVxcP2Ztstadu4QN3ymr5aVK9/iyP/cnTaLqXKFqbTBjAgnTYAcil/15OD&#x2B;z73hzeRnO2l3HY1VTa2mBdl7NpAWm7bdlO&#x2B;1l&#x2B;m3JZqobJSbjulqbbF89L37WE1WqHKBgB76bQBkFThctv63USO3MFiyz0q8gtc3HZTbruo06bKxkYmRkJbRv6b3XsL29Mpt929bbbdA7lwpy08NFKnLbn8Vbb1r89Apw1gQJI2APKqErYt7hrsCslefXHTSdtUdpLk22ded&#x2B;421hVJm5iNjVTZoFFD/fFu7C2VWfns/Szr42DQ3rxt3nuLJW1HblcsaUurygI1MGgh8F0Kk7QBDEjSBkB2Gfaq9oZniw251pO2mwHLbecmbTkztsVnbmIjo2Mj12KgD&#x2B;P8FadK2m6U2&#x2B;Ye8raH8ZJXJG3PX7/yWElbEqpsJ5K0AQxI0gZAA6rvVS1uLrzaQfjhpx87Ttqm8cptJyZtOWO2pjcyelX9TQ84xSB/ywmTtkm5bbOLkrbnh7x6rKStOlW200naAAb0qfYPAADvza9S5ptWOXV/7/fF25WvX2MfuTY&#x2B;ktId3Dg40fEbyxeL2dZvR08B8yKvPRpo2vyvOP8CpjN7lyvhj79UC5UrblhL36osUNcz79ZjNgDGpNMGQEtqTZLc1Wl7tvj17Xba7gYptx3vtKmysdEg9RcYUN9/3Tk7bXdlJkm&#x2B;fdp1Fctt13Xanh&#x2B;1&#x2B;FidtlpU2a6j0wYwIJ02AFoyPxjubHh1ym1bvq8qGxv1vREPg2urnd&#x2B;Z5w&#x2B;49Y/Xbspt56Z3HRwRY06VDQDOJWkDoDEGMWWzGLZdsYH19pnXHQy9Yt/xyMOPZGw2MppjYiR0zwKmrjJng7ItVK4bJpm8yMiK4&#x2B;fAYg/cdZdEJ8AAaI6kDYAmFd6r2rJN8MNPP97&#x2B;r8DPk83ilfDI5TZVNrabN3RlbNC9Qdr5OZdDgbNBsW&#x2B;UaqFyermNptWqsu2N2QLfBQDqcp82ABpWeNja/fTu2/uubbmvW85NqINK3rnt4EX49l2nvfdpc1c2tjMxEsY0wt/&#x2B;c&#x2B;cpz8rHndsezF&#x2B;slZfprFu1uU9bFQkXqB2vTt2nDWBAOm0ANKzwIKaHylqeDaM8SpbbjhS/pmvKbQ1V2d4&#x2B;hAJMjIRhmSRZl3Lbg2GnMoyjlSqb1SkA7dJpA6AHtWavvTrbO2yn7a6nctvGTlvCk8KvntYuRnUj1FmALTp&#x2B;N8jcabtTbtvrlFqbTltJCReoI6xOddoABqTTBkAPktz15LaPsPEW8X0bqtymysYuHW&#x2B;sA3vN3wSU28pTbqNvqmwAUIxOGwBdKV9u25KrDdhpuwvc5DxbuW2905bwpPCrZ7aLkUGtAi6QXH9vDk102u6U2zbSaWtFwgXqUCfAdNoABiRpA6A3hfsikra3Sk6SfPvM6xb3el4lbbW2MCZVtjapsgHrOnuXaCtpm/Z/evYRtk371zOBBa2krbAqa9S9q9O&#x2B;l6aSNoABSdoA6FC2sG3wpO2m3XLbYtKW8KTwq2fueyOjFZ1toAMX6em9ormk7Ua57a3AKytpKybhAnXME2CSNoABSdoA6FbJQUzrYZuk7abRcttD0qbKxl79DYUDLtXHm0ajSduk3LbB3jWtpK0MVbY8JG0AA5K0AdCzJOU2Sdtcc&#x2B;W2edLWUMw2yEZGcj3VU4CSOnj3aDdpu1FuW7HrxX37xZK24xJW2RafdpzVqaQNYECSNgA6V2WvajFUk7TdtVVuu23iHPzlUWUbUAcb5UBdTZfbWk/aplHDtmlbbLP99ZW0Xa2JKtvbh3RG0gYwIEkbAEMov1c131aQtC1qpdx2/FJZlW1ATe&#x2B;PA3m0&#x2B;2bSQdI2lT0blCpvi4Vt09OrvOVrJG1hqmxpSdoABiRpA2AU5fsl980FSdsrTZTbjlwqq7INSJUNOFej7yp7k7bb1&#x2B;dcHSm3LVq5S/Hi0vfhn95J2mISxmxWp3eSNoABSdoAGEitsE3StiJ/2Ba&#x2B;VBazDajRDXEgv&#x2B;bKbYFO28MRpVSGLbdNq4nOSti2QtJ2UMKMbfFpR16aStoABiRpA2A4hfeq/vi730va3sqct8Uula/bX7ORkVZz&#x2B;&#x2B;BAW9p6kzmStG354iqU254FwjZJ2xEJYzYnwJ5J2gAGJGkDYERVeieStnVpw7a9l8qqbANSZQPKaOjd5mDStuXrq1Bue7Y3bJO0hR2J2VTZSpK0AQxI0gbAoCretu0m5/5RdQnztl2XyqpsA2po4xvoQxPltl6Tthvltge7wjZJW4AqW1skbQADkrQBMLTykyTv/znz/lFd2cK2jZfKqmxjamK/G&#x2B;hP/oy/76RtUm5bsjFvk7TtpcrWHEkbwIAkbQCMrla5Lfn&#x2B;UXWBC/iLsq4tl8qqbAPKv80N9C35u1D3SduNctuz59dx/ZWVtK1QZWuUpA1gQJI2AMi&#x2B;VzWsJOW29UtlVbYxedMAkkjbrA0kbVOb7f&#x2B;9n9dl7jL7rHDeNidpi1Fla5ekDWBAkjYA&#x2B;FXavarBVS&#x2B;3rVwqq7KNyXsFkErO7P940rbxIUkot62QtO2VsMq2&#x2B;LRWp69I2gAGJGkDgH/IuVdF3XLb4qWyKtuYvEUAOSV8d7ouafvj736fM4FTbntF0rZLE1W2tw8ZnKQNYECSNgD4Jwn3qripVW57vlQWs43JmwOQXKrG7aVJ28Znq0K5bdHKXFBJ250qWzckbQADkrQBwIJUe1XcVSm3zS&#x2B;VZWzD8p4ANCHPmYCrk7btz1mectui&#x2B;wsnaVukytYTSRvAgCRtALAsz14VDwqX2z599800TV&#x2B;&#x2B;/CxmG5O3AqAtSd61Yknb9C5ICz9tYSXPBjUUtp3&#x2B;M/SRtKmy9UfSBjAgSRsArFFkyankBtYtafvl2&#x2B;9jDw&#x2B;kgDYy8kiyYQ2wV/UFzClJ2/OjFp&#x2B;2oTu3FbvL7C4V87aD37qDpC1hzOYE2HGSNoABfar9AwBAavcLpM&#x2B;fv57vuVPX4tX&#x2B;&#x2B;l7Dx1//XH6P4O2Gmpgts/k&#x2B;tb0SoC2jLWCeE7gMnj/TFz/6518fXgYcSekOhj2LrkjvOvPbP/3h4MTI2Iu&#x2B;/mu2uDS1OgWAt3TaAOA9vZa0CpTbYp02Vbam&#x2B;ZMH&#x2B;lDx3axwp23vdymsWLnt4FqicLnt&#x2B;Ldrt9OmytY3nTaAAUnaAGCr6oOYWBTbF9i&#x2B;QxFI2tyVrWliNqAzVRYwVyRtr54zf9I2uXPbNd&#x2B;oxaQtYca2&#x2B;LSWpkdI2gAGJGkDgB1swad13QbWrqRNla11AnWgS&#x2B;UXMOGkbXqdnDWdtN2MXG67QnNJm5htEJI2gAFJ2gBgH2FbWheV27YnbapsTfOnDfSt8LvcWUnb/IEdJG3T2OW20zWUtLWSsb19CFtI2gAG9Kn2DwAAjfny5ef7VdN804rqFm/Y/nZj4pTdhLf3ireRkZyYDehe4QVMgcQrf6i2KLBcCS8YwvHMNE2//dMfDoZD3LUSs71d0AIAr&#x2B;i0AUCQrfm0zj0t/rbTJmNrnYmRwFBqldsOdtrWS3KB71Kdcttx&#x2B;TttrWRsbx/CLjptAAPSaQOAoPm1k3JbKrHT4rH9BRsZTfv8&#x2B;WsxGzCa/sptxb7LuZTbutdKzKbKBgDH6bQBwFF26tM65bT4q05b4A5wdjFSUUsFBpd5AfN867WVTtvtH7UYtt0ot4Wl7bS1krG9fQgxOm0AA9JpA4Cj5gfDldtSua7c9nYjQ8yW3Hx/2T4IMKamFzDPudpzFNeKxRWCclu7WonZVNkA4EQ6bQBwDv2YzI6cFn/otKmytc6fKsCDhOW2t7HZ4k3appabbdP&#x2B;5cqR2KyPclu2TlutjG3a/3tidXopnTaAAem0AcA5Ct/1hF1ip8WfH6XK1joxG8AzC5gk9i5XjnSSlNtOV7HKtitmU2UDgCvotAHAyWzlZxY41bvxUKqMLb&#x2B;EpQ2APFItYMbstN3tXVQMW25L0mnLWWVbfGar0zJ02gAGJGkDgPOl2qviwd6w7e2lspk8&#x2B;fmTBNgoz6GElbDtIU7rL2mbjg2&#x2B;3uvgoqVi3pYhaWvlrmxvH8KJJG0AA5K0AcBV8uxV8Wz7BsT6pbKNjPz8JQLskuR0wuBJ200r5bapUt5WN2lTZeMVSRvAgCRtAHChJHtVLNoYkr26VJaxNUHMBhCQYQFzPGnrI4FTbltRMWlTZWOFpA1gQJI2ALhWhr0qVrzdkli8VLaRkZ8/PYCD6h5WeJW0PWdmi4na4sNf5W33L04byCm3LaqStKmy8ZakDWBAkjYAKEGxJrP12OzhUlnG1gR/cQCnqHhq4YqkbfHhr54hG&#x2B;W2Z&#x2B;WTNlU2tpC0AQxI0gYAhWjYJPfqIPD8UtlGRhPEbAAnyha2HUza3j7D4hfkodw2VzJpO5ixTQVjNkvTuixEAcYkaQOAcoRtyS3ugHz67ptpmr58&#x2B;dlGRn7&#x2B;xAAuUmXv&#x2B;KKk7flJGkraJuW2mWJJmyobG4nZAIYlaQOA0lyAJfewbXFL2n759vuHL7ORkY2/LIBLlT/N8JyW7Zr9uD1saytpu1Fum4okbapsbOS8F8DgPtX&#x2B;AQBgOPdLr8&#x2B;fv55fkpHE232Kj7/&#x2B;2V5GNmI2gKvN32CbWMA0EZiFPS9FvvrL31ZCnSOrlyMp3XRGWFXL8Spb7F/d&#x2B;ou1&#x2B;LSWpnXNF6LWogBjkrQBQAXza7Am9qpGs7LBYSMjm3libWsD4FKFFzA//PTjwbTs9vDF51lvvDVhcU2yHu0cCduO5G2//dMf2srbjv/AJkaOw0IUgEnSBgAVKbcl97xtYSMjGyeIAcorvIA5JWw7/jw5LZ4NUm47qFaVbQpNjLQ6rch5LwDu3KcNACoz0z&#x2B;52wvkpcnGHw5AXXneh9/ep&#x2B;3VLdnu/32L92l7EKg6dXDnttPv09bQXdnePoSrydgAmJO0AUAKLtXSkrQllGd7F2BwGRYwW8Kz&#x2B;z9aDNU6SNpuArfvuigZeuuUsO3cpK3WuMgpVGULfy&#x2B;OsxAF4JmkDQCycM2Wk6Qtmwy7ugDcVV/APCdt2&#x2B;/B1lnSNg1WbjsraVNlY7vq73gA5OQ&#x2B;bQCQxfxSzW3b4JmbYQAkZAGTyqs7t&#x2B;19yEYd3LnNXdnYzh2CAXhFpw0A0pElpKLTloQTxADJ1VrA6LQtGqHcdrDTpsrGdhaiAKzTaQOAdO4Xb/MGD4zMCWKA/CxgUomV28Lfrrlymyob24nZAHhLpw0AknJFl4ROW13&#x2B;EACaU7jc9rbTtlJ067jTdtdxuS3WaVNlYxfjRgDYQqcNAJKad3ccDGdMYjaAFhVewGwMxn746cfOIrSNlNtOfP6SVba3D&#x2B;Fq7hAMwHY6bQCQnbChLp22WmxtADSt8ALm1ku7Z2nPRbfn/34ao9N211&#x2B;5bVenLW2VbfGZZWzVuQQDYBedNgDIbn5pp9zGCJwgBuhA4Xb&#x2B;SmVtcW7kgBbDm0HKbZmrbGK2hNwhGIC9dNoAoBmyhyp02gpzghigM1Xe2J/TtR9&#x2B;&#x2B;nHxv3z&#x2B;4l47bXfdlNu2dNpU2djFQhSAGJ02AGjG/GC4chtdcoIYoD9V2vnPaZlm29045TZVNnYRswEQptMGAI1xBViYTlsZfrEBule4nb8lWhuz03bXerltpdNWsco27f93KGPLwPgQAI7QaQOAxhS&#x2B;6wkUIGYDGEHhdv44gVlYr&#x2B;W2uhMjV/4VqbLl5A7BAByn0wYArRJOlKHTdjVbGwBDKbyAWW&#x2B;2Dd5puwvEPxnKbc&#x2B;dNlU29nJJBcApJG0A0DBXhgVI2q7jFxhgWEkmSUra7lqcJPmQtNWtsu19WjFbBs57AXAWSRsANM8l4qUkbRcRswEMrsoHwWKoJmm7K1luOx41nbgGLllle/sQCrAQBeBckjYA6IFrxetI2q4gHgZgShC2SdqeNVRuO2s5oco2GpdOAJxO0gYAnXDFeBFJ27n8ogLwoOIkSUnbK02U247/5qiyDch5LwCuIGkDgK64dDydpO1EYjYAFpX/gLila5K2FfnLbQfXvddFg4GckgIsRAG4jqQNAHrjGvJckraziIEBWFExbJO0rchcbgsvLVTZBuQSCYBLSdoAoE9SjbNI2o6ztQHARlUWMJK2dWnLbbHfFlW2AbkyAuBqkjYA6JZ44xSStoP8HgKwS61y252k7VmsqnV1uW1vfKLKNiALUQDKkLQBQM9cWx4naTvCCWIAAuqGbZK2V7KV23YtM0rGbDK2JFwKAVCMpA0A&#x2B;iftOELSFmNrA4CDCi9g7mGbpG1FqrBt42&#x2B;IKtuYXAEBUJKkDQCGIPYIk7QF&#x2B;H0D4BRVym2StreS5G1bohQx24AsRAEoT9IGAKNwzRkjadvLCWIATmQBk1OGsG19ySFjG5N3DACqkLQBwFikIHtJ2raztQHARSxgcgrcouzEAGzlt0LMNiZvFADUImkDgOGIQ3aRtG3k9wqAS/mgyaliuW0xVrkuY1t8chlbEt4fAKhL0gYAI3Itup2kbQsniAEowydOTlXKbc&#x2B;/DKpsY8qhFjwAABTZSURBVHJpA0B1kjYAGJe9qi0kbetsbQBQmAVMTuXLbfPfBFW2YXlDACADSRsADE1M8pakbYXfHwCq8AGUVsly26fvvrn9h1&#x2B;&#x2B;/T72DJMqW8u8DwCQh6QNAEbnGnWdpO0VJ4gBqMsnUU7Fym0HkzZVtqa5hAEgFUkbADBN9qpek7Q9s7UBQBI&#x2B;knKKVcH25m1HkjZVtqa5cgEgG0kbAPAre1WLJG0P/J4AkIoPprSuLrfFkrZY4CdmS8LfOwA5SdoAgH9w7fpM0jbnBDEAOfmEyunSclsgaVNla5pLFQDSkrQBAI/sVc1J2m5sbQCQnI&#x2B;qtC4qt&#x2B;1N2sRsTXOFAkBmkjYAYIG9qjtJ2&#x2B;T3AYBG&#x2B;MBK64py2/akTcbWNH/XAOT3qfYPAABkNL&#x2B;InV/cMqD5CWK7GwBkNv&#x2B;osoBJ5eOvf37Orr76y9/Ws7RT4i4xW9PEbAA0QacNAFhjTsvInTZbGwA0ykdYWieW29522gJPK2NLxZUIAK3QaQMA1swPhjsbPhR7lAC0Szs/rVfltrePCnyjlX&#x2B;6WKcTs&#x2B;Uxv/SwEAUgP502AOC9kUOXMTtttjYA6INPtLQC5baHh7zqtKmytW7kSw8AGiVpAwC2GvOid7SkbcxXGYCO&#x2B;WjLLBB63R&#x2B;ymLS5K1vrpOMAtMj0SABgK4OYumcvEoD&#x2B;WMBktjhJcn2Y5KtgbHEu5cMzb382yjMxEoB26bQBALsNdQ08TqdtqJcVgAH5pMssUG67v6C/fPu9jK11znsB0DRJGwAQMc7F8AhJ2zivJgCD85GX2d48bGN0KmbLTwoOQOskbQBA0CB7Vd0nbYO8jgBw44Mvs12p2Nt4RsaWn79HAPogaQMADun&#x2B;CGrfSVv3Lx8ALPIJmNnGhGz9RRSz5SdmA6AbkjYA4Ki&#x2B;L5J7Tdr6ftUA4C0fhZltyclWkrbAXd8oTNoNQE8kbQDACTreq&#x2B;oyaev49QKA7XwgJreety1GNaps&#x2B;fm7A6A/kjYA4DRdHk3tL2nr8mUCgDCfjJmtJGfPL5wqW35iNgC6JGkDAM7U38VzT0lbf68OAJzCR2Ryi3nbp&#x2B;&#x2B;&#x2B;uf2HL19&#x2B;VmVrglQbgF59qv0DAABdmV82zzetqM4eIgC8YgGT3HpmJmbL7/Pnr8VsAHTsN7V/AACgN7eL59u19OfPX7uWzsDWBgCss4BJ7pacLYZqi19JHs57AdA9nTYA4BL3q&#x2B;j5CVbKc4IYALazgEnubYomZstmvhC1FgWgVzptAMBVvnz5&#x2B;X5p7Wx4FU4QA8Beym3JvSq3ydiysRAFYBw6bQDAheZnVx0ML8wJYgAIU25L7iFXE7NlI2YDYChffXx81P4ZAID&#x2B;tXuxffvJW/yZb9r6yQEgFR&#x2B;pmZmPnZaXBoDR6LQBACXML7MdDL&#x2B;UPUEAOIt2PuziDsEAjEnSBgAUYq&#x2B;qABMjAeB0JknCFs57ATAsSRsAUJS9qos4QQwA19HOh3XOewEwMkkbAFCavarTOUEMAFfTzodFznsBgKQNAKjAXtWJnCAGgGK082HOeS8AmCRtAEBF9qoOcoIYAMrTzocb570A4EbSBgDUZK8qzAliAKhFO5/BOe8FAHOSNgCgsoe9KttVWzhBDADVWcAwJue9AOCBpA0ASEG5bSMniAEgDwsYRuO8FwA8k7QBAFnYq3rLCWIAyMYkSQbhvBcAvCJpAwASMUlyhRPEAJCWBQx9c94LAFZI2gCAdJTbHjhBDAD5WcDQK&#x2B;e9AGCdpA0AyMggpjsniAGgFRYwdMZ5LwDYQtIGAORlEJMTxADQHAsY&#x2B;uC8FwBsJGkDAFIbdhCTE8QA0K5hFzB0w3kvANhO0gYAZDfgICYniAGgdQMuYOiD814AsJekDQBowziDmJwgBoBujLOAoQ/OewFAgKQNAGhG94OYnCAGgP50v4ChG857AUCMpA0AaEnHg5icIAaAXj0sYDpbw9AB570A4AhJGwDQnv72qpwgBoDuKbeRk/NeAHCQpA0AaFI3e1VOEAPAODpu59Mo570A4DhJGwDQqg72qpwgBoAB9dfOp0XOewHAWSRtAEDb2t2rcoIYAIbVTTufRjnvBQAnkrQBAM1rbq/KCWIAoIN2Po1y3gsAziVpAwB60NBelRPEAMBdu&#x2B;18WuS8FwBcQdIGAPQj/16VE8QAwIPm2vk0ynkvALiIpA0A6EravSoniAGAVxpq59Mo570A4DqSNgCgNwn3qpwgBgDeyt/Op0XOewHA1SRtAECf8uxVOUEMAGyUtp1Po5z3AoACJG0AQLeq71U5QQwA7JWwnU&#x2B;jnPcCgDIkbQBAzx72qkpuVzlBDACE5Wnn0yLnvQCgJEkbANC/wuW2h60NuxsAQED1dj6Nct4LAAqTtAEAQyi2V2VrAwA4i0mS7OW8FwCUJ2kDAEZRYJKkmA0AOJ1JkmxhYiQA1CJpAwDGclG5zcRIAOA6JkmyznkvAKhI0gYADOf0QUy2NgCAq5kkySvOewFAXZI2AGBQZw1iErMBAMWYJMmciZEAkIGkDQAY18FBTCZGAgDlmSTJjfNeAJCEpA0AGFp4EJOtDQCgFpMkcd4LAPKQtAEA7B7EJGYDAKozSXJMJkYCQDaSNgCAado8iMnESAAgD5MkR&#x2B;O8FwAkJGkDAPjV20FMtjYAgGweFjDyto457wUAOUnaAAD&#x2B;yau9KjEbAJCWclvfTIwEgMy&#x2B;&#x2B;vj4qP0zAACk82qLytYGAJDZOHnMgP9LpwH&#x2B;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&#x2B;Z4qjRy2mRgJANxI2gAAAADYZx62DZi3zatsYjYAGJykDQAAAIDdxpwkaWIkAPBA0gYAAABAxGiTJE2MBACeSdoAAAAAiBtkkqSJkQDAIkkbAAAAAIf0PUnSxEgAYIWkDQAAAICjep0kaWIkALBO0gYAAADAOTqbJGliJADwlqQNAAAAgNP0MUnSxEgAYCNJGwAAAABnan2SpImRAMB2kjYAAAAAztfoJEkTIwGAXSRtAAAAAFyirUmSJkYCAAGSNgAAAACu0sokSRMjAYAYSRsAAAAA10o&#x2B;SdLESAAgTNIGAAAAwOVyTpI0MRIAOEjSBgAAAEAJD5Mkq&#x2B;dtJkYCAMdJ2gAAAAAoJ0m5zcRIAOAUkjYAAAAAiqobtpkYCQCcSNIGAAAAQGm1JkmaGAkAnEvSBgAAAEAdhcttJkYCAKeTtAEAAABQTZmwzcRIAOAikjYAAAAAarp6kqSJkQDAdSRtAAAAANR3UbnNxEgA4FKSNgAAAABSeCi3HXw2EyMBgAIkbQAAAAAkcsokSRMjAYAyJG0AAAAA5HJwkqSJkQBAMZI2AAAAANKJTZI0MRIAKEzSBgAAAEBSuyZJmhgJAJQnaQMAAAAgr42TJE2MBACqkLQBAAAAkNr6JEkTIwGAir76&#x2B;Pio/TMAAAAAwHvrAyTFbABAeZI2AAAAAJqxGLbJ2ACAWiRtAAAAADRmnreJ2QCAitynDQAAAIDG3NM1MRsAUJdOGwAAAAAAAETotAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAAREjaAAAAAAAAIELSBgAAAAAAABGSNgAAAAAAAIiQtAEAAAAAAECEpA0AAAAAAAAiJG0AAAAAAAAQIWkDAAAAAACACEkbAAAAAAAARPw/bPd9dJdDNccAAAAASUVORK5CYII=" />
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>